[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "vicuna-13b_response": "Answer: Bazex's syndrome is a name synonym of Acrokeratosis paraneoplastica. It is a skin condition that can be associated with malignancies of the upper respiratory or digestive tracts. The case report describes a 71-year-old man with a dedifferentiated carcinoma of the parotid gland and metastatic cervical lymph nodes, who also had Bazex's syndrome. The literature review suggests that Bazex's syndrome and Acrokeratosis paraneoplastica are interchangeable terms for the same condition.",
    "vicuna-13b_fact_raw": "1. Bazex's syndrome is a synonym for Acrokeratosis paraneoplastica.\n2. Acrokeratosis paraneoplastica is often associated with malignancies of the upper respiratory or digestive tracts.\n3. A case report described a 71-year-old man with a dedifferentiated carcinoma of the parotid gland and metastatic cervical lymph nodes who had Bazex's syndrome.\n4. The literature review suggests that Bazex's syndrome and Acrokeratosis paraneoplastica are used interchangeably.",
    "vicuna-13b_fact": [
      "Bazex's syndrome is a synonym for Acrokeratosis paraneoplastica.",
      "Acrokeratosis paraneoplastica is often associated with malignancies of the upper respiratory or digestive tracts.",
      "A case report described a 71-year-old man with a dedifferentiated carcinoma of the parotid gland and metastatic cervical lymph nodes who had Bazex's syndrome.",
      "The literature review suggests that Bazex's syndrome and Acrokeratosis paraneoplastica are used interchangeably."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "vicuna-13b_response": "Sotos syndrome and Weaver syndrome are two distinct overgrowth syndromes that share some similarities in terms of clinical features, such as height and head circumference above the 97th percentile, advanced bone age, and developmental delay. However, they have distinctive facial appearances and different genetic causes.\nSotos syndrome is caused by a 2.2-Mb chromosome 5q35 microdeletion, encompassing the NSD1 gene. Intragenic mutations and large deletions of NSD1 have been reported to be the major cause of Sotos syndrome. In contrast, Weaver syndrome is caused by a different genetic mutation, which has been identified as a 1.5-Mb microdeletion on chromosome 16p13.11.\nWhile both syndromes share some similarities in terms of clinical features, the genetic causes and underlying mechanisms are different. Therefore, they should not be considered the same condition. It is important to note that a diagnosis of either Sotos syndrome or Weaver syndrome should be made by a qualified medical professional based on a comprehensive clinical evaluation and genetic testing.",
    "vicuna-13b_fact_raw": "1. Sotos syndrome is caused by a 2.2-Mb chromosome 5q35 microdeletion, encompassing the NSD1 gene.\n2. Sotos syndrome is associated with intragenic mutations and large deletions of the NSD1 gene.\n3. Weaver syndrome is caused by a 1.5-Mb microdeletion on chromosome 16p13.11.\n4. Both Sotos and Weaver syndromes share clinical features such as height and head circumference above the 97th percentile, advanced bone age, and developmental delay.\n5. Sotos and Weaver syndromes differ in their distinctive facial appearances and genetic causes.",
    "vicuna-13b_fact": [
      "Sotos syndrome is caused by a 2.2-Mb chromosome 5q35 microdeletion, encompassing the NSD1 gene.",
      "Sotos syndrome is associated with intragenic mutations and large deletions of the NSD1 gene.",
      "Weaver syndrome is caused by a 1.5-Mb microdeletion on chromosome 16p13.11.",
      "Both Sotos and Weaver syndromes share clinical features such as height and head circumference above the 97th percentile, advanced bone age, and developmental delay.",
      "Sotos and Weaver syndromes differ in their distinctive facial appearances and genetic causes."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Sotos syndrome is caused by either a mutation or deletion in the NSD1 gene, but specifically identifying it as a \"2.2-Mb chromosome 5q35 microdeletion\" is not accurate for all cases. The size of the deletion can vary.\n2. TRUE\n3. FALSE [correction]: Weaver syndrome is often associated with mutations in the EZH2 gene, not a specific microdeletion on chromosome 16p13.11.\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "vicuna-13b_response": "The releases of JASPAR database are as follows:\n1. JASPAR 2004: This was the first release of the JASPAR database, which contained 107 non-redundant, curated profiles of transcription factor binding sites.\n2. JASPAR 2008: The second release expanded the database to 214 non-redundant, curated profiles, including the addition of new transcription factor families and the introduction of a new special collection for matrix profiles derived from in vitro experiments.\n3. JASPAR 2015: The third release expanded the database to 341 non-redundant, curated profiles, including the addition of new transcription factor families and the introduction of new special collections for matrix profiles derived from ChIP-seq and ChIP-chip experiments.\n4. JASPAR 2020: The fourth release of the JASPAR database is the largest expansion of the core database to date, with 457 non-redundant, curated profiles. This release includes the addition of profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments, as well as 177 yeast TF binding profiles. The database also introduced a new yeast division, and versioning of matrices was introduced to reflect updates to older models. The classification of TF families was also improved, and a curated catalog of mammalian TFs was provided to extend the use of JASPAR profiles to additional TFs belonging to the same structural family. The changes in the database set it ready for more rapid acquisition of new high-throughput data sources, and three new special collections were introduced to provide matrix profile data produced by recent alternative high-throughput approaches.",
    "vicuna-13b_fact_raw": "1. JASPAR 2004 was the first release of the JASPAR database and contained 107 non-redundant, curated profiles of transcription factor binding sites.\n2. JASPAR 2008 expanded the database to 214 non-redundant, curated profiles and included the addition of new transcription factor families and a special collection for matrix profiles from in vitro experiments.\n3. JASPAR 2015 saw the expansion of the database to 341 non-redundant, curated profiles, with additions including new transcription factor families and special collections for matrix profiles from ChIP-seq and ChIP-chip experiments.\n4. JASPAR 2020 is the fourth release, expanding the core database to 457 non-redundant, curated profiles and including 177 yeast TF binding profiles, a new yeast division, versioning of matrices, and improved classification of TF families.\n5. With the release of JASPAR 2020, three new special collections were introduced to provide matrix profile data produced by recent alternative high-throughput approaches.",
    "vicuna-13b_fact": [
      "JASPAR 2004 was the first release of the JASPAR database and contained 107 non-redundant, curated profiles of transcription factor binding sites.",
      "JASPAR 2008 expanded the database to 214 non-redundant, curated profiles and included the addition of new transcription factor families and a special collection for matrix profiles from in vitro experiments.",
      "JASPAR 2015 saw the expansion of the database to 341 non-redundant, curated profiles, with additions including new transcription factor families and special collections for matrix profiles from ChIP-seq and ChIP-chip experiments.",
      "JASPAR 2020 is the fourth release, expanding the core database to 457 non-redundant, curated profiles and including 177 yeast TF binding profiles, a new yeast division, versioning of matrices, and improved classification of TF families.",
      "With the release of JASPAR 2020, three new special collections were introduced to provide matrix profile data produced by recent alternative high-throughput approaches."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: JASPAR 2020 is not the fourth release, as there have been several versions in the intervening years (e.g., releases in 2010, 2014, 2016, and 2018).\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "vicuna-13b_response": "The function of the viral KP4 protein is not mentioned in the given information. The information states that the P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of the viral RNA-dependent RNA polymerase and that phosphorylation of the P protein can positively or negatively regulate viral gene expression, depending on the precise phosphorylation sites. It also mentions that sumoylation, a process of adding small ubiquitin-like modifier (SUMO) to proteins posttranslationally, plays an important role in regulating protein function. The information states that the P protein of PIV5 was found to be sumoylated with SUMO1 in both transfected and infected cells and that the K254 residue of the P protein is within a consensus sumoylation motif. It also states that mutation of the P protein at K254 to arginine (P-K254R) reduced PIV5 minigenome activity, as well as the sumoylation level of the P protein, and that incorporation of K254R into a recombinant PIV5 (rPIV5-P-K254R) resulted in a virus that grew to a lower titer and had lower levels of viral RNA synthesis and protein expression than wild-type PIV5, suggesting that sumoylation of the P protein at K254 is important for PIV5 growth. However, the information does not mention the function of the viral KP4 protein.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "vicuna-13b_response": "Yes, DITPA is a thyroid hormone analog that has been utilized in experimental and clinical studies. The patent application WO2008106213 describes the beneficial effects of DITPA, such as stimulating weight loss in overweight mammals, lowering of triglyceride levels, and treating metabolic syndrome in humans. The human population of patients selected in the studies mentioned had a body mass index greater than 25. Two examples of human clinical studies employing DITPA have been mentioned, including a study on body weight reduction and another study on the improvement of metabolic abnormalities in obese adults.",
    "vicuna-13b_fact_raw": "1. DITPA is a thyroid hormone analog.\n2. DITPA has been used in experimental and clinical studies.\n3. The patent application WO2008106213 describes beneficial effects of DITPA like stimulating weight loss and lowering triglyceride levels.\n4. Clinical studies involving DITPA selected patients with a body mass index greater than 25.\n5. Human clinical studies have used DITPA for body weight reduction and improvement of metabolic abnormalities in obese adults.",
    "vicuna-13b_fact": [
      "DITPA is a thyroid hormone analog.",
      "DITPA has been used in experimental and clinical studies.",
      "The patent application WO2008106213 describes beneficial effects of DITPA like stimulating weight loss and lowering triglyceride levels.",
      "Clinical studies involving DITPA selected patients with a body mass index greater than 25.",
      "Human clinical studies have used DITPA for body weight reduction and improvement of metabolic abnormalities in obese adults."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements concerning DITPA (3-iodothyronamine) being a thyroid hormone analog and its use in studies are correct. However, without access to the specific patent application WO2008106213 and specific clinical study designs, it is impossible to assess the accuracy of the specific claims made in statements 3, 4, and 5. These details are essential to determine the truth value of those statements, and without them, we have to answer \"UNKNOWN\".",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "vicuna-13b_response": "The COUGER tool is not mentioned in Document-0. It is possible that the COUGER tool is a tool used in a different field or context. Can you provide any additional information or context about the COUGER tool?",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "vicuna-13b_response": "Yes, there are drugs for Tick-borne Encephalitis. The document mentions a drug called cytoflavin, which was found to be effective in treating neuroinfections associated with Tick-borne Encephalitis. The drug was shown to reduce general brain, focal brain and neuropsychological disorders, as well as decrease the endogenous hyperproduction of NO metabolites in patients who received the drug compared to those who did not. The recommended dose of the drug is 10.0 ml once a day intravenously in drops for 7-10 days.",
    "vicuna-13b_fact_raw": "1. Cytoflavin is a drug used to treat neuroinfections associated with Tick-borne Encephalitis.\n2. Cytoflavin was found to reduce general and focal brain, as well as neuropsychological disorders, in patients.\n3. Cytoflavin can decrease the endogenous hyperproduction of NO metabolites in patients.\n4. The recommended dose for Cytoflavin is 10.0 ml once a day intravenously in drops.\n5. The recommended course of treatment with Cytoflavin for Tick-borne Encephalitis is 7-10 days.",
    "vicuna-13b_fact": [
      "Cytoflavin is a drug used to treat neuroinfections associated with Tick-borne Encephalitis.",
      "Cytoflavin was found to reduce general and focal brain, as well as neuropsychological disorders, in patients.",
      "Cytoflavin can decrease the endogenous hyperproduction of NO metabolites in patients.",
      "The recommended dose for Cytoflavin is 10.0 ml once a day intravenously in drops.",
      "The recommended course of treatment with Cytoflavin for Tick-borne Encephalitis is 7-10 days."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Cytoflavin is not specifically used to treat neuroinfections associated with Tick-borne Encephalitis; it is a metabolic agent used to improve brain metabolism and blood flow.\n2. TRUE\n3. TRUE\n4. UNKNOWN: The specific recommended dosing for Cytoflavin can vary and should be determined by a medical professional.\n5. UNKNOWN: The length of treatment with Cytoflavin can depend on the specific condition and patient response and should be prescribed by a healthcare provider.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "vicuna-13b_response": "The University of California, Santa Cruz Genome Browser Database is one of the genome browser databases that provides DNA shape annotations. It contains sequence and annotation data for the genomes of 13 vertebrate and 19 invertebrate species. The database offers a wide variety of annotations at all scales, from the single nucleotide level up to a full chromosome, including assembly data, genes and gene predictions, mRNA and EST alignments, and comparative genomics, regulation, expression, and variation data. The database is optimized for fast interactive performance with web tools that provide powerful visualization and querying capabilities for mining the data. The Genome Browser also includes new features such as VisiGene, a fully integrated in situ hybridization image browser, phyloGif, for drawing evolutionary tree diagrams, a redesigned Custom Track feature, an expanded SNP annotation track, and many new display options. The Genome Browser, other tools, downloadable data files, and links to documentation and other information can be found at <http://genome.ucsc.edu/>.",
    "vicuna-13b_fact_raw": "1. The University of California, Santa Cruz Genome Browser Database provides DNA shape annotations.\n2. The database contains sequence and annotation data for the genomes of 13 vertebrate and 19 invertebrate species.\n3. The database offers annotations at various scales, including single nucleotide to full chromosome levels.\n4. The Genome Browser includes a feature called VisiGene, which is an integrated in situ hybridization image browser.\n5. The UCSC Genome Browser can be accessed at the URL http://genome.ucsc.edu/.",
    "vicuna-13b_fact": [
      "The University of California, Santa Cruz Genome Browser Database provides DNA shape annotations.",
      "The database contains sequence and annotation data for the genomes of 13 vertebrate and 19 invertebrate species.",
      "The database offers annotations at various scales, including single nucleotide to full chromosome levels.",
      "The Genome Browser includes a feature called VisiGene, which is an integrated in situ hybridization image browser.",
      "The UCSC Genome Browser can be accessed at the URL http://genome.ucsc.edu/."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "vicuna-13b_response": "Answer: Mutations in the EZH2 gene are associated with Weaver syndrome. This is supported by the trio-based whole-exome sequencing of two families affected by Weaver syndrome, which identified two different de novo mutations in the EZH2 gene in the affected probands. Sanger sequencing of EZH2 in a third classically-affected proband also identified a third de novo mutation in this gene. These findings indicate that mutations in EZH2 cause Weaver syndrome.",
    "vicuna-13b_fact_raw": "1. Mutations in the EZH2 gene are associated with Weaver syndrome.\n2. Trio-based whole-exome sequencing of two families affected by Weaver syndrome identified de novo mutations in the EZH2 gene in the affected probands.\n3. Sanger sequencing identified a de novo mutation in the EZH2 gene in a third classically-affected proband of Weaver syndrome.",
    "vicuna-13b_fact": [
      "Mutations in the EZH2 gene are associated with Weaver syndrome.",
      "Trio-based whole-exome sequencing of two families affected by Weaver syndrome identified de novo mutations in the EZH2 gene in the affected probands.",
      "Sanger sequencing identified a de novo mutation in the EZH2 gene in a third classically-affected proband of Weaver syndrome."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "vicuna-13b_response": "Based on the information provided in Document-0, human proteins that are subject to a dimer-to-tetramer transition include the human pregnancy zone protein (PZP) and its derivatives. PZP forms dimeric/tetrameric species with a molecular weight of 360/720 kDa and binds to proteinases that cause the cleavage of internal thiol esters in the molecule. The binding of proteinases such as chymotrypsin (CT) or reaction with methylamine (MA) causes transition to a new similar conformational state. The reactivity of selected monoclonal antibodies against PZP towards the three PZP derivatives demonstrated differences in the reactivity pattern. PZP and PZP.MA share one determinant, which is missing on the PZP.CT complex. PZP after transition to PZP.CT, but not to PZP.MA, presents a neodeterminant detected by one of six monoclonal antibodies. The findings demonstrate that at least three different conformational states exist for PZP and its derivatives. Access to discriminating immunochemical tools makes possible an evaluation of the relative abundance of the different complexes in vivo.",
    "vicuna-13b_fact_raw": "1. The human pregnancy zone protein (PZP) undergoes a transition from dimeric to tetrameric species.\n2. The molecular weight of PZP's dimeric and tetrameric species are 360 kDa and 720 kDa, respectively.\n3. Binding of proteinases like chymotrypsin (CT) or reaction with methylamine (MA) causes PZP to transition to a similar conformational state.\n4. PZP reacts with selected monoclonal antibodies differently after binding with CT or MA, indicating changes in its conformational state.\n5. Three different conformational states exist for PZP and its derivatives, as demonstrated by the differences in reactivity patterns with monoclonal antibodies.",
    "vicuna-13b_fact": [
      "The human pregnancy zone protein (PZP) undergoes a transition from dimeric to tetrameric species.",
      "The molecular weight of PZP's dimeric and tetrameric species are 360 kDa and 720 kDa, respectively.",
      "Binding of proteinases like chymotrypsin (CT) or reaction with methylamine (MA) causes PZP to transition to a similar conformational state.",
      "PZP reacts with selected monoclonal antibodies differently after binding with CT or MA, indicating changes in its conformational state.",
      "Three different conformational states exist for PZP and its derivatives, as demonstrated by the differences in reactivity patterns with monoclonal antibodies."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nReason for UNKNOWN: The statements involve specific scientific facts regarding the behavior and properties of the human pregnancy zone protein (PZP). Without access to the relevant scientific literature or specific knowledge on the biochemistry of PZP, it is not possible to accurately verify these statements. An expert in biochemical research on PZP or related proteins would be required to validate or correct these claims.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "vicuna-13b_response": "The protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is protein kinase A (PKA). In the document, it is stated that the association between the PLN and SERCA2a (the protein that is responsible for the relaxation as well as the contractility of heart muscle cells) is inhibited by cAMP-dependent phosphorylation of the PLN fusion protein and by usage of anti-PLN monoclonal antibody. It is also diminished by substitution at the phosphorylation site of PLN of Ser(16) to Asp. These results suggest that PLN can bind SERCA2a in the absence of the membrane domains and that the modifications of the cytoplasmic domain of PLN that activate SERCA2a parallel the disruption of the association between the two fusion proteins. It has been shown that the removal of PLN inhibition of SERCA2a rescues cardiac function and morphology in the mouse dilated cardiomyopathy model.",
    "vicuna-13b_fact_raw": "1. Protein kinase A (PKA) interacts with phospholamban (PLN) and is an anti-apoptotic protein.\n2. cAMP-dependent phosphorylation of the PLN fusion protein inhibits the association between PLN and SERCA2a.\n3. The use of anti-PLN monoclonal antibody inhibits the association between PLN and SERCA2a.\n4. Substitution at the phosphorylation site of PLN of Ser(16) to Asp diminishes PLN's ability to bind SERCA2a.\n5. The removal of PLN inhibition of SERCA2a rescues cardiac function and morphology in the mouse dilated cardiomyopathy model.",
    "vicuna-13b_fact": [
      "Protein kinase A (PKA) interacts with phospholamban (PLN) and is an anti-apoptotic protein.",
      "cAMP-dependent phosphorylation of the PLN fusion protein inhibits the association between PLN and SERCA2a.",
      "The use of anti-PLN monoclonal antibody inhibits the association between PLN and SERCA2a.",
      "Substitution at the phosphorylation site of PLN of Ser(16) to Asp diminishes PLN's ability to bind SERCA2a.",
      "The removal of PLN inhibition of SERCA2a rescues cardiac function and morphology in the mouse dilated cardiomyopathy model."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Protein kinase A (PKA) is known to phosphorylate phospholamban (PLN), leading to the activation of the calcium pump SERCA2a in cardiac muscle cells. PKA does have roles that could be described as anti-apoptotic, but it is context-dependent.\n\n2. TRUE: cAMP-dependent phosphorylation of phospholamban (PLN) by PKA typically reduces the inhibitory effect of PLN on SERCA2a. The phosphorylation of PLN leads to its dissociation from SERCA2a, increasing calcium uptake into the sarcoplasmic reticulum.\n\n3. UNKNOWN: The use of anti-PLN monoclonal antibody could potentially inhibit the association between PLN and SERCA2a, depending on the epitope the antibody binds to and the subsequent conformational effects, if any. However, without specific details about the antibody and its mode of action, this cannot be determined as universally true or false.\n\n4. TRUE: The substitution of serine (Ser) to aspartic acid (Asp) at residue 16, a phosphorylation site in PLN, indeed mimics a constitutively phosphorylated state due to the negative charge of Asp. This can diminish PLN's ability to inhibit SERCA2a since phosphorylation of Ser(16) relieves the inhibition of SERCA2a by PLN.\n\n5. TRUE: Research has shown that genetically removing PLN or inhibiting its function can rescue cardiac function and improve morphology in animal models of dilated cardiomyopathy, which supports the statement given.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "vicuna-13b_response": "Answer: Based on the information provided in Document-0, it can be inferred that vitamin D supplementation alone did not reduce the incidence of falls resulting in injury in elderly women living at home who had fallen during the previous year. However, regular exercise was found to be effective in reducing the incidence of falls resulting in injury. Therefore, it is recommended to consider regular exercise as a means to reduce the risk of falls in older people.",
    "vicuna-13b_fact_raw": "1. Vitamin D supplementation alone did not reduce the incidence of falls resulting in injury in elderly women who had fallen during the previous year.\n2. Regular exercise was found to be effective in reducing the incidence of falls resulting in injury among elderly people.\n3. Regular exercise is recommended to reduce the risk of falls in older people.",
    "vicuna-13b_fact": [
      "Vitamin D supplementation alone did not reduce the incidence of falls resulting in injury in elderly women who had fallen during the previous year.",
      "Regular exercise was found to be effective in reducing the incidence of falls resulting in injury among elderly people.",
      "Regular exercise is recommended to reduce the risk of falls in older people."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN (Without the specific study or source, it's unclear whether this statement about the efficacy of Vitamin D supplementation on reducing falls is true or false.)\n2. TRUE (It is widely supported by medical research that regular exercise contributes to fall prevention in elderly people through improved strength, balance, and overall physical health.)\n3. TRUE (Regular exercise is commonly recommended to reduce the risk of falls among older individuals, as it can help maintain or improve balance, muscle strength, coordination, and flexibility.)",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "vicuna-13b_response": "Based on the provided information, there is an association between Jarid2 and miR-155 in Th17 cells in the context of TNBS-induced colitis. The study found that miR-155 inhibition reduced the proportion of Th17 cells in spleens and mesenteric lymph nodes (MLNs) and the level of Th17 cell-associated cytokines IL-6, IL-17A, IL-17F, and IL-21 in colon tissues. Additionally, the study discovered that Jarid2 was significantly elevated by miR-155 inhibition, and Notch1 expression was inversely correlated with Jarid2. These findings suggest that miR-155 inhibition regulates the differentiation and function of Th17 cells, and Jarid2/Notch1 is closely related to this process.",
    "vicuna-13b_fact_raw": "1. There is an association between Jarid2 and miR-155 in Th17 cells in the context of TNBS-induced colitis.\n2. Inhibition of miR-155 reduced the proportion of Th17 cells in spleens and mesenteric lymph nodes.\n3. Inhibition of miR-155 also reduced the level of Th17-associated cytokines IL-6, IL-17A, IL-17F, and IL-21 in colon tissues.\n4. Jarid2 expression was elevated following miR-155 inhibition.\n5. There is an inverse correlation between Notch1 expression and Jarid2.",
    "vicuna-13b_fact": [
      "There is an association between Jarid2 and miR-155 in Th17 cells in the context of TNBS-induced colitis.",
      "Inhibition of miR-155 reduced the proportion of Th17 cells in spleens and mesenteric lymph nodes.",
      "Inhibition of miR-155 also reduced the level of Th17-associated cytokines IL-6, IL-17A, IL-17F, and IL-21 in colon tissues.",
      "Jarid2 expression was elevated following miR-155 inhibition.",
      "There is an inverse correlation between Notch1 expression and Jarid2."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements refer to specific scientific findings about the association between Jarid2 and miR-155, their implications on Th17 cells and TNBS-induced colitis, and the effects on cytokines and Notch1 expression. Without access to the specific study or scientific literature that these statements come from, it is not possible to accurately determine their truthfulness. These require subject-matter expertise and the context of the specific research to verify.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "vicuna-13b_response": "The human hoxD cluster contains 4 genes.",
    "vicuna-13b_fact_raw": "1. The human hoxD cluster contains 4 genes.",
    "vicuna-13b_fact": [
      "The human hoxD cluster contains 4 genes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE",
    "vicuna-13b_judge": [
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "vicuna-13b_response": "Phosphorylation consensus motifs for Casein Kinase 1 (CK1) are sequences of amino acids that are recognized and phosphorylated by CK1 enzymes. These motifs typically include a specific sequence of serine, threonine, or tyrosine residues, followed by a consensus sequence of amino acids that CK1 enzymes use to recognize and phosphorylate these residues.\nBased on the provided document, it does not provide a list of specific phosphorylation consensus motifs for CK1. However, it does provide information on the crystal structures of PF4800567, a potent and selective inhibitor of CK1, bound to the kinase domains of human CK1 and CK1, as well as an apo CK1 crystal structure. These structures provide a molecular basis for the strong and specific inhibitor interactions with CK1 and suggest clues for further development of CK1 inhibitors.\nIt is important to note that CK1 is a family of enzymes that are involved in a wide range of cellular processes, and different members of the CK1 family may have different phosphorylation consensus motifs. Therefore, it is important to consult the literature and experimental data for specific information on the phosphorylation consensus motifs for different members of the CK1 family.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the human AspH (hAspH) gene encodes two isoforms of the protein, one with a length of 2.6 kb and the other with a length of 4.3 kb, as revealed by Northern blot analyses. The deduced amino acid sequence of the hAspH cDNA encodes a protein of 757 amino acids (85 kDa). The N-terminal portion of the hAspH protein is different from the bovine AspH (bAspH) protein. In vitro transcription and translation in the presence of canine pancreas microsomes yielded a 56-kDa protein, and Western blot analyses of membrane fractions from MG63 cells with AspH-specific antibodies revealed a protein of the same M(r), suggesting a posttranslational cleavage of the catalytic C-terminus in the lumen of the endoplasmic reticulum.",
    "vicuna-13b_fact_raw": "1. The human ASPH (Aspartate beta-hydroxylase) gene encodes two isoforms of the protein.\n2. One isoform encoded by the ASPH gene has a length of 2.6 kb and the other has a length of 4.3 kb as shown by Northern blot analyses.\n3. The deduced amino acid sequence of the hAspH cDNA encodes a protein of 757 amino acids, which has a molecular weight of 85 kDa.\n4. The N-terminal portion of the hAspH protein differs from the bovine AspH (bAspH) protein.\n5. In vitro transcription and translation in the presence of canine pancreas microsomes produced a 56-kDa protein, and Western blot analyses of MG63 cells with AspH-specific antibodies revealed a protein of the same molecular weight.",
    "vicuna-13b_fact": [
      "The human ASPH (Aspartate beta-hydroxylase) gene encodes two isoforms of the protein.",
      "One isoform encoded by the ASPH gene has a length of 2.6 kb and the other has a length of 4.3 kb as shown by Northern blot analyses.",
      "The deduced amino acid sequence of the hAspH cDNA encodes a protein of 757 amino acids, which has a molecular weight of 85 kDa.",
      "The N-terminal portion of the hAspH protein differs from the bovine AspH (bAspH) protein.",
      "In vitro transcription and translation in the presence of canine pancreas microsomes produced a 56-kDa protein, and Western blot analyses of MG63 cells with AspH-specific antibodies revealed a protein of the same molecular weight."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The statement about the ASPH gene encoding two isoforms of the protein may be true, but without specific references to scientific literature or genetic databases, it is not possible to definitively confirm or deny this claim.\n\n2. UNKNOWN: The statement about the lengths of the isoforms (2.6 kb and 4.3 kb) detected by Northern blot analyses is specific and could be confirmed with molecular data, but without access to the relevant scientific literature or data, it is not possible to verify the accuracy of these figures.\n\n3. UNKNOWN: The information about the deduced amino acid sequence and the molecular weight of the protein requires access to bioinformatics data or scientific literature for verification.\n\n4. UNKNOWN: The statement about the N-terminal portion of the hAspH protein differs from the bovine AspH protein is again very specific and would require comparison of the sequences from human and bovine proteins to confirm or refute, which cannot be done without access to the necessary scientific data.\n\n5. UNKNOWN: The information about the molecular weight of the in vitro transcribed and translated protein, and its detection in Western blot analyses with specific antibodies, is empirical data that would need to be checked against experimental results found in scientific publications or reports. Without this information, the veracity of the statement cannot be determined.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "vicuna-13b_response": "Empagliflozin was approved by the FDA on October 25, 2019.",
    "vicuna-13b_fact_raw": "1. Empagliflozin was approved by the FDA on October 25, 2019.",
    "vicuna-13b_fact": [
      "Empagliflozin was approved by the FDA on October 25, 2019."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Empagliflozin was approved by the FDA on August 1, 2014.",
    "vicuna-13b_judge": [
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "vicuna-13b_response": "The results of loss of the protein Lon1 in the plant Arabidopsis have not been specifically mentioned in the given document. However, the document provides information on the characterization of protein degradation rate and its determinants in the Arabidopsis thaliana rosette using 15N labeling approaches. The study found that the degradation rate of proteins in Arabidopsis varies from several hours to several months and is influenced by protein complex membership and specific protein domains. The study also identified rapidly degrading subunits in plastids and proteins whose degradation rate changed in different leaves of the rosette, correlated with leaf growth rate. The document also mentions the calculation of protein turnover energy costs in different leaves and their key determinants within the proteome.",
    "vicuna-13b_fact_raw": "1. The degradation rate of proteins in Arabidopsis can range from several hours to several months.\n2. Protein complex membership and specific protein domains influence the protein degradation rate in Arabidopsis.\n3. Rapidly degrading protein subunits were identified in the plastids of Arabidopsis.\n4. The degradation rate of proteins changes in different leaves of the Arabidopsis rosette and correlates with leaf growth rate.\n5. The study included calculation of protein turnover energy costs in different leaves of Arabidopsis and identified key determinants within the proteome.",
    "vicuna-13b_fact": [
      "The degradation rate of proteins in Arabidopsis can range from several hours to several months.",
      "Protein complex membership and specific protein domains influence the protein degradation rate in Arabidopsis.",
      "Rapidly degrading protein subunits were identified in the plastids of Arabidopsis.",
      "The degradation rate of proteins changes in different leaves of the Arabidopsis rosette and correlates with leaf growth rate.",
      "The study included calculation of protein turnover energy costs in different leaves of Arabidopsis and identified key determinants within the proteome."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The degradation rate of proteins can indeed range from several hours to several months in various organisms, including Arabidopsis, as it depends on various factors such as protein function, localization, and structure.\n2. TRUE: It is well-established that protein complex membership and specific protein domains can influence the protein degradation rate in many organisms, so this is likely true for Arabidopsis as well.\n3. TRUE: Studies have shown that rapidly degrading protein subunits can be identified in various organelles, including plastids, so this statement is plausible for Arabidopsis.\n4. TRUE: It is reasonable that the degradation rate of proteins might change in different leaves of the Arabidopsis rosette and correlate with factors like leaf growth rate, as developmental stage can influence protein stability and turnover.\n5. TRUE: The calculation of protein turnover energy costs, along with identifying key determinants within the proteome, is a plausible component of comprehensive studies on protein degradation in different leaves of Arabidopsis.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "vicuna-13b_response": "Answer: Yes, a linker histone exists in the yeast genome. The study used genetic and genomic approaches to explore the regulation of linker histone binding in the yeast, Saccharomyces cerevisiae. The study found that increased expression of Hho1, the yeast linker histone, resulted in a severe growth defect, despite only subtle changes in chromatin structure. The growth defect was rescued by mutations that increase histone acetylation. Genome-wide analysis of linker histone occupancy revealed an inverse correlation with histone tail acetylation in both yeast and mouse embryonic stem cells. These results suggest that histone acetylation negatively regulates linker histone binding in S. cerevisiae and other organisms and provide important insight into how chromatin structure is regulated and maintained to both facilitate and repress transcription.",
    "vicuna-13b_fact_raw": "1. A linker histone exists in the yeast genome of Saccharomyces cerevisiae.\n2. Increased expression of Hho1, the yeast linker histone, can result in a severe growth defect.\n3. The growth defect caused by increased expression of Hho1 in yeast can be rescued by mutations that increase histone acetylation.\n4. There is an inverse correlation between linker histone occupancy and histone tail acetylation in Saccharomyces cerevisiae.\n5. The study found similar patterns of inverse correlation between linker histone occupancy and histone tail acetylation in both yeast and mouse embryonic stem cells.",
    "vicuna-13b_fact": [
      "A linker histone exists in the yeast genome of Saccharomyces cerevisiae.",
      "Increased expression of Hho1, the yeast linker histone, can result in a severe growth defect.",
      "The growth defect caused by increased expression of Hho1 in yeast can be rescued by mutations that increase histone acetylation.",
      "There is an inverse correlation between linker histone occupancy and histone tail acetylation in Saccharomyces cerevisiae.",
      "The study found similar patterns of inverse correlation between linker histone occupancy and histone tail acetylation in both yeast and mouse embryonic stem cells."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The yeast Saccharomyces cerevisiae does not have a canonical linker histone; instead, other proteins like Hho1p fulfill similar roles but are not true homologues to linker histones found in multicellular eukaryotes.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN (Without the specific study reference, it's not possible to verify whether the study found similar patterns in yeast and mouse embryonic stem cells.)",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "vicuna-13b_response": "Based on the provided document, there is no evidence that tomato juice specifically lowers cholesterol levels. The study found that there was a significant reduction in total cholesterol and LDL-C levels in the control group, but no significant differences were observed in the remainder of the assessed parameters. However, the study did find that tomato juice may have favorable effects on lipid metabolism.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "vicuna-13b_response": "Hsp70, a protein chaperone, has been found to interact with ARE (AU-rich elements) substrates in vitro and in vivo. In the in vitro studies, it was found that Hsp70 forms direct, high-affinity complexes with ARE substrates based on the specific recognition of U-rich sequences by both the ATP- and peptide-binding domains. The in vivo studies in HeLa cells showed that suppressing Hsp70 destabilized an ARE reporter mRNA, indicating a novel ARE-directed mRNA-stabilizing role for this protein. Hsp70 also bound and stabilized endogenous ARE-containing mRNAs encoding VEGF and Cox-2, which involved a mechanism that was unaffected by an inhibitor of its protein chaperone function. The stabilization of VEGF mRNA coincided with the accumulation of Hsp70 protein in HL60 promyelocytic leukemia cells recovering from acute thermal stress. The study suggests that the binding and stabilization of selected ARE-containing mRNAs may contribute to the cytoprotective effects of Hsp70 following cellular stress but may also provide a novel mechanism linking constitutively elevated Hsp70 expression to the development of aggressive neoplastic phenotypes.",
    "vicuna-13b_fact_raw": "1. Hsp70 interacts with ARE (AU-rich elements) substrates in vitro and in vivo.\n2. Hsp70 forms direct, high-affinity complexes with ARE substrates based on the recognition of U-rich sequences.\n3. Suppressing Hsp70 in HeLa cells destabilized an ARE reporter mRNA.\n4. Hsp70 can stabilize endogenous ARE-containing mRNAs such as those encoding VEGF and Cox-2.\n5. The stabilization mechanism for ARE-containing mRNAs by Hsp70 is unaffected by an inhibitor of its protein chaperone function.",
    "vicuna-13b_fact": [
      "Hsp70 interacts with ARE (AU-rich elements) substrates in vitro and in vivo.",
      "Hsp70 forms direct, high-affinity complexes with ARE substrates based on the recognition of U-rich sequences.",
      "Suppressing Hsp70 in HeLa cells destabilized an ARE reporter mRNA.",
      "Hsp70 can stabilize endogenous ARE-containing mRNAs such as those encoding VEGF and Cox-2.",
      "The stabilization mechanism for ARE-containing mRNAs by Hsp70 is unaffected by an inhibitor of its protein chaperone function."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Hsp70 is known to interact with AU-rich elements (ARE) substrates both in vitro and in vivo.\n2. TRUE: Hsp70 has been shown to form direct, high-affinity complexes with ARE substrates, and this interaction typically involves recognition of U-rich sequences within the AREs.\n3. TRUE: Experiments where Hsp70 is suppressed in cells, such as HeLa cells, often lead to the destabilization of ARE-containing mRNAs, hence affecting an ARE reporter mRNA as stated.\n4. TRUE: Endogenous ARE-containing mRNAs, such as those for Vascular Endothelial Growth Factor (VEGF) and Cyclooxygenase-2 (Cox-2), have been reported to be stabilized by Hsp70 under certain conditions.\n5. UNKNOWN: The statement about the stabilization mechanism for ARE-containing mRNAs by Hsp70 being unaffected by an inhibitor of its protein chaperone function is difficult to evaluate without specific experimental context or results indicating this. The function of Hsp70 as a chaperone and its mRNA binding ability could be interconnected or separate, and the effect of an inhibitor could very well depend on the specifics of the mechanism, which are not provided here.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "vicuna-13b_response": "Based on the information provided in the document, the Type 2 deiodinase (D2) is present in skeletal muscle. This was determined by the authors' findings that the human D2 messenger RNA is 7-8 kilobases and is expressed in brain, placenta, and skeletal muscle. Additionally, Type 2 deiodinase activity was also present in human skeletal muscle.",
    "vicuna-13b_fact_raw": "1. Type 2 deiodinase (D2) is present in human skeletal muscle.\n2. Human D2 messenger RNA is 7-8 kilobases in length.\n3. D2 messenger RNA is expressed in the brain, placenta, and skeletal muscle.\n4. Type 2 deiodinase activity is found in human skeletal muscle.",
    "vicuna-13b_fact": [
      "Type 2 deiodinase (D2) is present in human skeletal muscle.",
      "Human D2 messenger RNA is 7-8 kilobases in length.",
      "D2 messenger RNA is expressed in the brain, placenta, and skeletal muscle.",
      "Type 2 deiodinase activity is found in human skeletal muscle."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: Human D2 messenger RNA is approximately 1.6 kilobases in length.\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "vicuna-13b_response": "Inflammatory caspases are a group of enzymes that play a crucial role in regulating inflammation and cell death. The document mentions two specific caspases, caspase-1 and caspase-12, and their involvement in regulating intestinal homeostasis, inflammation, and tumorigenesis.\nCaspase-1 is a key player in the inflammasome, a complex that plays a crucial role in the induction of inflammation in response to cellular stress. The document states that caspase-1(-/-) mice exhibited defects in mucosal tissue repair and succumbed rapidly after dextran sulfate sodium administration. This phenotype was rescued by administration of exogenous interleukin-18 and was partially reproduced in mice deficient in the inflammasome adaptor ASC. These findings suggest that caspase-1 is necessary for the induction of inflammation in response to injury, which is necessary for tissue repair and maintenance of immune tolerance.\nOn the other hand, caspase-12 is an inflammatory caspase that is involved in the regulation of inflammation and repair in the gut. The document states that caspase-12(-/-) mice were resistant to acute colitis and showed signs of enhanced repair. Together with their increased inflammatory response, the enhanced repair response of Casp12(-/-) mice rendered them more susceptible to colorectal cancer induced by azoxymethane (AOM)+DSS. These findings suggest that caspase-12 plays a critical role in regulating the balance between inflammation and repair in the gut and that dysregulation of caspase-12 can lead to the development of colorectal cancer.\nIn summary, the inflammatory caspases, specifically caspase-1 and caspase-12, play a crucial role in regulating inflammation and cell death in the gut. They are essential effectors of inflammation and cell death and are involved in the regulation of intestinal homeostasis, inflammation, and tumorigenesis.",
    "vicuna-13b_fact_raw": "1. Caspase-1 is involved in the inflammasome, a complex that induces inflammation in response to cellular stress.\n2. Caspase-1(-/-) mice showed defects in mucosal tissue repair and rapid succumbing after dextran sulfate sodium administration, which could be rescued by administration of exogenous interleukin-18.\n3. Caspase-12 is an inflammatory caspase involved in the regulation of inflammation and repair in the gut.\n4. Caspase-12(-/-) mice were resistant to acute colitis and showed enhanced repair capabilities.\n5. Dysregulation of caspase-12 can lead to the development of colorectal cancer.",
    "vicuna-13b_fact": [
      "Caspase-1 is involved in the inflammasome, a complex that induces inflammation in response to cellular stress.",
      "Caspase-1(-/-) mice showed defects in mucosal tissue repair and rapid succumbing after dextran sulfate sodium administration, which could be rescued by administration of exogenous interleukin-18.",
      "Caspase-12 is an inflammatory caspase involved in the regulation of inflammation and repair in the gut.",
      "Caspase-12(-/-) mice were resistant to acute colitis and showed enhanced repair capabilities.",
      "Dysregulation of caspase-12 can lead to the development of colorectal cancer."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Caspase-12 is an anti-inflammatory protease that usually reduces the inflammasome activation. It is caspase-1 that is involved in inflammasome-related inflammation.\n4. FALSE [correction]: Since caspase-12 is an anti-inflammatory caspase, the statement about caspase-12(-/-) mice being resistant to acute colitis and showing enhanced repair capabilities could be misleading or incorrect without specific context. Typically, caspase-1 or related inflammatory caspases might be implicated in such a finding.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "vicuna-13b_response": "Based on the information provided in Document-0, there is no direct link between the Aurora B kinase and the polycomb protein ring1B. The document discusses a novel splicing variant of Aurora C, named Aurora C-SV, which is expressed at high levels in human testis and regulates chromosome segregation and cytokinesis. The document also mentions that Aurora C-SV associates with chromosomes during prophase and metaphase, and then transfers to the central spindle midzone and the cortex where the contract ring forms during the transition from anaphase to telophase. However, it does not mention anything about the link between Aurora C-SV and ring1B.",
    "vicuna-13b_fact_raw": "1. There is no direct link between the Aurora B kinase and the polycomb protein ring1B according to Document-0.\n2. Document-0 discusses a novel splicing variant of Aurora C, named Aurora C-SV.\n3. Aurora C-SV is expressed at high levels in human testis.\n4. Aurora C-SV regulates chromosome segregation and cytokinesis.\n5. Aurora C-SV associates with chromosomes during prophase and metaphase and transfers to the central spindle midzone and the cortex during the transition from anaphase to telophase.",
    "vicuna-13b_fact": [
      "There is no direct link between the Aurora B kinase and the polycomb protein ring1B according to Document-0.",
      "Document-0 discusses a novel splicing variant of Aurora C, named Aurora C-SV.",
      "Aurora C-SV is expressed at high levels in human testis.",
      "Aurora C-SV regulates chromosome segregation and cytokinesis.",
      "Aurora C-SV associates with chromosomes during prophase and metaphase and transfers to the central spindle midzone and the cortex during the transition from anaphase to telophase."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout having access to the hypothetical \"Document-0,\" I am unable to confirm or correct the statements provided about Aurora B kinase, polycomb protein ring1B, and Aurora C-SV. The information given does not offer enough context or evidence to determine the truthfulness of the statements.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are overlapping alternative donor sites and acceptor sites. These sites are confirmed to be alternatively spliced as both sites in a pair are supported by a protein, by a full-length mRNA, or by expressed sequence tags (ESTs) from at least two independent clone libraries. Overlapping sites may clash with consensus requirements and pairs with a site shift of four nucleotides are the most abundant, despite the frameshift in the protein-coding region that they introduce. The site usage in pairs is usually uneven, and the major site is more frequently conserved in other mammalian genomes. Overlapping alternative donor sites and acceptor sites may have different functional roles: alternative splicing of overlapping acceptor sites leads mainly to microvariations in protein sequences; whereas alternative donor sites often lead to frameshifts and thus either yield major differences in the protein sequence and structure, or generate nonsense-mediated decay-inducing mRNA isoforms likely involved in regulated unproductive splicing pathways.",
    "vicuna-13b_fact_raw": "1. Overlapping alternative donor sites and acceptor sites are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates.\n2. Both sites in a pair of overlapping alternative donor and acceptor sites are supported by a protein, by a full-length mRNA, or by expressed sequence tags (ESTs) from at least two independent clone libraries.\n3. Pairs with a site shift of four nucleotides are the most abundant among overlapping splice site motifs, despite their introduction of a frameshift in the protein-coding region.\n4. The major site in pairs of overlapping alternative donor and acceptor sites is more frequently conserved in other mammalian genomes.\n5. Alternative splicing of overlapping acceptor sites typically leads to microvariations in protein sequences, whereas alternative donor sites can lead to frameshifts or generate nonsense-mediated decay-inducing mRNA isoforms.",
    "vicuna-13b_fact": [
      "Overlapping alternative donor sites and acceptor sites are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates.",
      "Both sites in a pair of overlapping alternative donor and acceptor sites are supported by a protein, by a full-length mRNA, or by expressed sequence tags (ESTs) from at least two independent clone libraries.",
      "Pairs with a site shift of four nucleotides are the most abundant among overlapping splice site motifs, despite their introduction of a frameshift in the protein-coding region.",
      "The major site in pairs of overlapping alternative donor and acceptor sites is more frequently conserved in other mammalian genomes.",
      "Alternative splicing of overlapping acceptor sites typically leads to microvariations in protein sequences, whereas alternative donor sites can lead to frameshifts or generate nonsense-mediated decay-inducing mRNA isoforms."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "vicuna-13b_response": "The event that results in the acetylation of S6K1 is growth factor stimulation.",
    "vicuna-13b_fact_raw": "1. The acetylation of S6K1 is a result of growth factor stimulation.",
    "vicuna-13b_fact": [
      "The acetylation of S6K1 is a result of growth factor stimulation."
    ],
    "vicuna-13b_judge_raw": "UNKNOWN",
    "vicuna-13b_judge": [
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "vicuna-13b_response": "Based on the given information, it appears that the cause of episodic ataxia type 6 (EA6) is not yet fully understood. While EA2 is known to be caused by mutations in the calcium channel (CACNA1A) and typically begins before age 20 years, the molecular basis of late-onset EA2 is still unclear. However, a case of late-onset EA2 has been associated with a first multiple-base pair insertion in CACNA1A, which suggests that genetically induced reduction in calcium channel function may be associated with late-onset EA2. It is important to note that this information is based on a single case study and further research is needed to determine the underlying cause of EA6.",
    "vicuna-13b_fact_raw": "1. Episodic ataxia type 6 (EA6) is a condition with an unclearly understood cause.\n2. Episodic ataxia type 2 (EA2) is known to be caused by mutations in the CACNA1A gene.\n3. EA2 typically begins before the age of 20 years.\n4. A case of late-onset EA2 has been associated with a multiple-base pair insertion in the CACNA1A gene.\n5. A genetically induced reduction in calcium channel function may be associated with late-onset EA2, as suggested by a single case study.",
    "vicuna-13b_fact": [
      "Episodic ataxia type 6 (EA6) is a condition with an unclearly understood cause.",
      "Episodic ataxia type 2 (EA2) is known to be caused by mutations in the CACNA1A gene.",
      "EA2 typically begins before the age of 20 years.",
      "A case of late-onset EA2 has been associated with a multiple-base pair insertion in the CACNA1A gene.",
      "A genetically induced reduction in calcium channel function may be associated with late-onset EA2, as suggested by a single case study."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "vicuna-13b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add a methyl group to chromosomes, which plays a role in regulating gene expression. In the study, 12 chitinases (Chts) and chitin deacetylases (CDAs) were identified in Bactrocera dorsalis using genome-wide searching and transcript profiling. These enzymes are important for chitin metabolism in insects. The study also found that all 12 Cht-related proteins contained at least one chitinase catalytic domain, but only four possessed chitin-binding domains. The phylogenetic analysis revealed that seven CDAs were clustered into five groups, and all had one chitin deacetylase catalytic domain. However, only six exhibited chitin-binding domains. The study also showed that the transcript levels of the 12 Cht-related genes and 6 CDA genes varied considerably among eggs, larvae, pupae and adults, as well as among different tissues of larvae and adults.",
    "vicuna-13b_fact_raw": "1. Chromomethylases are present in animal genomes.\n2. Chromomethylases are enzymes that add a methyl group to chromosomes, which helps regulate gene expression.\n3. In Bactrocera dorsalis, 12 chitinases and chitin deacetylases were identified using genome-wide searching and transcript profiling.\n4. All 12 chitinase-related proteins in the study contained at least one chitinase catalytic domain, while only four possessed chitin-binding domains.\n5. The study indicated that the transcript levels of the 12 chitinase-related genes and 6 chitin deacetylase genes varied among different developmental stages and tissues in Bactrocera dorsalis.",
    "vicuna-13b_fact": [
      "Chromomethylases are present in animal genomes.",
      "Chromomethylases are enzymes that add a methyl group to chromosomes, which helps regulate gene expression.",
      "In Bactrocera dorsalis, 12 chitinases and chitin deacetylases were identified using genome-wide searching and transcript profiling.",
      "All 12 chitinase-related proteins in the study contained at least one chitinase catalytic domain, while only four possessed chitin-binding domains.",
      "The study indicated that the transcript levels of the 12 chitinase-related genes and 6 chitin deacetylase genes varied among different developmental stages and tissues in Bactrocera dorsalis."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Chromomethylases are typically found in plant genomes, not animal genomes.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The correction to statement 1 assumes the common understanding that chromomethylases are predominantly identified in plants. For statements 3, 4, and 5, without access to the specific study being referenced, it is not possible to verify the information provided about Bactrocera dorsalis (the oriental fruit fly). Therefore, those statements' veracity remains unknown.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "vicuna-13b_response": "The package for transcription factor binding sites (TFBS) analysis available in R/Bioconductor is TFBSTools. It is a toolkit for handling TFBS profile matrices, scanning sequences and alignments, including whole genomes, and querying the JASPAR database. The package is implemented in R and available under GPL-2 license from the Bioconductor website. The authors can be contacted at [ge.tan09@imperial.ac.uk](mailto:ge.tan09@imperial.ac.uk) and supplementary data are available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. TFBSTools is available for transcription factor binding sites (TFBS) analysis in R/Bioconductor.\n2. TFBSTools includes functionalities for handling TFBS profile matrices and scanning sequences.\n3. TFBSTools can scan alignments, including whole genomes.\n4. TFBSTools allows querying the JASPAR database.\n5. The package is available under the GPL-2 license from the Bioconductor website.",
    "vicuna-13b_fact": [
      "TFBSTools is available for transcription factor binding sites (TFBS) analysis in R/Bioconductor.",
      "TFBSTools includes functionalities for handling TFBS profile matrices and scanning sequences.",
      "TFBSTools can scan alignments, including whole genomes.",
      "TFBSTools allows querying the JASPAR database.",
      "The package is available under the GPL-2 license from the Bioconductor website."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "vicuna-13b_response": "I'm sorry, but Document-0 does not contain any information about clinical trials for prevention of sarcopenia. It describes a meeting of an international task force that discussed guidelines for designing and executing randomized clinical trials of sarcopenia treatments, including practical issues, regulatory issues, and the need for standardization and harmonization. The document does not provide a list of specific clinical trials for prevention of sarcopenia.",
    "vicuna-13b_fact_raw": "1. Document-0 describes a meeting of an international task force that discussed guidelines for designing and executing randomized clinical trials of sarcopenia treatments.\n2. The mentioned task force meeting addressed practical issues, regulatory issues, and the need for standardization and harmonization of sarcopenia treatment trials.\n3. Document-0 does not provide a list of specific clinical trials for the prevention of sarcopenia.",
    "vicuna-13b_fact": [
      "Document-0 describes a meeting of an international task force that discussed guidelines for designing and executing randomized clinical trials of sarcopenia treatments.",
      "The mentioned task force meeting addressed practical issues, regulatory issues, and the need for standardization and harmonization of sarcopenia treatment trials.",
      "Document-0 does not provide a list of specific clinical trials for the prevention of sarcopenia."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout additional context or the actual content of \"Document-0,\" it is not possible to accurately assess the truthfulness of these statements.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "vicuna-13b_response": "The database of molecular recognition features in membrane proteins is mpMoRFsDB. It is a publicly available mySQL database that provides information on small, intrinsically disordered regions in proteins that undergo a disorder-to-order transition on binding to their partners. These regions are involved in protein-protein interactions and may function as the initial step in molecular recognition. The database contains information on transmembrane and peripheral membrane proteins, and the position of transmembrane protein MoRFs is determined in relation to a protein's topology. The database also includes a Jmol applet for visualization of the structures. It can be accessed at <http://bioinformatics.biol.uoa.gr/mpMoRFsDB>.",
    "vicuna-13b_fact_raw": "1. mpMoRFsDB is the database of molecular recognition features in membrane proteins.\n2. mpMoRFsDB is a publicly available mySQL database.\n3. The database focuses on small, intrinsically disordered regions in proteins that bind to their partners going from disorder to order.\n4. mpMoRFsDB includes information on both transmembrane and peripheral membrane proteins.\n5. mpMoRFsDB provides a Jmol applet for the visualization of protein structures.",
    "vicuna-13b_fact": [
      "mpMoRFsDB is the database of molecular recognition features in membrane proteins.",
      "mpMoRFsDB is a publicly available mySQL database.",
      "The database focuses on small, intrinsically disordered regions in proteins that bind to their partners going from disorder to order.",
      "mpMoRFsDB includes information on both transmembrane and peripheral membrane proteins.",
      "mpMoRFsDB provides a Jmol applet for the visualization of protein structures."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: mpMoRFsDB is not specifically known to be a mySQL database as no details have been provided regarding its underlying database management system.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "vicuna-13b_response": "Yes, rivaroxaban is metabolized in the kidneys. The PBPK model developed in the study indicates that rivaroxaban is metabolized by the cytochrome P450 (CYP) 3A4/5 and 2J2 pathways and excreted via the kidneys. The model also suggests that the renal clearance of rivaroxaban is an important factor affecting its pharmacokinetics. The predicted fold increase of rivaroxaban AUC values when combined with inhibitors such as ketoconazole, ritonavir, and clarithromycin were 2.3, 2.2, and 1.3, respectively, indicating that these drugs can affect the metabolism of rivaroxaban.",
    "vicuna-13b_fact_raw": "1. Rivaroxaban is metabolized by the cytochrome P450 (CYP) 3A4/5 and 2J2 pathways.\n2. Rivaroxaban is excreted via the kidneys.\n3. Renal clearance is an important factor affecting the pharmacokinetics of rivaroxaban.\n4. Combining rivaroxaban with the inhibitor ketoconazole can lead to a predicted 2.3 fold increase of rivaroxaban AUC values.\n5. Combining rivaroxaban with the inhibitors ritonavir and clarithromycin can lead to predicted fold increases of rivaroxaban AUC values of 2.2 and 1.3, respectively.",
    "vicuna-13b_fact": [
      "Rivaroxaban is metabolized by the cytochrome P450 (CYP) 3A4/5 and 2J2 pathways.",
      "Rivaroxaban is excreted via the kidneys.",
      "Renal clearance is an important factor affecting the pharmacokinetics of rivaroxaban.",
      "Combining rivaroxaban with the inhibitor ketoconazole can lead to a predicted 2.3 fold increase of rivaroxaban AUC values.",
      "Combining rivaroxaban with the inhibitors ritonavir and clarithromycin can lead to predicted fold increases of rivaroxaban AUC values of 2.2 and 1.3, respectively."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Combining rivaroxaban with the inhibitor ketoconazole can lead to a predicted increase in rivaroxaban AUC values, but the exact fold increase can vary. Clinical guidelines suggest significant increases can be expected but do not typically give a precise multiple such as 2.3 fold.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "vicuna-13b_response": "Based on the given document, it is stated that the expression of TRalpha 1, TRalpha 2, TRbeta 1 and T3-regulated genes was studied in different parts of the heart, namely the right atrium (RA), left ventricular wall (LVW) and apex. The results indicate that AM and Dron affected TR expression in the RA similarly by decreasing TRalpha 1 and beta 1 expression by about 50%. In the LVW, AM and Dron decreased TRbeta 1 and, interestingly, AM increased TRalpha 1. In the apex, AM also increased TRalpha 2. The changes seen in T3-dependent gene expression are reminiscent of foetal reprogramming. Therefore, it can be concluded that TRalpha 2 is regulated by AM and Dron in the heart, specifically in the left ventricular wall and apex, where AM increased TRalpha 1 and TRalpha 2 expression, respectively.",
    "vicuna-13b_fact_raw": "1. TRalpha1, TRalpha2, TRbeta1, and T3-regulated gene expressions were studied in different parts of the heart.\n2. In the right atrium (RA), AM and Dron decreased TRalpha1 and TRbeta1 expression by about 50%.\n3. In the left ventricular wall (LVW), AM and Dron treatment resulted in a decrease in TRbeta1 expression.\n4. Also in the LVW, AM treatment increased TRalpha1 expression.\n5. In the apex of the heart, AM treatment increased TRalpha2 expression.",
    "vicuna-13b_fact": [
      "TRalpha1, TRalpha2, TRbeta1, and T3-regulated gene expressions were studied in different parts of the heart.",
      "In the right atrium (RA), AM and Dron decreased TRalpha1 and TRbeta1 expression by about 50%.",
      "In the left ventricular wall (LVW), AM and Dron treatment resulted in a decrease in TRbeta1 expression.",
      "Also in the LVW, AM treatment increased TRalpha1 expression.",
      "In the apex of the heart, AM treatment increased TRalpha2 expression."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to specific scientific findings related to gene expression studies in various parts of the heart, involving TRalpha1, TRalpha2, TRbeta1, and possibly thyroid hormone T3. Without the original context or access to the specific scientific study these statements are referencing, it is not possible to verify the accuracy of these claims. Therefore, the truthfulness of these statements remains unknown.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "vicuna-13b_response": "There are several biomedical question answering systems available, including:\n1. BM25: A statistical model that uses a combination of term frequency and inverse document frequency to rank the relevance of documents to a given question.\n2. DROP: A neural model that uses a combination of pre-trained language models and fine-tuned biomedical models to answer questions.\n3. HITS: A statistical model that uses a combination of term frequency, inverse document frequency, and a bias term to rank the relevance of documents to a given question.\n4. PRECIS: A neural model that uses a combination of pre-trained language models and fine-tuned biomedical models to answer questions.\n5. PAG: A neural model that uses a combination of pre-trained language models and fine-tuned biomedical models to answer questions.\nIn addition to these systems, there are also several other systems that use various combinations of machine learning and natural language processing techniques to answer biomedical questions.",
    "vicuna-13b_fact_raw": "1. BM25 is a statistical model that ranks the relevance of documents to questions using term frequency and inverse document frequency.\n2. DROP is a neural model that combines pre-trained language models with fine-tuned biomedical models to answer questions.\n3. HITS is a statistical model that employs term frequency, inverse document frequency, and a bias term for ranking document relevance to questions.\n4. PRECIS is a neural model that combines pre-trained language models with fine-tuned biomedical models for question answering.\n5. PAG is a neural model using pre-trained language models in conjunction with fine-tuned biomedical models to answer questions.",
    "vicuna-13b_fact": [
      "BM25 is a statistical model that ranks the relevance of documents to questions using term frequency and inverse document frequency.",
      "DROP is a neural model that combines pre-trained language models with fine-tuned biomedical models to answer questions.",
      "HITS is a statistical model that employs term frequency, inverse document frequency, and a bias term for ranking document relevance to questions.",
      "PRECIS is a neural model that combines pre-trained language models with fine-tuned biomedical models for question answering.",
      "PAG is a neural model using pre-trained language models in conjunction with fine-tuned biomedical models to answer questions."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: BM25 is indeed a statistical ranking function that uses term frequency (TF) and inverse document frequency (IDF) to rank documents based on their relevance to a given query.\n2. UNKNOWN: Without more context, it's difficult to ascertain the specifics of the DROP model. The name \"DROP\" is not well-known as a standard acronym or name for a neural model in the field.\n3. FALSE [correction]: HITS (Hyperlink-Induced Topic Search) is not primarily concerned with term frequency and inverse document frequency. Instead, it is an algorithm used to rate web pages, based on a concept of \"hubs\" and \"authorities.\"\n4. UNKNOWN: Similar to the DROP model, without additional context, it is challenging to verify the details of the PRECIS model. PRECIS was traditionally understood as a system of bibliographic control and indexing, not a neural model.\n5. UNKNOWN: PAG is not a well-known acronym or standard name for a neural model specifically aimed at biomedical question answering. Additional context is needed to verify this statement.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "vicuna-13b_response": "The transcription factor that activates the betalain pathway is not specified in the given information. However, it is mentioned that a biased agonist for the type 1 parathyroid hormone (PTH)-PTH-related protein receptor (PTH1R), (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr), activates the beta-arrestin pathway but not the classic G protein signaling pathway. In mice, PTH-betaarr induces anabolic bone formation, as does the nonselective agonist PTH(1-34), which activates both mechanisms. The results show that a biased agonist selective for the beta-arrestin pathway can elicit a response in vivo distinct from that elicited by nonselective agonists.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "vicuna-13b_response": "The preferred technologies for the enrichment of phosphorylated peptides in global quantitative phosphoproteomics are:\n1. TiO(2) phosphopeptide pre-enrichment step\n2. IMAC (SIMAC) for multi- and mono-phosphorylated peptide separation\n3. HILIC for mono-phosphorylated peptide separation\nThese technologies are used in a multi-dimensional phosphoproteomics strategy for comprehensive large-scale phosphoproteomics, which combines well-established enrichment and fraction methods. The strategy includes an initial TiO(2) phosphopeptide pre-enrichment step followed by post-fractionation using IMAC (SIMAC) and HILIC to separate multi- and mono-phosphorylated peptides, respectively. The advantages of this strategy include high specificity, reduced sample preparation workload, low adsorptive losses, and the ability to identify and quantify phosphopeptides with high sensitivity and specificity. This strategy has been demonstrated by quantitative investigation of early interferon-signaling in low quantities of insulinoma cells, resulting in the identification of ~6600 unique phosphopeptides from 300 g of peptides/condition with an enrichment specificity of >94%.",
    "vicuna-13b_fact_raw": "1. TiO2 (Titanium dioxide) is used as a pre-enrichment step for phosphopeptides in global quantitative phosphoproteomics.\n2. IMAC (Immobilized Metal Affinity Chromatography), specifically SIMAC (Sequential Elution from IMAC), is used for separating multi- and mono-phosphorylated peptides.\n3. HILIC (Hydrophilic Interaction Liquid Chromatography) is used for separating mono-phosphorylated peptides in phosphoproteomic analyses.\n4. The outlined strategy has enabled the identification of approximately 6600 unique phosphopeptides from 300 g of peptides per condition.\n5. An enrichment specificity of greater than 94% was achieved using this comprehensive large-scale phosphoproteomics strategy.",
    "vicuna-13b_fact": [
      "TiO2 (Titanium dioxide) is used as a pre-enrichment step for phosphopeptides in global quantitative phosphoproteomics.",
      "IMAC (Immobilized Metal Affinity Chromatography), specifically SIMAC (Sequential Elution from IMAC), is used for separating multi- and mono-phosphorylated peptides.",
      "HILIC (Hydrophilic Interaction Liquid Chromatography) is used for separating mono-phosphorylated peptides in phosphoproteomic analyses.",
      "The outlined strategy has enabled the identification of approximately 6600 unique phosphopeptides from 300 g of peptides per condition.",
      "An enrichment specificity of greater than 94% was achieved using this comprehensive large-scale phosphoproteomics strategy."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The use of TiO2 (Titanium dioxide) for pre-enrichment in global quantitative phosphoproteomics is a specific detail that could be true, but without a reference to a source that confirms this use, it's hard to determine its accuracy.\n\n2. TRUE: IMAC is indeed a technique used in phosphoproteomics to separate phosphopeptides, and SIMAC is a refinement of this technique that allows for sequential elution, which can help distinguish between multi- and mono-phosphorylated peptides.\n\n3. TRUE: HILIC is commonly used in phosphoproteomics for the separation of peptides, including mono-phosphorylated peptides, due to its ability to retain highly polar molecules.\n\n4. UNKNOWN: The identification of approximately 6600 unique phosphopeptides from a specific amount of starting material is a detailed quantitative claim that requires specific experimental results to confirm, so without access to the particular study or publication, the truth of this statement can't be determined.\n\n5. UNKNOWN: The claim of achieving an enrichment specificity of greater than 94% is also a quantitative detail which would need specific experimental evidence to confirm. Without the data or source, the accuracy of this statement remains unknown.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "vicuna-13b_response": "The disorder described in the report is rated by Palmini classification.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it is stated that new data on viruses isolated from patients with subacute thyroiditis have been reported. The document describes the characteristic morphological, cytological, some physico-chemical and biological features of the isolated viruses and discusses a possible role of these viruses in human and animal health disorders. However, it is also mentioned that the isolated viruses remain unclassified so far.\nTherefore, based on the information provided in Document-0, it cannot be concluded whether viruses are involved in the etiology of human subacute thyroiditis or not. Further research and studies are needed to determine the role of viruses in the development of this condition.",
    "vicuna-13b_fact_raw": "1. New data have been reported on viruses isolated from patients with subacute thyroiditis.\n2. The document describes the isolated viruses' characteristic morphological, cytological, some physico-chemical, and biological features.\n3. A possible role of these viruses in human and animal health disorders is discussed in the document.\n4. The isolated viruses from patients with subacute thyroiditis remain unclassified.\n5. It is undetermined whether viruses are involved in the etiology of human subacute thyroiditis based on the information provided.",
    "vicuna-13b_fact": [
      "New data have been reported on viruses isolated from patients with subacute thyroiditis.",
      "The document describes the isolated viruses' characteristic morphological, cytological, some physico-chemical, and biological features.",
      "A possible role of these viruses in human and animal health disorders is discussed in the document.",
      "The isolated viruses from patients with subacute thyroiditis remain unclassified.",
      "It is undetermined whether viruses are involved in the etiology of human subacute thyroiditis based on the information provided."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nWithout specific information from the actual document or data, I cannot accurately verify the truthfulness of statements 1 through 4. However, statement 5 asserts uncertainty which is consistent with the language (\"it is undetermined\"), so it is reasonable to assume it is true given no contradicting information.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "vicuna-13b_response": "Based on the provided information, it appears that STAT3 is involved in EIF2AK2-dependent suppression of autophagy. The study found that inhibitors of STAT3 stimulated autophagic flux and that genetic inhibition of STAT3 resulted in increased autophagy, while overexpression of STAT3 variants inhibited autophagy. Additionally, the study found that the SH2 domain of STAT3 interacts with the catalytic domain of EIF2AK2 and that pharmacological and genetic inhibition of STAT3 stimulated the activating phosphorylation of EIF2AK2, leading to eIF2 hyperphosphorylation. The study also found that PKR depletion inhibited autophagy and that STAT3-targeting chemicals and palmitate caused the disruption of inhibitory STAT3-PKR interactions, followed by PKR-dependent eIF2 phosphorylation, which facilitates autophagy induction. Overall, these findings suggest that STAT3 and PKR act as interacting partners to regulate autophagy and that STAT3 inhibition can induce autophagy through the PKR-dependent pathway.",
    "vicuna-13b_fact_raw": "1. STAT3 is involved in EIF2AK2-dependent suppression of autophagy according to a study mentioned.\n2. Inhibitors of STAT3 stimulated autophagic flux based on the study findings.\n3. Genetic inhibition of STAT3 resulted in increased autophagy, as found by the study.\n4. The SH2 domain of STAT3 interacts with the catalytic domain of EIF2AK2.\n5. Pharmacological and genetic inhibition of STAT3 stimulated the activating phosphorylation of EIF2AK2, leading to eIF2 hyperphosphorylation.",
    "vicuna-13b_fact": [
      "STAT3 is involved in EIF2AK2-dependent suppression of autophagy according to a study mentioned.",
      "Inhibitors of STAT3 stimulated autophagic flux based on the study findings.",
      "Genetic inhibition of STAT3 resulted in increased autophagy, as found by the study.",
      "The SH2 domain of STAT3 interacts with the catalytic domain of EIF2AK2.",
      "Pharmacological and genetic inhibition of STAT3 stimulated the activating phosphorylation of EIF2AK2, leading to eIF2 hyperphosphorylation."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe provided statements relate to specific scientific findings about STAT3, its relation to EIF2AK2, and the effects on autophagy. Without access to the study mentioned, it's impossible to determine the accuracy of these statements. Moreover, they contain specialized knowledge that requires expert understanding in molecular biology and the context of the particular research study.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "vicuna-13b_response": "Theatre is a software tool used for genomic analysis, specifically for the comparative analysis of genomic sequences to identify motifs that are likely to be involved in the regulation of gene expression. It serves as an interface to commonly used sequence analysis tools and biological sequence databases to determine or predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in families of DNA sequences. The information is displayed in a user-friendly manner, allowing users to easily understand the results and identify patterns that might not have been noticed otherwise. Additionally, Theatre can produce publication-quality color hardcopies of the predicted features in aligned genomic sequences.\nThe case study provided in the document demonstrates the use of Theatre in analyzing the p53 promoter region of four mammalian species and two fish species. The results show differences in the p53 promoter region of the four mammals and the two fish species, highlighting the utility of Theatre in comparing and contrasting genomic sequences across different species.\nTo use Theatre, users can access the tool at <http://www.hgmp.mrc.ac.uk/Registered/Webapp/theatre/>.",
    "vicuna-13b_fact_raw": "1. Theatre is a software tool used for genomic analysis.\n2. Theatre is designed to identify motifs in genomic sequences that may be involved in the regulation of gene expression.\n3. The tool serves as an interface for commonly used sequence analysis tools and biological sequence databases.\n4. Theatre allows the prediction of positions for coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.\n5. The case study mentioned showed the use of Theatre to analyze the p53 promoter region in both mammalian and fish species.",
    "vicuna-13b_fact": [
      "Theatre is a software tool used for genomic analysis.",
      "Theatre is designed to identify motifs in genomic sequences that may be involved in the regulation of gene expression.",
      "The tool serves as an interface for commonly used sequence analysis tools and biological sequence databases.",
      "Theatre allows the prediction of positions for coding regions, repetitive sequences, and transcription factor binding sites in DNA sequences.",
      "The case study mentioned showed the use of Theatre to analyze the p53 promoter region in both mammalian and fish species."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Theatre is not a known software tool for genomic analysis. The statement may be referring to a different tool or could be completely fabricated.\n2. UNKNOWN: Since Theatre is not recognized as a genomic analysis tool, it's unknown whether it's designed to identify motifs. If referring to a real but differently named tool, that tool's functionality remains unspecified.\n3. UNKNOWN: With no knowledge of a genomic analysis tool called Theatre, it's impossible to confirm if it serves as an interface for sequence analysis tools and databases.\n4. UNKNOWN: The functions of Theatre cannot be confirmed as true since the existence or specifics of such a software tool is not established.\n5. UNKNOWN: Without confirmation of the existence of the software tool Theatre, the veracity of a case study involving its use cannot be determined.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "vicuna-13b_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is not explicitly mentioned in the given information. However, it can be inferred that the new implementation of the Smith-Waterman algorithm on a Graphics Processing Units (GPU) has achieved a performance of 21.4 GCUPS, which is 1.13 times better than the state-of-the-art implementation on an NVIDIA GTX 275 graphics card. Therefore, the execution time of the algorithm would depend on the specific sequences being aligned, the hardware used, and other factors that affect the performance of the algorithm.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "vicuna-13b_response": "Based on the information provided in the document, FLVCR1 is a member of the SLC22 protein family, which is a part of the SLC (Solute carriers) superfamily of polyspecific membrane transporters responsible for uptake of a wide range of organic anions and cations, including numerous endo- and xenobiotics. The document states that the zebrafish has 20 slc22 genes, which are organized in the same functional subgroups as human SLC22 members. The document also states that the tissue expression profiles of slc22 transcripts were analyzed using qRT-PCR determinations in nine zebrafish tissues, and that the analysis revealed high expression of oct1 in kidney, especially in females, followed by oat3 and oat2c in females, oat2e in males and orctl4 in females. Based on this information, it can be inferred that FLVCR1 is a member of the SLC22 protein family and is likely to be involved in the uptake of a wide range of organic anions and cations in zebrafish.",
    "vicuna-13b_fact_raw": "1. FLVCR1 is a member of the SLC22 protein family.\n2. The SLC22 protein family is part of the SLC superfamily of polyspecific membrane transporters.\n3. Members of the SLC22 protein family are responsible for the uptake of a wide range of organic anions and cations, including endo- and xenobiotics.\n4. The zebrafish has 20 slc22 genes organized in the same functional subgroups as human SLC22 members.\n5. The tissue expression profiles of slc22 transcripts in zebrafish were analyzed using qRT-PCR determinations in nine different tissues.",
    "vicuna-13b_fact": [
      "FLVCR1 is a member of the SLC22 protein family.",
      "The SLC22 protein family is part of the SLC superfamily of polyspecific membrane transporters.",
      "Members of the SLC22 protein family are responsible for the uptake of a wide range of organic anions and cations, including endo- and xenobiotics.",
      "The zebrafish has 20 slc22 genes organized in the same functional subgroups as human SLC22 members.",
      "The tissue expression profiles of slc22 transcripts in zebrafish were analyzed using qRT-PCR determinations in nine different tissues."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nNote: The number of slc22 genes in zebrafish and their functional subgroup organization could vary or could have been revealed through research unknown to the cutoff knowledge, and specific details about the methods used to analyze tissue expression profiles, such as the use of qRT-PCR and the number of tissues analyzed, would require specific literature or data and are beyond general knowledge.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "vicuna-13b_response": "GATA-1, a transcription factor, has been found to interact with other transcription factors and chromatin remodeling cofactors through the biotinylation tagging approach. The biotinylation tagging approach involves the use of biotin and streptavidin to capture and identify proteins that interact with a specific protein of interest. In this case, GATA-1 was tagged with a short peptide sequence and biotinylated by the bacterial BirA biotin ligase. The biotinylated GATA-1 was then captured by streptavidin, and the associated proteins were identified by mass spectrometry. This approach led to the characterization of several distinct GATA-1 complexes with other transcription factors and chromatin remodeling cofactors that are involved in the activation and repression of gene targets.",
    "vicuna-13b_fact_raw": "1. GATA-1 is a transcription factor that interacts with other transcription factors and chromatin remodeling cofactors.\n2. The biotinylation tagging approach uses biotin and streptavidin to identify proteins interacting with a target protein.\n3. In studying GATA-1 interactions, GATA-1 was tagged with a short peptide sequence.\n4. Bacterial BirA biotin ligase was used to biotinylate GATA-1.\n5. Mass spectrometry was used to identify the proteins associated with biotinylated GATA-1.",
    "vicuna-13b_fact": [
      "GATA-1 is a transcription factor that interacts with other transcription factors and chromatin remodeling cofactors.",
      "The biotinylation tagging approach uses biotin and streptavidin to identify proteins interacting with a target protein.",
      "In studying GATA-1 interactions, GATA-1 was tagged with a short peptide sequence.",
      "Bacterial BirA biotin ligase was used to biotinylate GATA-1.",
      "Mass spectrometry was used to identify the proteins associated with biotinylated GATA-1."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAll statements are consistent with common methodologies and experimental approaches used in molecular biology to study protein interactions, assuming they refer to the specific context of an experiment using these techniques for GATA-1.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "vicuna-13b_response": "The outcome of TAF10 interacting with the GATA1 transcription factor is not specified in the given information. However, the document states that TAF10 interacts directly with GATA1 and is enriched on the GATA1 locus in human fetal erythroid cells. Additionally, the document suggests a cross talk between canonical TFIID and SAGA complexes and cell-specific transcription activators during development and differentiation.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "vicuna-13b_response": "Yes, there are Decision support systems for chronic pain management. These systems use algorithms and other tools to assist healthcare providers in making treatment decisions for patients with chronic pain. One example of such a system is the computer-based decision support (CBDS) system mentioned in Document-0, which was found to enhance the ability of primary care physicians (PCPs) to manage chronic pain. The system generated structured summaries for 50 chronic pain patients referred to a pain clinic and used by a pain specialist to determine appropriate pain therapy. The system then sent letters to the referring physicians outlining these recommendations. Separately, five board-certified PCPs used the CBDS system to \"treat\" the 50 cases and were found to prescribe additional pain therapy in 85% of evaluations, with a medical appropriateness score of 5.5 +/- 0.1. The use of such systems may improve the ability of PCPs to manage chronic pain and may also facilitate screening of consults to optimize specialist utilization. However, it is important to note that the success of these systems depends on the quality of the data entered and the accuracy of the algorithms used.",
    "vicuna-13b_fact_raw": "1. Decision support systems exist to assist healthcare providers in making treatment decisions for patients with chronic pain.\n2. The computer-based decision support (CBDS) system generated structured summaries for 50 chronic pain patients referred to a pain clinic.\n3. The CBDS system was used by a pain specialist to determine appropriate pain therapy.\n4. After using the CBDS system, five board-certified primary care physicians prescribed additional pain therapy in 85% of evaluations.\n5. A medical appropriateness score of 5.5 +/- 0.1 was associated with the actions taken by the primary care physicians using the CBDS system.",
    "vicuna-13b_fact": [
      "Decision support systems exist to assist healthcare providers in making treatment decisions for patients with chronic pain.",
      "The computer-based decision support (CBDS) system generated structured summaries for 50 chronic pain patients referred to a pain clinic.",
      "The CBDS system was used by a pain specialist to determine appropriate pain therapy.",
      "After using the CBDS system, five board-certified primary care physicians prescribed additional pain therapy in 85% of evaluations.",
      "A medical appropriateness score of 5.5 +/- 0.1 was associated with the actions taken by the primary care physicians using the CBDS system."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Decision support systems are indeed tools that exist to assist healthcare providers, including in the area of treatment decisions for patients with chronic pain.\n2. UNKNOWN: Without specific context or reference, it is not possible to determine the truth or falsity of this statement about the number of patients for whom the system generated structured summaries.\n3. UNKNOWN: This statement's validity depends on the specific CBDS system being referenced, which is not given, so it cannot be confirmed as true or false definitively.\n4. UNKNOWN: This statement is specific in nature and implies results from a study or implementation, but without additional context or the source of this information, its truth cannot be verified.\n5. UNKNOWN: This statement involves statistical information that is precise, but without context or a source, the validity of the medical appropriateness score's association with physician actions cannot be confirmed.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "vicuna-13b_response": "Based on the provided document, the subcellular localization of the protein angiogenin is the perinuclear region at 30 minutes after internalization in aortic smooth muscle cells. It is also observed to disperse throughout the cytoplasm after internalization. In conditions favoring receptor-mediated endocytosis, internalization of iodinated angiogenin showed a first peak at 5 minutes and then further increased for up to 24 hours. The half-life of the molecule, calculated as 12 hours in chase experiments, could contribute to its intracellular accumulation. In addition to the 14-kDa protein, a 8.7-kDa fragment was observed at 24 hours, and three fragments with molecular mass of 10.5, 8.7, and 6.1 kDa were detected at 48 hours. The data suggest that human angiogenin is specifically internalized and processed by aortic smooth muscle cells.",
    "vicuna-13b_fact_raw": "1. Angiogenin localizes to the perinuclear region in aortic smooth muscle cells 30 minutes after internalization.\n2. Angiogenin is dispersed throughout the cytoplasm after internalization.\n3. Internalization of iodinated angiogenin in conditions favoring receptor-mediated endocytosis exhibits a first peak at 5 minutes and then increases up until 24 hours.\n4. The half-life of angiogenin is calculated as 12 hours in chase experiments.\n5. A 8.7-kDa fragment of angiogenin is observed at 24 hours, and fragments with molecular masses of 10.5, 8.7, and 6.1 kDa are detected at 48 hours.",
    "vicuna-13b_fact": [
      "Angiogenin localizes to the perinuclear region in aortic smooth muscle cells 30 minutes after internalization.",
      "Angiogenin is dispersed throughout the cytoplasm after internalization.",
      "Internalization of iodinated angiogenin in conditions favoring receptor-mediated endocytosis exhibits a first peak at 5 minutes and then increases up until 24 hours.",
      "The half-life of angiogenin is calculated as 12 hours in chase experiments.",
      "A 8.7-kDa fragment of angiogenin is observed at 24 hours, and fragments with molecular masses of 10.5, 8.7, and 6.1 kDa are detected at 48 hours."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correctness of these statements depends on specific experimental results or data related to angiogenin behavior, internalization, and degradation, as well as its half-life which would have to be verified with scientific research. Without access to the specific passage or scientific study from which these statements are extracted, it is not possible to validate or correct them.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "vicuna-13b_response": "Based on the provided information, Ranolazine (RAN) has been found to have greater effects on the recovery of cardiac function in diabetic rat hearts following myocardial infarction (MI) compared to nondiabetic hearts. The study showed that RAN improved the recovery of function in both nondiabetic and diabetic postinfarcted hearts, but the effect was greater and achieved statistical significance only in the diabetic group. The study found that RAN resulted in increased levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted hearts without changes in the activation of mitogen-activated protein kinases (MAPKs; p38 MAPK, c-Jun N-terminal kinase, and extracellular signal-regulated kinase).\nIn addition, the study found that in diabetic hearts, RAN resulted in a significant increase in the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban (a target of Akt signaling) and increased levels of phosphorylated calcium-regulated adenosine monophosphate-activated protein kinase (AMPK). These findings suggest that RAN may activate the Akt/mTOR and AMPK signaling pathways in diabetic hearts, which may contribute to its beneficial effects on cardiac function.\nIt is important to note that the study was conducted on rats and the results may not necessarily translate to humans. However, the study provides insights into the potential mechanisms by which RAN may affect kinase signaling activation in the heart, particularly in diabetic patients. Further research is needed to confirm these findings and to fully understand the effects of RAN on cardiac function in diabetic patients.",
    "vicuna-13b_fact_raw": "1. Ranolazine (RAN) has been found to improve the recovery of cardiac function in diabetic rat hearts following myocardial infarction more than in nondiabetic hearts.\n2. The effect of RAN on improving recovery of function achieved statistical significance only in the diabetic group in the study.\n3. Ranolazine resulted in increased levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted rat hearts.\n4. Ranolazine did not change the activation of mitogen-activated protein kinases (MAPKs) in infarcted rat hearts.\n5. The study indicated that ranolazine may activate the Akt/mTOR and AMPK signaling pathways in diabetic hearts.",
    "vicuna-13b_fact": [
      "Ranolazine (RAN) has been found to improve the recovery of cardiac function in diabetic rat hearts following myocardial infarction more than in nondiabetic hearts.",
      "The effect of RAN on improving recovery of function achieved statistical significance only in the diabetic group in the study.",
      "Ranolazine resulted in increased levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted rat hearts.",
      "Ranolazine did not change the activation of mitogen-activated protein kinases (MAPKs) in infarcted rat hearts.",
      "The study indicated that ranolazine may activate the Akt/mTOR and AMPK signaling pathways in diabetic hearts."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific study or passage these statements refer to, I cannot verify the accuracy of the statements provided. The statements are very specific to the results of a particular scientific study on the effects of Ranolazine on rat hearts, and the information required to confirm or correct these statements would only be found within that study or related expert analysis.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it can be inferred that the regulation of Vsr endonuclease is not independent of the growth phase of bacteria. The document suggests that Vsr endonuclease has been hypothesized to regulate mutation in stationary-phase cells, and overexpression of Vsr does increase the stationary-phase reversion of a Lac-frameshift allele. However, the absence of Vsr has no effect on stationary-phase mutation. Therefore, it can be concluded that Vsr endonuclease has a role in regulating mutation in stationary-phase cells, and its effects are not artifactual.\nIt is important to note that the regulation of Vsr endonuclease may not be the same in all growth phases of bacteria, and further research is needed to fully understand its role in bacterial growth and mutation.",
    "vicuna-13b_fact_raw": "1. The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.\n2. Vsr endonuclease has been hypothesized to regulate mutation in stationary-phase cells.\n3. Overexpression of Vsr increases the stationary-phase reversion of a Lac-frameshift allele.\n4. The absence of Vsr does not affect stationary-phase mutation.\n5. The effects of Vsr endonuclease are not artifactual.",
    "vicuna-13b_fact": [
      "The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.",
      "Vsr endonuclease has been hypothesized to regulate mutation in stationary-phase cells.",
      "Overexpression of Vsr increases the stationary-phase reversion of a Lac-frameshift allele.",
      "The absence of Vsr does not affect stationary-phase mutation.",
      "The effects of Vsr endonuclease are not artifactual."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The absence of Vsr may affect stationary-phase mutation, as Vsr endonuclease is involved in DNA repair which can influence mutation rates.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "vicuna-13b_response": "Answer: The computational tool for the prediction of beta-barrel transmembrane proteins is called \"transFold\". It is a novel method that uses pairwise interstrand residue statistical potentials derived from globular proteins to predict the supersecondary structure of transmembrane beta-barrel proteins. The algorithm employs a generalized hidden Markov model, specifically a multitape S-attribute grammar, to describe potential beta-barrel supersecondary structures. It then computes the minimum free energy beta-barrel structure by dynamic programming. This approach differs from other methods that use traditional machine learning to solve this problem, as it does not require a training phase on known TMB structures and is the first to explicitly capture and predict long-range interactions. The transFold algorithm outperforms previous programs for predicting TMBs on smaller proteins (less than or equal to 200 residues) and matches their performance for straightforward recognition of longer proteins. However, it performs well for multimeric porins when an important functional motif in loops is initially identified. The transFold algorithm can be used to make contact predictions and location predictions for sequences predicted to form TMBs.",
    "vicuna-13b_fact_raw": "1. The computational tool \"transFold\" is used for the prediction of beta-barrel transmembrane proteins.\n2. \"transFold\" uses pairwise interstrand residue statistical potentials derived from globular proteins.\n3. It employs a generalized hidden Markov model, specifically a multitape S-attribute grammar.\n4. The \"transFold\" algorithm computes the minimum free energy beta-barrel structure by dynamic programming.\n5. The algorithm does not require a training phase on known TMB structures.",
    "vicuna-13b_fact": [
      "The computational tool \"transFold\" is used for the prediction of beta-barrel transmembrane proteins.",
      "\"transFold\" uses pairwise interstrand residue statistical potentials derived from globular proteins.",
      "It employs a generalized hidden Markov model, specifically a multitape S-attribute grammar.",
      "The \"transFold\" algorithm computes the minimum free energy beta-barrel structure by dynamic programming.",
      "The algorithm does not require a training phase on known TMB structures."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: \"transFold\" uses pairwise interstrand residue statistical potentials derived from known transmembrane beta-barrel (TMB) proteins, not globular proteins.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The \"transFold\" algorithm typically requires a training phase on known TMB structures to derive the statistical potentials necessary for its predictions.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "vicuna-13b_response": "The Galassi classification is used for bipolar affective disorder. The paper describes three measures of the period prevalence of bipolar affective disorder, based upon treatment with lithium, two of which are of the \"unobtrusive\" type. The agreement was found between the three approaches, and the utility of these for general use is discussed. Lithium carbonate is a prophylactic drug used for bipolar affective disorder, and its use has been demonstrated beyond doubt for this disorder. The occurrence of mania in this disorder enables this aspect of the condition to be used as a marker.",
    "vicuna-13b_fact_raw": "1. The Galassi classification is used for bipolar affective disorder.\n2. The Galassi paper discusses three measures of the period prevalence of bipolar affective disorder based on treatment with lithium.\n3. Lithium carbonate is used as a prophylactic drug for bipolar affective disorder.\n4. The occurrence of mania in bipolar affective disorder can be used as a marker.",
    "vicuna-13b_fact": [
      "The Galassi classification is used for bipolar affective disorder.",
      "The Galassi paper discusses three measures of the period prevalence of bipolar affective disorder based on treatment with lithium.",
      "Lithium carbonate is used as a prophylactic drug for bipolar affective disorder.",
      "The occurrence of mania in bipolar affective disorder can be used as a marker."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The Galassi classification is used for temporal bone pneumatization patterns in otology, not for bipolar affective disorder.\n2. FALSE [correction]: The statement appears to be false since the Galassi classification is not associated with bipolar affective disorder but rather with otology. Therefore, it would not discuss measures of the period prevalence of bipolar affective disorder based on treatment with lithium.\n3. TRUE: Lithium carbonate is indeed used as a prophylactic drug for bipolar affective disorder to stabilize mood and prevent the recurrence of both manic and depressive episodes.\n4. TRUE: The occurrence of mania can be used as a marker since it is a defining feature of bipolar I disorder. In clinical settings, the presence of a manic episode may be a significant marker for the diagnosis of bipolar affective disorder.",
    "vicuna-13b_judge": [
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "vicuna-13b_response": "Shapiro Syndrome is a rare neurological disorder characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum. It is a rare entity and fewer than 100 cases have been reported so far. The syndrome can present with episodes of generalized hyperhidrosis, hypotonia, impaired consciousness, and hypothermia with onset before the first year of age. The diagnosis of Shapiro Syndrome is often difficult and requires a combination of clinical, electroencephalographic, and neuroimaging data.\nThe patient in the case study described in the document is a 4-year-old patient with early-onset Shapiro Syndrome Variant. The patient had episodes characterized by generalized hyperhidrosis, hypotonia, impaired consciousness, and hypothermia with onset before the first year of age. The electroencephalogram (EEG) showed rhythmic low- to medium-voltage theta waves without clear epileptiform activity. The brain MRI was normal, and Shapiro Syndrome Variant was hypothesized. The patient was started on treatment with pizotifen, and after 2 years, the patient showed a reduction in frequency and duration of episodes.\nThe case is of particular interest to specialists because Shapiro Syndrome Variant is a rare syndrome, and the patient had a very early onset of symptoms. The report also provides information on the treatment with pizotifen therapy, which produced a good response in the patient.\nIn summary, Shapiro Syndrome is a rare neurological disorder characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum. It is a rare entity and fewer than 100 cases have been reported so far. The diagnosis of Shapiro Syndrome is often difficult and requires a combination of clinical, electroencephalographic, and neuroimaging data. The patient in the case study described in the document is a 4-year-old patient with early-onset Shapiro Syndrome Variant, and the report provides information on the treatment with pizotifen",
    "vicuna-13b_fact_raw": "1. Shapiro Syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum.\n2. Fewer than 100 cases of Shapiro Syndrome have been reported as of the knowledge cutoff date.\n3. Symptoms of Shapiro Syndrome can onset before the first year of age.\n4. Diagnosis of Shapiro Syndrome requires clinical, electroencephalographic, and neuroimaging data.\n5. Pizotifen therapy has been reported to reduce the frequency and duration of episodes in a patient with Shapiro Syndrome Variant.",
    "vicuna-13b_fact": [
      "Shapiro Syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and agenesis of the corpus callosum.",
      "Fewer than 100 cases of Shapiro Syndrome have been reported as of the knowledge cutoff date.",
      "Symptoms of Shapiro Syndrome can onset before the first year of age.",
      "Diagnosis of Shapiro Syndrome requires clinical, electroencephalographic, and neuroimaging data.",
      "Pizotifen therapy has been reported to reduce the frequency and duration of episodes in a patient with Shapiro Syndrome Variant."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Shapiro Syndrome is characterized by the triad of recurrent spontaneous hypothermia, hyperhidrosis, and corpus callosum agenesis is not a necessary component for the diagnosis, although it can be present in some cases, so this component of the statement should not have been included.\n2. TRUE \n3. TRUE \n4. TRUE \n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "vicuna-13b_response": "Based on the given information, the disease linked to mutations within BRAG1 is not specified. The report describes a 36-week male infant who suffered from congenital central hypoventilation syndrome (CCHS) and Hirschsprung's disease, and further mutations of BRAF oncogene were found. The report suggests a novel association between these mutations and the shared qualities of tumorigenesis between BRAF and PHOX2B. Therefore, the information provided does not directly answer the question about the disease linked to mutations within BRAG1.",
    "vicuna-13b_fact_raw": "1. The report describes a case of a 36-week male infant with congenital central hypoventilation syndrome (CCHS).\n2. The same male infant also suffered from Hirschsprung's disease.\n3. Mutations of the BRAF oncogene were found in the mentioned infant.\n4. The report suggests an association between these mutations and tumorigenesis.\n5. The association involves the BRAF oncogene and PHOX2B.",
    "vicuna-13b_fact": [
      "The report describes a case of a 36-week male infant with congenital central hypoventilation syndrome (CCHS).",
      "The same male infant also suffered from Hirschsprung's disease.",
      "Mutations of the BRAF oncogene were found in the mentioned infant.",
      "The report suggests an association between these mutations and tumorigenesis.",
      "The association involves the BRAF oncogene and PHOX2B."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE (as CCHS and Hirschsprung's disease can co-occur in some cases; however, without specific details from the actual report, this cannot be confirmed)\n3. FALSE [correction]: Mutations of the PHOX2B gene, not the BRAF oncogene, are commonly associated with congenital central hypoventilation syndrome (CCHS).\n4. UNKNOWN (The statement is vague because it does not specify which mutations and tumorigenesis it's referring to, though BRAF mutations are associated with tumor formation in general)\n5. FALSE [correction]: The commonly known association with CCHS involves the PHOX2B gene, not the BRAF oncogene. However, without specifying what the report suggests about BRAF and PHOX2B, it is difficult to correct this statement accurately. If the report does suggest a direct association between BRAF and PHOX2B, that would be new information not commonly recognized in the medical literature by my knowledge cutoff.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "vicuna-13b_response": "The main inhibitor of protein phosphatase 1 (PP1) is Protein phosphatase inhibitor-1 (PPI-1). PPI-1 is a heat-stable and large Stokes radius protein that lacks extensive secondary structures, suggesting that it may interact with many proteins or ligands during stress conditions. PPI-1 has been shown to act as a protective molecule, inhibiting protein aggregation and guarding E. coli cells against various stresses. Therefore, PPI-1 has a physiological function as a protective molecule as well as a regulator of protein serine/threonine phosphatases.",
    "vicuna-13b_fact_raw": "1. Protein phosphatase inhibitor-1 (PPI-1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PPI-1 is a heat-stable protein.\n3. PPI-1 has a large Stokes radius.\n4. PPI-1 lacks extensive secondary structures.\n5. PPI-1 acts as a protective molecule that inhibits protein aggregation and guards E. coli cells against various stresses.",
    "vicuna-13b_fact": [
      "Protein phosphatase inhibitor-1 (PPI-1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PPI-1 is a heat-stable protein.",
      "PPI-1 has a large Stokes radius.",
      "PPI-1 lacks extensive secondary structures.",
      "PPI-1 acts as a protective molecule that inhibits protein aggregation and guards E. coli cells against various stresses."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without additional context, it's unclear if Protein Phosphatase Inhibitor-1 (PPI-1) is the main inhibitor of Protein Phosphatase 1 (PP1). There may be other inhibitors as well, and \"main\" could be context-dependent.\n2. TRUE: Protein phosphatase inhibitor-1 (PPI-1) is generally described as heat-stable, which is a characteristic feature of this type of molecule.\n3. UNKNOWN: The Stokes radius is a measure of a molecule's effective size in solution. Without specific data or reference, its unclear whether PPI-1 has a large Stokes radius.\n4. UNKNOWN: Without specific structural data on PPI-1, it is difficult to confirm the extent of its secondary structures.\n5. FALSE [correction]: The description of PPI-1 protecting E. coli cells against various stresses and inhibiting protein aggregation appears to be a mix-up with heat shock proteins or molecular chaperones. PPI-1 is generally not described this way; instead, its main known function is the inhibition of protein phosphatase 1 (PP1).",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "vicuna-13b_response": "Adaptive (stationary-phase) mutagenesis is a process that occurs in the gram-positive bacterium Bacillus subtilis, and it is subject to regulation involving at least two of the genes that are involved in the regulation of post-exponential phase prokaryotic differentiation, i.e., comA and comK. A functional RecA protein was not required for this type of mutagenesis, which suggests that a small subpopulation(s) of the culture is involved in adaptive mutagenesis and that this subpopulation(s) is hypermutable. The existence of such a hypermutable subpopulation(s) raises important considerations with respect to evolution, the development of specific mutations, the nature of bacterial populations, and the level of communication among bacteria in an ecological niche.",
    "vicuna-13b_fact_raw": "1. Adaptive mutagenesis in Bacillus subtilis is regulated by at least the comA and comK genes.\n2. A functional RecA protein is not required for adaptive mutagenesis in Bacillus subtilis.\n3. Adaptive mutagenesis in Bacillus subtilis involves a hypermutable subpopulation(s) of the bacterial culture.\n4. The hypermutable subpopulation(s) involved in adaptive mutagenesis in Bacillus subtilis has implications for evolution and bacterial population dynamics.",
    "vicuna-13b_fact": [
      "Adaptive mutagenesis in Bacillus subtilis is regulated by at least the comA and comK genes.",
      "A functional RecA protein is not required for adaptive mutagenesis in Bacillus subtilis.",
      "Adaptive mutagenesis in Bacillus subtilis involves a hypermutable subpopulation(s) of the bacterial culture.",
      "The hypermutable subpopulation(s) involved in adaptive mutagenesis in Bacillus subtilis has implications for evolution and bacterial population dynamics."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: A functional RecA protein is typically required for adaptive mutagenesis in Bacillus subtilis, as RecA is involved in the regulation of genetic processes such as DNA repair and recombination that can lead to mutations.\n3. TRUE\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "vicuna-13b_response": "Erucism is a condition that is caused by exposure to the venom-containing spines of the gum leaf skeletoniser (Uraba lugens), a recently established caterpillar in the Auckland region. The spines can cause adverse reactions in humans, characterized by a stinging sensation, itching, and the formation of wheals. These symptoms are similar to those of contact dermatitis, and medical practitioners in the Auckland region should consider exposure to U. lugens in the differential diagnosis of contact dermatitis.",
    "vicuna-13b_fact_raw": "1. Erucism is caused by exposure to the venom-containing spines of the gum leaf skeletoniser (Uraba lugens).\n2. The gum leaf skeletoniser (Uraba lugens) caterpillar is a recently established species in the Auckland region.\n3. Symptoms of erucism include a stinging sensation, itching, and the formation of wheals.\n4. These symptoms of erucism are similar to those of contact dermatitis.\n5. Medical practitioners in the Auckland region are advised to consider exposure to Uraba lugens in the differential diagnosis of contact dermatitis.",
    "vicuna-13b_fact": [
      "Erucism is caused by exposure to the venom-containing spines of the gum leaf skeletoniser (Uraba lugens).",
      "The gum leaf skeletoniser (Uraba lugens) caterpillar is a recently established species in the Auckland region.",
      "Symptoms of erucism include a stinging sensation, itching, and the formation of wheals.",
      "These symptoms of erucism are similar to those of contact dermatitis.",
      "Medical practitioners in the Auckland region are advised to consider exposure to Uraba lugens in the differential diagnosis of contact dermatitis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nResponse explanations:\n1. Erucism is a type of dermatitis caused by caterpillars or moths, and the gum leaf skeletoniser has spines that can cause such reactions.\n2. Without a specific time reference or detailed information on the establishment of the species in the Auckland region, it's not possible to determine the truth of this statement.\n3. The symptoms listed are consistent with reactions to caterpillar or moth spines, which can cause erucism.\n4. The symptoms of erucism can be similar to those of contact dermatitis, which is an irritation of the skin from contact with various substances.\n5. It is reasonable advice for medical practitioners to consider various causes of dermatitis, including environmental factors like exposure to certain caterpillars, in their diagnosis.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "vicuna-13b_response": "Hydrochlorothiazide (HCTZ) is a diuretic medication that is primarily used to treat hypertension, also known as high blood pressure. It is a thiazide diuretic, which works by increasing the excretion of sodium and chloride ions in the urine, leading to a decrease in blood volume and a decrease in blood pressure. HCTZ belongs to class IV of the Biopharmaceutics Classification System, which refers to drugs that are poorly absorbed from the gastrointestinal tract and are primarily eliminated by urinary excretion.\nThe use of HCTZ is contraindicated in patients with anuria, hypersensitivity to hydrochlorothiazide, or other sulfonamide-derived drugs. Additionally, it should be used with caution in patients with impaired hepatic or renal function, and in patients who are volume depleted, such as those with heart failure or cirrhosis. HCTZ should also be used with caution in patients who are taking other medications that can affect potassium levels, such as potassium-sparing diuretics or ACE inhibitors.\nIn conclusion, HCTZ is a diuretic medication used to treat hypertension, but its use is contraindicated in certain patients and should be used with caution in others. It is important to consider the patient's medical history and other medications they are taking when prescribing or using HCTZ.",
    "vicuna-13b_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat hypertension, which is high blood pressure.\n2. HCTZ is a thiazide diuretic that works by increasing the excretion of sodium and chloride in the urine.\n3. The drug belongs to class IV of the Biopharmaceutics Classification System, indicating it is poorly absorbed from the gastrointestinal tract and primarily eliminated by urinary excretion.\n4. HCTZ is contraindicated in patients with anuria or hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs.\n5. HCTZ should be used with caution in patients with impaired hepatic or renal function, and in those who are volume depleted, such as with heart failure or cirrhosis.",
    "vicuna-13b_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat hypertension, which is high blood pressure.",
      "HCTZ is a thiazide diuretic that works by increasing the excretion of sodium and chloride in the urine.",
      "The drug belongs to class IV of the Biopharmaceutics Classification System, indicating it is poorly absorbed from the gastrointestinal tract and primarily eliminated by urinary excretion.",
      "HCTZ is contraindicated in patients with anuria or hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs.",
      "HCTZ should be used with caution in patients with impaired hepatic or renal function, and in those who are volume depleted, such as with heart failure or cirrhosis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The drug belongs to class I of the Biopharmaceutics Classification System, indicating it is highly soluble and highly permeable.\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "vicuna-13b_response": "Yes, silicon has been used in the treatment of incontinence. In the document, it states that transurethral submission therapy of polydimethylsiloxane (PDS) was used to treat incontinence after radical prostatectomy (RP). The patients had a mean duration of incontinence after RP of 28 months and were treated with PDS injection therapy. The treatment resulted in five patients being dry after the therapy, one patient improving significantly but still requiring two pads during the day, and three patients requiring a second injection. The mean of 7.5 mL of PDS was used per patient, and the side-effects of therapy were minimal. The conclusion of the study is that because PDS has excellent biocompatibility, few side-effects or complications, transurethral injection therapy using silicone particles is a justifiable procedure for treating incontinence after RP.",
    "vicuna-13b_fact_raw": "1. Silicon, in the form of polydimethylsiloxane (PDS), has been used in the treatment of incontinence after radical prostatectomy.\n2. The patients treated with PDS injection therapy had a mean duration of incontinence after radical prostatectomy of 28 months.\n3. Five patients became dry after receiving PDS injection therapy for incontinence.\n4. The mean amount of PDS used per patient for the treatment was 7.5 mL.\n5. The study concluded that transurethral injection therapy using silicone particles is a justifiable procedure for treating incontinence after radical prostatectomy due to PDS's excellent biocompatibility and minimal side effects or complications.",
    "vicuna-13b_fact": [
      "Silicon, in the form of polydimethylsiloxane (PDS), has been used in the treatment of incontinence after radical prostatectomy.",
      "The patients treated with PDS injection therapy had a mean duration of incontinence after radical prostatectomy of 28 months.",
      "Five patients became dry after receiving PDS injection therapy for incontinence.",
      "The mean amount of PDS used per patient for the treatment was 7.5 mL.",
      "The study concluded that transurethral injection therapy using silicone particles is a justifiable procedure for treating incontinence after radical prostatectomy due to PDS's excellent biocompatibility and minimal side effects or complications."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThese statements regard specific medical treatments and outcomes that aren't common knowledge, and without the specific research or study referenced, it's impossible to determine the truthfulness of these claims. Medical studies and treatments are very specific, and the data can vary from one study to another. Therefore, without the original context or access to the relevant medical literature, the validity of these statements cannot be ascertained.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "vicuna-13b_response": "The association between the moon cycle and the rupture risk of intracranial aneurysms has been studied in the past. A study conducted on 111 patients with aneurysmal subarachnoid hemorrhage (SAH) found that there was an incidence peak for aneurysm rupture during the phase of new moon, which was statistically significant (p < 0.001) (Document-0). This suggests that the moon cycle may affect the incidence of intracranial aneurysm rupture, with the new moon being associated with an increased risk of aneurysmal SAH. However, the study did not observe any seasonal variation in the incidence of SAH.\nIt is important to note that this is just one study and more research is needed to confirm the association between the moon cycle and the rupture risk of intracranial aneurysms. Additionally, other factors such as stress, physical activity, and changes in blood pressure may also play a role in the rupture of intracranial aneurysms and should be considered when evaluating the risk of rupture.",
    "vicuna-13b_fact_raw": "1. A study was conducted on 111 patients with aneurysmal subarachnoid hemorrhage (SAH).\n2. The study found a statistically significant incidence peak for aneurysm rupture during the new moon phase.\n3. The significance level of the study's finding was p < 0.001.\n4. The study did not find any seasonal variation in the incidence of aneurysmal subarachnoid hemorrhage (SAH).\n5. The study suggested the moon cycle might impact the incidence of intracranial aneurysm rupture.",
    "vicuna-13b_fact": [
      "A study was conducted on 111 patients with aneurysmal subarachnoid hemorrhage (SAH).",
      "The study found a statistically significant incidence peak for aneurysm rupture during the new moon phase.",
      "The significance level of the study's finding was p < 0.001.",
      "The study did not find any seasonal variation in the incidence of aneurysmal subarachnoid hemorrhage (SAH).",
      "The study suggested the moon cycle might impact the incidence of intracranial aneurysm rupture."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe reason for labelling the first four statements as UNKNOWN is because without specific information or a reference to the actual study and its published results, it is impossible to verify the details regarding the number of patients, findings related to the moon phase, significance levels, or seasonal variations. However, for statement 5, since it mentions the study suggested a possibility (the impact of the moon cycle on aneurysm rupture), this could be true if such a suggestion or hypothesis was indeed proposed in the study's conclusions or discussions, which is a common practice in scientific studies looking to explain their findings or propose areas for further research.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "vicuna-13b_response": "Yes, the HuR protein is known to regulate the splicing process. The document states that \"although it serves as a model of RNA-protein interactions, many features of HuR's interactions with RNAs remain unknown,\" and \"we revealed several thousand novel HuR-interacting RNAs, including hundreds of non-coding RNAs such as natural antisense transcripts from stress responsive loci.\" Additionally, the document states that \"we provided evidence that secondary structures of 66-75 nucleotides enhance HuR's recognition of its specific RNA targets composed of short primary sequence patterns,\" and \"we observed a striking enrichment for members of ubiquitin ligase pathways among the HuR-interacting mRNAs, suggesting a new role for HuR in the regulation of protein degradation to mirror its known function in protein translation.\" These findings suggest that HuR protein regulates the splicing process by interacting with RNAs and affecting their stability and translation.",
    "vicuna-13b_fact_raw": "1. The HuR protein is known to regulate the splicing process.\n2. The document reveals that several thousand novel HuR-interacting RNAs were discovered, including hundreds of non-coding RNAs.\n3. The document provides evidence that secondary structures of 66-75 nucleotides enhance HuR protein's recognition of RNA targets.\n4. There is an enrichment for members of ubiquitin ligase pathways among the HuR-interacting mRNAs.\n5. The document suggests a new role for HuR in the regulation of protein degradation.",
    "vicuna-13b_fact": [
      "The HuR protein is known to regulate the splicing process.",
      "The document reveals that several thousand novel HuR-interacting RNAs were discovered, including hundreds of non-coding RNAs.",
      "The document provides evidence that secondary structures of 66-75 nucleotides enhance HuR protein's recognition of RNA targets.",
      "There is an enrichment for members of ubiquitin ligase pathways among the HuR-interacting mRNAs.",
      "The document suggests a new role for HuR in the regulation of protein degradation."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The HuR protein is known to regulate gene expression post-transcriptionally, but it is primarily associated with mRNA stability and translation, rather than splicing.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "vicuna-13b_response": "The known functions for the prothymosin alpha c-terminal peptide are related to its role as a nuclear protein. Two lines of evidence have been presented that strongly implicate prothymosin alpha as a nuclear protein:\n1. In COS cells transfected with the human prothymosin alpha gene, copious amounts of prothymosin alpha were present in sealed nuclei obtained by treating these cells with cytochalasin B and enucleating them centrifugally.\n2. Constructs in which human prothymosin alpha nucleic acid sequences were fused in-frame either near the amino terminus of the beta-galactosidase gene in pCH110 or at the carboxyl terminus, when expressed in COS cells, resulted in nuclear localization of the fusion protein. Indirect immunofluorescence in situ was used as the assay. The basic cluster of amino acids at the carboxyl terminus of prothymosin alpha, TKKQKT, has been identified as part of the nuclear targeting signal, whereas the basic cluster of amino acids situated within the thymosin alpha 1 sequence at the amino terminus failed to effect nuclear transport.",
    "vicuna-13b_fact_raw": "1. Prothymosin alpha c-terminal peptide functions as a nuclear protein.\n2. Human prothymosin alpha, when overexpressed in COS cells, can be found in large amounts within the nuclei.\n3. Enucleating COS cells transfected with the human prothymosin alpha gene results in the presence of prothymosin alpha in sealed nuclei.\n4. Fusion proteins of human prothymosin alpha nucleic acid sequences and beta-galactosidase gene result in nuclear localization when expressed in COS cells.\n5. The amino acid sequence TKKQKT at the carboxyl terminus of prothymosin alpha is part of the nuclear targeting signal.",
    "vicuna-13b_fact": [
      "Prothymosin alpha c-terminal peptide functions as a nuclear protein.",
      "Human prothymosin alpha, when overexpressed in COS cells, can be found in large amounts within the nuclei.",
      "Enucleating COS cells transfected with the human prothymosin alpha gene results in the presence of prothymosin alpha in sealed nuclei.",
      "Fusion proteins of human prothymosin alpha nucleic acid sequences and beta-galactosidase gene result in nuclear localization when expressed in COS cells.",
      "The amino acid sequence TKKQKT at the carboxyl terminus of prothymosin alpha is part of the nuclear targeting signal."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Prothymosin alpha is primarily a nuclear protein, but it is not specifically referred to as a \"c-terminal peptide.\" The statement may have meant to simply describe prothymosin alpha (ProT) as a nuclear protein without the specification of a \"c-terminal peptide.\"\n2. TRUE: Human prothymosin alpha is known to localize predominantly to the nucleus when overexpressed in cells, such as COS cells.\n3. UNKNOWN: This statement is unclear because enucleation typically refers to the removal of the nucleus from a cell. If COS cells transfected with the human prothymosin alpha gene were enucleated, prothymosin alpha would not be expected to be present inside nuclei as the nuclei themselves would have been removed. However, the presence of prothymosin alpha in \"sealed nuclei,\" without further context, leaves the statement difficult to evaluate.\n4. TRUE: Fusion proteins that combine nuclear localization signals (like those in human prothymosin alpha) with other proteins (such as beta-galactosidase) can result in the nuclear localization of the expressed fusion proteins in cells.\n5. TRUE: The amino acid sequence TKKQKT at the carboxyl terminus of prothymosin alpha is indeed crucial for its nuclear localization, which acts as a part of the nuclear targeting signal.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "vicuna-13b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is (47)LQVVR(51). This was determined through the use of AmylPred, an \"aggregation-prone\" peptide prediction algorithm, which identified this pentapeptide within the HCC sequence. Further studies revealed that this peptide was capable of self-assembling into amyloid-like fibrils in vitro, as demonstrated by electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies. Therefore, it can be concluded that the (47)LQVVR(51) peptide has an important role in HCC fibrillization.",
    "vicuna-13b_fact_raw": "1. The peptide (47)LQVVR(51) plays a pivotal role in human cystatin C fibrillization.\n2. AmylPred was used to identify the peptide (47)LQVVR(51) as \"aggregation-prone.\"\n3. The peptide (47)LQVVR(51) within the human cystatin C sequence is capable of self-assembling into amyloid-like fibrils in vitro.\n4. Electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies were used to analyze the peptide's ability to form fibrils.",
    "vicuna-13b_fact": [
      "The peptide (47)LQVVR(51) plays a pivotal role in human cystatin C fibrillization.",
      "AmylPred was used to identify the peptide (47)LQVVR(51) as \"aggregation-prone.\"",
      "The peptide (47)LQVVR(51) within the human cystatin C sequence is capable of self-assembling into amyloid-like fibrils in vitro.",
      "Electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies were used to analyze the peptide's ability to form fibrils."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout the specific context or source material to verify the statements about the peptide (47)LQVVR(51) and its role in human cystatin C fibrillization or the experimental methods used, it is not possible to determine the truthfulness of these statements. They are specific claims that require domain expertise and access to the appropriate scientific studies or literature for verification.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "vicuna-13b_response": "Based on the information provided in the document, it can be inferred that the concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol). The document states that amifostine induces the HIF1 alpha protein levels in cell lines and in vivo experiments with Wistar rats. Additionally, the document states that amifostine administration results in increased HIF1 alpha accumulation in normal tissues. Therefore, it can be concluded that amifostine administration leads to an increase in the concentration of HIF-1 protein.",
    "vicuna-13b_fact_raw": "1. The concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).\n2. Amifostine induces HIF1 alpha protein levels in cell lines according to the document.\n3. In vivo experiments with Wistar rats show that amifostine administration increases HIF1 alpha protein levels.\n4. Amifostine leads to increased accumulation of HIF1 alpha in normal tissues.",
    "vicuna-13b_fact": [
      "The concentration of protein HIF-1 increases after the administration of the cytoprotective prodrug \"amifostine\" (ethyol).",
      "Amifostine induces HIF1 alpha protein levels in cell lines according to the document.",
      "In vivo experiments with Wistar rats show that amifostine administration increases HIF1 alpha protein levels.",
      "Amifostine leads to increased accumulation of HIF1 alpha in normal tissues."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n\nThe responses regarding the effects of amifostine on HIF1 alpha protein levels are based on the specific context and the research documents mentioned in the statements. Without having access to the actual data or documents, it is not possible to be entirely certain about the veracity of statements 1, 3, and 4. However, assuming that the given information in statements 2, 3, and 4 accurately reflects the content of the document, these responses reflect the claims made in your provided context. For statement 1, without the document for reference, we cannot confirm whether it's true or false, so it is marked as UNKNOWN.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "vicuna-13b_response": "Based on the given information, the histone mark deposited by Set7 is histone H4 Lys 20 methylation. This mark is a sign of constitutive and facultative heterochromatin and is essential for the process of mitosis. The methylation mark is highly stable and is maintained even in the absence of PR-Set7 protein.",
    "vicuna-13b_fact_raw": "1. Set7 deposits the histone mark of histone H4 Lys 20 methylation.\n2. Histone H4 Lys 20 methylation is associated with both constitutive and facultative heterochromatin.\n3. Histone H4 Lys 20 methylation is essential for the process of mitosis.\n4. The methylation mark deposited by Set7 is highly stable.\n5. The histone H4 Lys 20 methylation mark is maintained even in the absence of PR-Set7 protein.",
    "vicuna-13b_fact": [
      "Set7 deposits the histone mark of histone H4 Lys 20 methylation.",
      "Histone H4 Lys 20 methylation is associated with both constitutive and facultative heterochromatin.",
      "Histone H4 Lys 20 methylation is essential for the process of mitosis.",
      "The methylation mark deposited by Set7 is highly stable.",
      "The histone H4 Lys 20 methylation mark is maintained even in the absence of PR-Set7 protein."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Set7 (also known as SETD7) is known for depositing a methylation mark on Lysine 4 (K4) of histone H3, not Lysine 20 (K20) of histone H4.\n2. TRUE: Histone H4 Lys 20 methylation is indeed associated with both constitutive and facultative heterochromatin.\n3. TRUE: Histone H4 Lys 20 methylation has been implicated in the process of mitosis, specifically in the compaction and organization of chromosomes.\n4. UNKNOWN: The stability of the methylation mark deposited by Set7 is not specified in these statements, and without additional context, it's difficult to ascertain.\n5. UNKNOWN: The maintenance of the Histone H4 Lys 20 methylation mark in the absence of the specific methyltransferase enzyme (PR-Set7 or SETD8 for K20 of H4) is not clear from the given statements and would require further information to verify.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "vicuna-13b_response": "Based on the information provided in the document, it is stated that the protein hepcidin has four disulfide bridges with a particular connectivity that is difficult to reproduce and could induce a bias in quantification. Therefore, it can be inferred that the protein hepcidin has four disulfide bridges.",
    "vicuna-13b_fact_raw": "1. The protein hepcidin has four disulfide bridges.",
    "vicuna-13b_fact": [
      "The protein hepcidin has four disulfide bridges."
    ],
    "vicuna-13b_judge_raw": "1. TRUE",
    "vicuna-13b_judge": [
      "true"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the localization of the protein encoded by the gene DNAJC11 is currently unknown. However, the protein DNAJC12, which is similar to DNAJC11, is expressed in human LNCaP prostate cancer cells and its localization is found to be diffusely distributed in the cytoplasm. The protein is upregulated by the stress-inducing drug A23187 and by the stress-regulated transcription factor AIbZIP/CREB3L4. The results of an immunoaffinity-mass spectrometry approach in cells that express epitope-tagged DNAJC12 suggest that the protein interacts with several nucleotide-binding proteins and the most frequently identified partner of DNAJC12 in unstressed cells was Hsc70, a cognate Hsp70 chaperone, whereas in stressed cells, the ER chaperone BiP was frequently associated with DNAJC12. Immunoprecipitation experiments confirmed that the endogenous DNAJC12 and Hsc70 proteins interact in LNCaP cells. These results suggest that DNAJC12 may play a role in the regulation of Hsp70 function.",
    "vicuna-13b_fact_raw": "1. The localization of the protein encoded by the gene DNAJC11 is currently unknown.\n2. The protein DNAJC12 is expressed in human LNCaP prostate cancer cells.\n3. DNAJC12's localization in cells is diffusely distributed in the cytoplasm.\n4. The DNAJC12 protein is upregulated by the drug A23187 and by the transcription factor AIbZIP/CREB3L4.\n5. DNAJC12 interacts with nucleotide-binding proteins, including Hsc70 in unstressed cells and BiP in stressed cells.",
    "vicuna-13b_fact": [
      "The localization of the protein encoded by the gene DNAJC11 is currently unknown.",
      "The protein DNAJC12 is expressed in human LNCaP prostate cancer cells.",
      "DNAJC12's localization in cells is diffusely distributed in the cytoplasm.",
      "The DNAJC12 protein is upregulated by the drug A23187 and by the transcription factor AIbZIP/CREB3L4.",
      "DNAJC12 interacts with nucleotide-binding proteins, including Hsc70 in unstressed cells and BiP in stressed cells."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without current scientific literature or data, the localization of the protein encoded by the gene DNAJC11 cannot be confirmed.\n2. UNKNOWN: The expression of the protein DNAJC12 in human LNCaP prostate cancer cells cannot be determined as true or false without specific scientific data or research outcomes.\n3. UNKNOWN: The localization of DNAJC12 in cells as diffusely distributed in the cytoplasm needs verification from a scientific study or authoritative resource to be determined true or false.\n4. UNKNOWN: The information regarding DNAJC12 protein being upregulated by the drug A23187 and by the transcription factor AIbZIP/CREB3L4 requires data from scientific research to assess its validity.\n5. UNKNOWN: The interaction of DNAJC12 with nucleotide-binding proteins such as Hsc70 in unstressed cells and BiP in stressed cells would need to be confirmed by experimental evidence from peer-reviewed studies.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "vicuna-13b_response": "Based on the given information, it can be inferred that ultraconserved elements (UCEs) are depleted among copy number variants (CNVs) in the human genome. This depletion is observed in both large-scale human CNV datasets and in newly formed de novo CNVs. In contrast, CNVs that arise specifically in cancer cells are not depleted for UCEs and can even become enriched. The lack of depletion for UCEs from cancer CNVs may reflect the diseased state, and somatic CNVs that are not associated with disease are also depleted for UCEs. Additionally, it is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time. The depletion of UCEs from CNVs may be established through selection against UCE-disrupting CNVs without the requirement for meiotic divisions.",
    "vicuna-13b_fact_raw": "1. Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs) in the human genome.\n2. The depletion of UCEs among CNVs has been observed in large-scale human CNV datasets as well as in newly formed de novo CNVs.\n3. Copy number variants that arise specifically in cancer cells are not depleted of UCEs.\n4. Somatic CNVs not associated with disease are also depleted for UCEs.\n5. It is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time.",
    "vicuna-13b_fact": [
      "Ultraconserved elements (UCEs) are depleted among copy number variants (CNVs) in the human genome.",
      "The depletion of UCEs among CNVs has been observed in large-scale human CNV datasets as well as in newly formed de novo CNVs.",
      "Copy number variants that arise specifically in cancer cells are not depleted of UCEs.",
      "Somatic CNVs not associated with disease are also depleted for UCEs.",
      "It is possible to observe the CNVs of induced pluripotent stem (iPS) cells become depleted of UCEs over time."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Ultraconserved elements (UCEs) are indeed reported to be depleted among copy number variants (CNVs) in the human genome. UCEs are stretches of DNA that are highly conserved across different species, and they tend to be under strong selective pressure, which may explain their depletion in CNVs.\n\n2. TRUE: This statement is consistent with research findings. Large-scale analyses of human CNV datasets have shown that UCEs are not randomly distributed among CNVs but are instead less likely to be found in variable regions of the genome. This has also been observed in cases of newly formed de novo CNVs.\n\n3. TRUE: Copy number variants that arise specifically in cancer cells may not follow the same patterns as inherited CNVs or de novo CNVs in healthy cells. Cancer genomes can exhibit a different landscape of genomic alterations, and the selective pressures in cancer cells can differ from those in germ cells or somatic cells not affected by cancer.\n\n4. TRUE: Somatic CNVs not associated with disease have also been noted to be depleted for UCEs. This indicates that the depletion of UCEs in CNVs is a more general phenomenon not restricted to disease-related contexts.\n\n5. UNKNOWN: Without specific research data, it is difficult to determine whether CNVs of induced pluripotent stem (iPS) cells specifically become depleted of UCEs over time. Induced pluripotent stem cells can exhibit genomic instability, which might lead to CNVs, but the statement about UCE depletion over time requires more context and specific study references to be verified.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the substrate of the haspin kinase during mitosis is the Thr3 residue of histone H3. The document describes the construction of conjugates that target an aromatic fragment to the ATP-site of Haspin and a peptide mimicking the N-terminus of histone H3, and the development of inhibitors with subnanomolar affinity toward Haspin. The selectivity profiles of the novel conjugates were established by affinity studies with a model basophilic kinase and by a commercial 1-point inhibition assay with 43 protein kinases, but no specific information is given about the substrate during mitosis.",
    "vicuna-13b_fact_raw": "1. The substrate of the haspin kinase during mitosis is the Thr3 residue of histone H3.\n2. The document described the construction of conjugates that target the ATP-site of Haspin.\n3. A peptide mimicking the N-terminus of histone H3 was involved in the development of inhibitors with subnanomolar affinity toward Haspin.\n4. The selectivity profiles of the novel conjugates were established through affinity studies with a model basophilic kinase.\n5. A commercial 1-point inhibition assay with 43 protein kinases was used to establish selectivity profiles for the novel conjugates.",
    "vicuna-13b_fact": [
      "The substrate of the haspin kinase during mitosis is the Thr3 residue of histone H3.",
      "The document described the construction of conjugates that target the ATP-site of Haspin.",
      "A peptide mimicking the N-terminus of histone H3 was involved in the development of inhibitors with subnanomolar affinity toward Haspin.",
      "The selectivity profiles of the novel conjugates were established through affinity studies with a model basophilic kinase.",
      "A commercial 1-point inhibition assay with 43 protein kinases was used to establish selectivity profiles for the novel conjugates."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The primary substrate of haspin kinase during mitosis is indeed the Thr3 residue of histone H3. Haspin phosphorylates this residue, which plays a role in chromosome condensation and segregation.\n2. UNKNOWN: The statement provides insufficient information to determine its truth value without access to the document that outlines this research. The phrase \"the document\" refers to an external piece of content that isn't provided.\n3. UNKNOWN: Similar to statement 2, this statement cannot be assessed without additional context or access to the specific research findings discussed.\n4. UNKNOWN: Statement 4 refers to selectivity profiles but doesnt give enough context to determine the truth value. It would require additional information about the specific research methods and findings.\n5. UNKNOWN: This statement is about a specific assay used to establish selectivity profiles but doesn't provide sufficient information to assess its truth value. Verification would require more information about the research protocol and results or access to the referenced data.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "vicuna-13b_response": "Viroids are a unique class of self-replicating RNA viruses that replicate through a rolling circle mechanism that is exclusively RNA-dependent. The replication initiation sites of peach latent mosaic viroid (PLMVd) were determined through a universal initiation site for each of the PLMVd polarities (position A50/C51 and U284 for the plus and minus strands, respectively). This was identified by a rolling circle replication assay and found to be shared by a relatively wide repertoire of viroid variants. An in vitro selection procedure was then developed to identify a highly conserved CAGACG box in the vicinity of the initiation site, which contributes to delineating the initiation site and provides an explanation for the presence of a specific universal initiation site on the PLMVd molecule.",
    "vicuna-13b_fact_raw": "1. Viroids replicate through a rolling circle mechanism that is exclusively RNA-dependent.\n2. The replication initiation sites for peach latent mosaic viroid (PLMVd) are at position A50/C51 for the plus strand and U284 for the minus strand.\n3. These initiation sites were determined using a rolling circle replication assay.\n4. A highly conserved CAGACG box near the initiation site was identified through an in vitro selection procedure.\n5. The CAGACG box contributes to delineating the initiation site on the PLMVd molecule.",
    "vicuna-13b_fact": [
      "Viroids replicate through a rolling circle mechanism that is exclusively RNA-dependent.",
      "The replication initiation sites for peach latent mosaic viroid (PLMVd) are at position A50/C51 for the plus strand and U284 for the minus strand.",
      "These initiation sites were determined using a rolling circle replication assay.",
      "A highly conserved CAGACG box near the initiation site was identified through an in vitro selection procedure.",
      "The CAGACG box contributes to delineating the initiation site on the PLMVd molecule."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true, as viroids are known to replicate through an RNA-based rolling circle mechanism. However, the specificity of the replication initiation sites for peach latent mosaic viroid (PLMVd) mentioned in statements 2 to 5 would require access to detailed scientific literature to confirm, and such specific knowledge is not universally established or accessible without reviewing research on the subject. Therefore, the answers to statements 2 to 5 are \"UNKNOWN\".",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "vicuna-13b_response": "Based on the provided document, fibronectin can be considered as a potential serum biomarker for Duchenne muscular dystrophy (DMD). The study used a bottom-up proteomics approach to identify candidate biomarkers in serum samples from control subjects and DMD patients, and fibronectin was chosen for follow-up based on the differences in peptide spectral counts and sequence coverage observed between the DMD and control groups. Subsequently, fibronectin levels were determined with ELISA in 68 DMD patients, 38 milder Becker muscular dystrophy patients, 33 patients with other neuromuscular disorders, and 15 age-matched adult and child controls. The results showed a significant increase in fibronectin levels in DMD patients compared to age-matched controls, and progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years. Therefore, this study suggests that serum fibronectin levels may constitute a promising biomarker to monitor disease progression in DMD patients.",
    "vicuna-13b_fact_raw": "1. Fibronectin is considered a potential serum biomarker for Duchenne muscular dystrophy (DMD) according to the document provided.\n2. A bottom-up proteomics approach was used to identify candidate biomarkers for DMD in the study referenced.\n3. In the study, fibronectin levels were measured using ELISA in 68 DMD patients, 38 Becker muscular dystrophy patients, 33 patients with other neuromuscular disorders, and 15 age-matched controls.\n4. The results of the study indicated a significant increase in fibronectin levels in DMD patients compared to the age-matched controls.\n5. Progressive elevation of fibronectin levels was observed in longitudinal samples from 22 DMD patients over a follow-up period of 6 months to 4 years.",
    "vicuna-13b_fact": [
      "Fibronectin is considered a potential serum biomarker for Duchenne muscular dystrophy (DMD) according to the document provided.",
      "A bottom-up proteomics approach was used to identify candidate biomarkers for DMD in the study referenced.",
      "In the study, fibronectin levels were measured using ELISA in 68 DMD patients, 38 Becker muscular dystrophy patients, 33 patients with other neuromuscular disorders, and 15 age-matched controls.",
      "The results of the study indicated a significant increase in fibronectin levels in DMD patients compared to the age-matched controls.",
      "Progressive elevation of fibronectin levels was observed in longitudinal samples from 22 DMD patients over a follow-up period of 6 months to 4 years."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: A top-down proteomics approach was used to identify candidate biomarkers for DMD in the study referenced.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Progressive elevation of fibronectin levels was not observed in longitudinal samples from 22 DMD patients over a follow-up period of 6 months to 4 years; a single snapshot of fibronectin levels was provided at a given point in time, not longitudinally.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "vicuna-13b_response": "The DeepBlue Epigenomic Data Server contains data from four major epigenome projects, which are:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. ROADMAP (Regulatory Omics Assessment by Genome-wide Hypersensitivity and Methylation Profiling)\n3. BLUEPRINT (A Genome-wide Map of DNase I-sensitive Elements in the Human Genome)\n4. DEEP (A High-resolution Map of DNase I-sensitive Elements in the Human Genome)\nThese projects aim to establish a comprehensive understanding of the human epigenome and its role in various biological processes. The DeepBlue Epigenomic Data Server provides a user-friendly interface for retrieving and analyzing epigenomic data from these projects, making it easier for researchers to access and use this valuable information.",
    "vicuna-13b_fact_raw": "1. The DeepBlue Epigenomic Data Server contains data from the ENCODE project.\n2. The DeepBlue Epigenomic Data Server includes data from the ROADMAP project.\n3. Data from the BLUEPRINT project is contained in the DeepBlue Epigenomic Data Server.\n4. The DEEP project's data is available on the DeepBlue Epigenomic Data Server.",
    "vicuna-13b_fact": [
      "The DeepBlue Epigenomic Data Server contains data from the ENCODE project.",
      "The DeepBlue Epigenomic Data Server includes data from the ROADMAP project.",
      "Data from the BLUEPRINT project is contained in the DeepBlue Epigenomic Data Server.",
      "The DEEP project's data is available on the DeepBlue Epigenomic Data Server."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The DeepBlue Epigenomic Data Server does contain data from the ENCODE project.\n2. TRUE: The DeepBlue Epigenomic Data Server includes data from the ROADMAP project.\n3. TRUE: Data from the BLUEPRINT project is contained in the DeepBlue Epigenomic Data Server.\n4. TRUE: The DEEP project's data is available on the DeepBlue Epigenomic Data Server.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "vicuna-13b_response": "The tool that employs self-organizing maps for analyzing synonymous codon usage is called \"WoLF\" (Web-based tool for the analysis of codon usage and gene expression). It is available through the Pole Bioinformatique Lyonnais (PBIL) Web server at <http://pbil.univ-lyon1.fr/datasets/charif04/>. The WoLF tool provides a user-friendly implementation of within-group correspondence analysis, a method that can be used to analyze synonymous codon usage variability despite the variability in amino acid composition between proteins. The tool is demonstrated through a demo that allows users to reproduce the figures in the application note. The underlying software is distributed under a GPL license, and users can contact the PBIL team through their website for more information.",
    "vicuna-13b_fact_raw": "1. The \"WoLF\" (Web-based tool for the analysis of codon usage and gene expression) uses self-organizing maps for analyzing synonymous codon usage.\n2. WoLF is accessible through the Pole Bioinformatique Lyonnais (PBIL) Web server.\n3. The URL for accessing WoLF is <http://pbil.univ-lyon1.fr/datasets/charif04/>.\n4. WoLF tool implements within-group correspondence analysis to analyze synonymous codon usage.\n5. The software underlying WoLF tool is distributed under a GPL (General Public License).",
    "vicuna-13b_fact": [
      "The \"WoLF\" (Web-based tool for the analysis of codon usage and gene expression) uses self-organizing maps for analyzing synonymous codon usage.",
      "WoLF is accessible through the Pole Bioinformatique Lyonnais (PBIL) Web server.",
      "The URL for accessing WoLF is <http://pbil.univ-lyon1.fr/datasets/charif04/>.",
      "WoLF tool implements within-group correspondence analysis to analyze synonymous codon usage.",
      "The software underlying WoLF tool is distributed under a GPL (General Public License)."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: WoLF PSORT is accessible through the ExPASy bioinformatics resource portal, not through the Pole Bioinformatique Lyonnais (PBIL) Web server.\n3. FALSE [correction]: This appears to be a correct URL for a dataset related to codon usage analysis by PBIL, but it is not the URL for accessing the WoLF tool. The WoLF PSORT tool can be accessed at the URL <https://wolfpsort.hgc.jp/>.\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "vicuna-13b_response": "MINDY-1 is a gene that is expressed in the liver of mice and is involved in regulating energy metabolism. The knockout of this gene in mice (mINDY(-/-) mice) has been shown to reduce the hepatocellular ATP/ADP ratio, activate hepatic AMPK, induce PGC-1, inhibit ACC-2, and reduce SREBP-1c levels. These changes promote hepatic mitochondrial biogenesis, lipid oxidation, and energy expenditure, and attenuate hepatic de novo lipogenesis. The studies suggest that mIndy plays a profound role in mammalian energy metabolism and that mINDY might be a therapeutic target for the treatment of obesity and type 2 diabetes.",
    "vicuna-13b_fact_raw": "1. MINDY-1 is a gene expressed in the liver of mice.\n2. The knockout of the MINDY-1 gene in mice leads to a reduction in the hepatocellular ATP/ADP ratio.\n3. Knockout MINDY-1 mice show activation of hepatic AMPK and induction of PGC-1.\n4. Inactivation of the MINDY-1 gene in mice results in inhibition of ACC-2 and a reduction in SREBP-1c levels.\n5. Studies suggest that the MINDY-1 gene plays a significant role in mammalian energy metabolism and may be a potential therapeutic target for obesity and type 2 diabetes.",
    "vicuna-13b_fact": [
      "MINDY-1 is a gene expressed in the liver of mice.",
      "The knockout of the MINDY-1 gene in mice leads to a reduction in the hepatocellular ATP/ADP ratio.",
      "Knockout MINDY-1 mice show activation of hepatic AMPK and induction of PGC-1.",
      "Inactivation of the MINDY-1 gene in mice results in inhibition of ACC-2 and a reduction in SREBP-1c levels.",
      "Studies suggest that the MINDY-1 gene plays a significant role in mammalian energy metabolism and may be a potential therapeutic target for obesity and type 2 diabetes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Inactivation of the MINDY-1 gene in mice results in activation of ACC-2 and a reduction in SREBP-1c levels.\n5. TRUE\n\nIt should be noted that while the statements about the MINDY-1 gene seem plausible given its association with metabolic processes, specific experimental results regarding mechanistic functions like the impact on ACC-2 or SREBP-1c levels can only be confirmed with access to precise scientific research findings. My corrections are based on typical scientific understanding, but the validation of such statements would usually require a review of the primary research articles.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "vicuna-13b_response": "The software package available for the analysis of conserved genomic loci is Molecular Evolutionary Genetics Analysis (Mega). The latest version of Mega has been optimized for use on 64-bit computing systems and can analyze larger datasets. It includes advanced tools for phylogenomics and phylomedicine, and provides an advanced wizard for building timetrees. The new version also includes a feature to automatically predict gene duplication events in gene family trees. The 64-bit Mega is available in two interfaces: graphical and command line, and both versions are available for free from the website [www.megasoftware.net](http://www.megasoftware.net).",
    "vicuna-13b_fact_raw": "1. Molecular Evolutionary Genetics Analysis (Mega) is a software package for the analysis of conserved genomic loci.\n2. The latest version of Mega is optimized for 64-bit computing systems.\n3. Mega includes advanced tools for phylogenomics and phylomedicine.\n4. Mega features a wizard for building timetrees.\n5. The 64-bit version of Mega is available in graphical and command-line interfaces.",
    "vicuna-13b_fact": [
      "Molecular Evolutionary Genetics Analysis (Mega) is a software package for the analysis of conserved genomic loci.",
      "The latest version of Mega is optimized for 64-bit computing systems.",
      "Mega includes advanced tools for phylogenomics and phylomedicine.",
      "Mega features a wizard for building timetrees.",
      "The 64-bit version of Mega is available in graphical and command-line interfaces."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Molecular Evolutionary Genetics Analysis (MEGA) is a software package for comparative analysis of homologous gene sequences (primarily for inferring phylogenies and evolutionary studies) not specifically for the analysis of conserved genomic loci.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "vicuna-13b_response": "Based on the given information, the following three diseases are associated with the PIEZO2 gene:\n1. Arthrogryposis, spontaneously resolving respiratory insufficiency at birth, muscular atrophy predominantly of the distal lower limbs, scoliosis, and mild distal sensory involvement.\n2. Distal arthrogryposis 3 (DA3), distal arthrogryposis 5 (DA5), or Marden-Walker syndrome (MWKS), which encompass contractures of hands and feet, scoliosis, ophthalmoplegia, and ptosis.\n3. A not life-threatening, slowly progressive disorder that is likely due to loss of PIEZO2 protein in afferent neurons leading to disturbed proprioception causing aberrant muscle development and function.",
    "vicuna-13b_fact_raw": "1. The PIEZO2 gene is associated with a form of arthrogryposis that includes respiratory insufficiency at birth, muscular atrophy predominantly of the distal lower limbs, scoliosis, and mild distal sensory involvement.\n2. Distal arthrogryposis 3 (DA3), distal arthrogryposis 5 (DA5), and Marden-Walker syndrome (MWKS) are diseases associated with the PIEZO2 gene.\n3. The PIEZO2 gene is linked to a not life-threatening, slowly progressive disorder characterized by loss of PIEZO2 protein in afferent neurons, leading to disturbed proprioception and aberrant muscle development and function.",
    "vicuna-13b_fact": [
      "The PIEZO2 gene is associated with a form of arthrogryposis that includes respiratory insufficiency at birth, muscular atrophy predominantly of the distal lower limbs, scoliosis, and mild distal sensory involvement.",
      "Distal arthrogryposis 3 (DA3), distal arthrogryposis 5 (DA5), and Marden-Walker syndrome (MWKS) are diseases associated with the PIEZO2 gene.",
      "The PIEZO2 gene is linked to a not life-threatening, slowly progressive disorder characterized by loss of PIEZO2 protein in afferent neurons, leading to disturbed proprioception and aberrant muscle development and function."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The PIEZO2 gene is indeed associated with a spectrum of conditions that include features such as arthrogryposis with respiratory insufficiency at birth, muscle atrophy, scoliosis, and sensory involvement.\n\n2. FALSE [correction]: Distal arthrogryposis types 3 (DA3) and 5 (DA5) are associated with mutations in the PIEZO2 gene; however, Marden-Walker Syndrome (MWKS) has not been commonly associated with mutations in the PIEZO2 gene. Marden-Walker Syndrome is typically characterized by multiple joint contractures (arthrogryposis), a mask-like face with a small mouth, and other features. It is often associated with genetic changes in different genes or can occur for unknown reasons.\n\n3. UNKNOWN: While the PIEZO2 gene has been associated with disturbances in proprioception and muscle function, the statement as provided lacks specificity regarding a particular disorder. Additionally, whether PIEZO2 related disorders always lead to a loss of PIEZO2 protein is not stated. More information would be needed to confirm the accuracy of the entire statement.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "vicuna-13b_response": "The promotion of ERAP1-ERAP2 dimerization leads to the production of mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. The physical interaction with ERAP2 changes basic enzymatic parameters of ERAP1 and improves its substrate-binding affinity. This suggests that the formation of heterodimers by ERAP1 and ERAP2 facilitates trimming of epitope precursor peptides and enhances Ag presentation by cells displaying coordinated expression of the two enzymes.",
    "vicuna-13b_fact_raw": "1. ERAP1-ERAP2 dimerization leads to the more efficient production of mature epitopes compared to when the two enzymes are unable to dimerize.\n2. The interaction with ERAP2 changes basic enzymatic parameters of ERAP1.\n3. ERAP1's substrate-binding affinity is improved through its interaction with ERAP2.\n4. The formation of heterodimers by ERAP1 and ERAP2 facilitates the trimming of epitope precursor peptides.\n5. ERAP1-ERAP2 heterodimers enhance antigen presentation by cells that express both enzymes.",
    "vicuna-13b_fact": [
      "ERAP1-ERAP2 dimerization leads to the more efficient production of mature epitopes compared to when the two enzymes are unable to dimerize.",
      "The interaction with ERAP2 changes basic enzymatic parameters of ERAP1.",
      "ERAP1's substrate-binding affinity is improved through its interaction with ERAP2.",
      "The formation of heterodimers by ERAP1 and ERAP2 facilitates the trimming of epitope precursor peptides.",
      "ERAP1-ERAP2 heterodimers enhance antigen presentation by cells that express both enzymes."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: ERAP1-ERAP2 dimerization enhances the generation of correctly sized peptides for presentation by MHC class I molecules, which can lead to more efficient production of mature epitopes.\n2. TRUE: The interaction between ERAP1 and ERAP2 can alter the enzymatic properties of ERAP1, including substrate specificity and cleavage efficiency.\n3. UNKNOWN: Without specific data or a reference confirming the effect of ERAP2 interaction on ERAP1's substrate-binding affinity, it's difficult to ascertain the validity of this statement.\n4. TRUE: The heterodimer formation between ERAP1 and ERAP2 is known to aid in the trimming process of the epitope precursor peptides, thereby facilitating the production of peptides that can be presented by MHC class I molecules.\n5. TRUE: By enhancing the trimming of precursor peptides, ERAP1-ERAP2 heterodimers can facilitate the presentation of a broader repertoire of antigens by cells that express both enzymes, thereby enhancing antigen presentation.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "vicuna-13b_response": "R-spondin 1 and noggin are two different proteins that have been studied in the context of gallbladder function. R-spondin 1 is a protein that has been shown to play a role in the regulation of gallbladder contraction. Noggin, on the other hand, is a protein that has been shown to inhibit the activity of R-spondin 1.\nIn non-damaged gallbladders, R-spondin 1 and noggin likely play a role in the regulation of gallbladder contraction and the release of bile. Prostaglandins, such as prostaglandin E2, may regulate the activity of R-spondin 1 and noggin, and may play a role in the regulation of mucus release from the gallbladder epithelium. However, more research is needed to fully understand the function of R-spondin 1 and noggin in non-damaged gallbladders and their role in the regulation of gallbladder function.",
    "vicuna-13b_fact_raw": "1. R-spondin 1 is a protein involved in the regulation of gallbladder contraction.\n2. Noggin is a protein known to inhibit the activity of R-spondin 1.\n3. R-spondin 1 and noggin are involved in the regulation of the release of bile from the gallbladder.\n4. Prostaglandins, such as prostaglandin E2, may regulate the activity of R-spondin 1 and noggin.\n5. Prostaglandins may play a role in the regulation of mucus release from the gallbladder epithelium.",
    "vicuna-13b_fact": [
      "R-spondin 1 is a protein involved in the regulation of gallbladder contraction.",
      "Noggin is a protein known to inhibit the activity of R-spondin 1.",
      "R-spondin 1 and noggin are involved in the regulation of the release of bile from the gallbladder.",
      "Prostaglandins, such as prostaglandin E2, may regulate the activity of R-spondin 1 and noggin.",
      "Prostaglandins may play a role in the regulation of mucus release from the gallbladder epithelium."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: R-spondin 1 is a protein that is primarily known for its role in the regulation of Wnt signaling, which is critical for the development and regeneration of various tissues, but it is not specifically involved in the regulation of gallbladder contraction.\n\n2. FALSE [correction]: Noggin is a protein known to inhibit members of the Bone Morphogenetic Protein (BMP) family, not R-spondin 1.\n\n3. FALSE [correction]: While R-spondin 1 is involved in Wnt signaling and noggin inhibits BMPs, neither are specifically known for the regulation of the release of bile from the gallbladder. Regulation of bile release is more closely associated with hormonal controls, like cholecystokinin, and neuronal signals.\n\n4. UNKNOWN: While prostaglandins are involved in a wide range of bodily functions and could theoretically regulate a variety of proteins, the specific regulatory relationship between prostaglandins such as prostaglandin E2 and the proteins R-spondin 1 and noggin is unclear without more specific context.\n\n5. TRUE: Prostaglandins are known to play multiple roles in the gastrointestinal system and can be involved in the regulation of mucus secretion from epithelial cells, which could include the gallbladder epithelium.",
    "vicuna-13b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "vicuna-13b_response": "Document-0 suggests that NADPH oxidase 5 requires the presence of the heterodimeric cytochrome b558 for function. The study used a photoaffinity labeling and immunoblot analysis of membrane proteins from bovine neutrophils to investigate the presumed NADPH dehydrogenase function of cytochrome b558 in the neutrophil oxidase complex. The results showed that the oxidase was able to bind to high-affinity specific binding sites with a Kd of 5-6 microM, indicating a higher affinity of the oxidase for the photoprobe than for the substrate NADPH (KM = 30-40 microM). Upon photolabeling, the oxidase was fully inactivated. The study also revealed that the enzymatic deglycosylation of photolabeled neutrophil membranes shifted the masses of both the photolabeled band and the immunoreactive beta subunit from 80-100 to 55-65 kDa in accordance with the glycoprotein nature of the beta subunit.",
    "vicuna-13b_fact_raw": "1. NADPH oxidase 5 requires the heterodimeric cytochrome b558 for function according to Document-0.\n2. The study mentioned used photoaffinity labeling and immunoblot analysis of membrane proteins from bovine neutrophils.\n3. The oxidase complex demonstrated a higher affinity for the photoprobe than for the substrate NADPH, with a Kd of 5-6 microM compared to a KM of 30-40 microM.\n4. Photolabeling fully inactivated the oxidase.\n5. Enzymatic deglycosylation shifted the mass of a photolabeled band from 80-100 kDa to 55-65 kDa, indicating the glycoprotein nature of the beta subunit.",
    "vicuna-13b_fact": [
      "NADPH oxidase 5 requires the heterodimeric cytochrome b558 for function according to Document-0.",
      "The study mentioned used photoaffinity labeling and immunoblot analysis of membrane proteins from bovine neutrophils.",
      "The oxidase complex demonstrated a higher affinity for the photoprobe than for the substrate NADPH, with a Kd of 5-6 microM compared to a KM of 30-40 microM.",
      "Photolabeling fully inactivated the oxidase.",
      "Enzymatic deglycosylation shifted the mass of a photolabeled band from 80-100 kDa to 55-65 kDa, indicating the glycoprotein nature of the beta subunit."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nUnfortunately, without further context or the actual \"Document-0\" referenced in the statements, I cannot confirm the accuracy of these specific claims related to the study on NADPH oxidase 5, photolabeling, or any experimental results. My knowledge only extends up to the date of my last update, and without the source material or additional context, the truthfulness of these statements cannot be ascertained.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "vicuna-13b_response": "Document-0 provides information on the posttranslational processing of hepcidin, a hormone involved in regulating iron levels in the body. The document states that hepcidin is encoded as an 84 amino acid prepropeptide, which contains a typical N-terminal 24 amino acid endoplasmic reticulum targeting signal sequence and a 35 amino acid proregion (pro) with a consensus furin cleavage site. The cleavage site is immediately followed by the C-terminal 25 amino acid bioactive iron-regulatory hormone.\nThe document also states that the processing of hepcidin is mediated by the hepatic prohormone convertase furin. The document provides evidence that in the absence of furin inhibitor, hepcidin is processed in less than 1 hour and secreted as a 3 kDa form reactive with anti-mature but not anti-pro antibody. However, in the presence of furin inhibitors or furin siRNA, a 6 kDa form reactive with both anti-pro and anti-mature antibody was rapidly secreted into the medium.\nThe document also indicates that the processing of prohepcidin to hepcidin is not regulated by iron-transferrin or the HIF pathway. In conclusion, the document suggests that furin plays a crucial role in the posttranslational processing of hepcidin, and that this processing is not regulated by iron-transferrin or the HIF pathway.",
    "vicuna-13b_fact_raw": "1. Hepcidin is involved in regulating iron levels in the body.\n2. Hepcidin is initially encoded as an 84 amino acid prepropeptide with a typical N-terminal 24 amino acid endoplasmic reticulum targeting sequence.\n3. The proregion of hepcidin contains a 35 amino acid sequence with a consensus furin cleavage site.\n4. In the absence of furin inhibitor, hepcidin is processed in less than 1 hour to a secreted 3 kDa form.\n5. Processing of prohepcidin to hepcidin is not regulated by iron-transferrin or the HIF pathway.",
    "vicuna-13b_fact": [
      "Hepcidin is involved in regulating iron levels in the body.",
      "Hepcidin is initially encoded as an 84 amino acid prepropeptide with a typical N-terminal 24 amino acid endoplasmic reticulum targeting sequence.",
      "The proregion of hepcidin contains a 35 amino acid sequence with a consensus furin cleavage site.",
      "In the absence of furin inhibitor, hepcidin is processed in less than 1 hour to a secreted 3 kDa form.",
      "Processing of prohepcidin to hepcidin is not regulated by iron-transferrin or the HIF pathway."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The proregion of hepcidin contains a 40 amino acid sequence with a consensus furin cleavage site.\n4. UNKNOWN\n5. FALSE [correction]: Processing of prohepcidin to hepcidin is regulated by iron-transferrin and other pathways like the HIF pathway can have a regulatory role.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "vicuna-13b_response": "The largest metabolic gene cluster in yeast is not specified in the given document. However, it is known that yeast has several metabolic gene clusters, such as the GAL gene cluster, which is involved in the regulation of galactose metabolism. The GAL gene cluster is one of the largest metabolic gene clusters in yeast and contains genes that encode enzymes involved in the conversion of galactose to glucose, as well as genes involved in the regulation of this process.",
    "vicuna-13b_fact_raw": "1. Yeast has several metabolic gene clusters.\n2. The GAL gene cluster is involved in the regulation of galactose metabolism in yeast.\n3. The GAL gene cluster contains genes that encode enzymes for the conversion of galactose to glucose.\n4. The GAL gene cluster also contains genes that are involved in the regulation of the conversion process from galactose to glucose.",
    "vicuna-13b_fact": [
      "Yeast has several metabolic gene clusters.",
      "The GAL gene cluster is involved in the regulation of galactose metabolism in yeast.",
      "The GAL gene cluster contains genes that encode enzymes for the conversion of galactose to glucose.",
      "The GAL gene cluster also contains genes that are involved in the regulation of the conversion process from galactose to glucose."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The GAL gene cluster contains genes that encode enzymes for the conversion of galactose to glucose-1-phosphate, a precursor to glucose but not directly into glucose.\n4. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "vicuna-13b_response": "The role of LIMT lncRNA is to inhibit metastasis of cancer cells. LIMT is a long noncoding RNA that is depleted in basal-like and HER2-positive tumors and low expression of which predicts poor patient prognosis. The study found that EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. Additionally, LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo. Therefore, the study suggests that lncRNAs dynamically regulated by growth factors might act as novel drivers of cancer progression and serve as prognostic biomarkers.",
    "vicuna-13b_fact_raw": "1. LIMT lncRNA inhibits metastasis of cancer cells.\n2. LIMT is a long noncoding RNA that is depleted in basal-like and HER2-positive tumors.\n3. Low expression of LIMT predicts poor patient prognosis in the context of some cancers.\n4. EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter.\n5. LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo.",
    "vicuna-13b_fact": [
      "LIMT lncRNA inhibits metastasis of cancer cells.",
      "LIMT is a long noncoding RNA that is depleted in basal-like and HER2-positive tumors.",
      "Low expression of LIMT predicts poor patient prognosis in the context of some cancers.",
      "EGF rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter.",
      "LIMT inhibits extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nIt's important to note that while responses 1, 2, and 3 are consistent with current scientific understanding as of my knowledge cut-off in early 2023, the statements about specific molecular pathways such as in response 4 are highly specific and would require current and specific scientific literature for verification. Without access to such data or recent studies, I cannot confirm or refute the statement about EGF and histone deacetylation's impact on LIMT expression.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "vicuna-13b_response": "The R/Bioconductor package used for performing SNP enrichment analysis is TEQC (Target Enrichment Quality Control). TEQC is a package for quality assessment of target enrichment experiments. It provides various quality measures such as specificity and sensitivity of the capture, enrichment, per-target read coverage, and its relation to hybridization probe characteristics, coverage uniformity and reproducibility, and read duplicate analysis. TEQC also provides diagnostic plots for visual inspection of the data quality. It is implemented in R language (version >2.12.0) and is available as a Bioconductor package for Linux, Windows, and MacOS from [www.bioconductor.org](http://www.bioconductor.org).",
    "vicuna-13b_fact_raw": "1. The R/Bioconductor package used for performing SNP enrichment analysis is called TEQC (Target Enrichment Quality Control).\n2. TEQC provides quality measures such as specificity and sensitivity of the capture, enrichment, per-target read coverage, and its relation to hybridization probe characteristics.\n3. TEQC offers diagnostic plots for visual inspection of data quality.\n4. TEQC is implemented in R language (version >2.12.0).\n5. TEQC is available as a Bioconductor package for Linux, Windows, and MacOS.",
    "vicuna-13b_fact": [
      "The R/Bioconductor package used for performing SNP enrichment analysis is called TEQC (Target Enrichment Quality Control).",
      "TEQC provides quality measures such as specificity and sensitivity of the capture, enrichment, per-target read coverage, and its relation to hybridization probe characteristics.",
      "TEQC offers diagnostic plots for visual inspection of data quality.",
      "TEQC is implemented in R language (version >2.12.0).",
      "TEQC is available as a Bioconductor package for Linux, Windows, and MacOS."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The R/Bioconductor package for Target Enrichment Quality Control is known as 'TEQC'. However, SNP enrichment analysis is typically performed using different packages like 'SNPRelate' or 'GENE_E'.\n2. TRUE\n3. TRUE\n4. UNKNOWN (without the specific version information about TEQC it cannot be confirmed if it requires R version >2.12.0)\n5. TRUE (Bioconductor packages are generally available for Linux, Windows, and MacOS, assuming the dependencies of the package are also available on these platforms).",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "vicuna-13b_response": "The key players in radial glial specification to ependymal cells are radial glial cells and adult ependymal cells. Radial glial cells are neurogenic precursors, and after stroke, they acutely stimulate adult ependymal cell proliferation. Adult ependymal cells of the lateral ventricle have the genotype, phenotype, and morphology of radial glial cells and exhibit symmetrical division about the cell cleavage plane. Radial glial cells also derived from the subventricular zone (SVZ) support neuron migration after stroke. These findings suggest that adult ependymal cells can divide and transform into radial glial cells after stroke and function as neural progenitor cells to generate new neurons, acting as scaffolds to support neuroblast migration towards the ischemic boundary region.",
    "vicuna-13b_fact_raw": "1. Radial glial cells are specified to ependymal cells.\n2. Radial glial cells are neurogenic precursors.\n3. After a stroke, radial glial cells can stimulate adult ependymal cell proliferation.\n4. Adult ependymal cells of the lateral ventricle have the genotype, phenotype, and morphology of radial glial cells.\n5. Radial glial cells derived from the subventricular zone support neuron migration after a stroke.",
    "vicuna-13b_fact": [
      "Radial glial cells are specified to ependymal cells.",
      "Radial glial cells are neurogenic precursors.",
      "After a stroke, radial glial cells can stimulate adult ependymal cell proliferation.",
      "Adult ependymal cells of the lateral ventricle have the genotype, phenotype, and morphology of radial glial cells.",
      "Radial glial cells derived from the subventricular zone support neuron migration after a stroke."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Radial glial cells are progenitor cells that can give rise to various types of cells, including ependymal cells, but are not specifically \"specified\" to ependymal cells only; they can generate neurons and glia as well.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Adult ependymal cells and radial glial cells have distinct functions and morphology. Ependymal cells line the ventricles of the brain and do not retain the properties of radial glial cells, which are characteristically neurogenic precursors.\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "vicuna-13b_response": "Triple negative gliomas are a type of brain tumor that lacks the expression of the genes for the progesterone receptor (PR), the estrogen receptor (ER), and the human epidermal growth factor receptor 2 (HER2). These tumors are typically more aggressive and have a worse prognosis than other types of gliomas.\nThe characterization of triple negative gliomas is typically done through a combination of imaging studies, such as magnetic resonance imaging (MRI), and biopsy. MRI can provide detailed information about the size, shape, and location of the tumor, as well as any areas of abnormal tissue. A biopsy is a procedure in which a small sample of the tumor is removed and examined under a microscope to determine the type of tumor and its aggressiveness.\nIn addition to imaging and biopsy, other diagnostic tests may be used to characterize triple negative gliomas, such as blood tests to measure the levels of certain proteins or genetic tests to look for specific genetic mutations.\nOverall, the characterization of triple negative gliomas involves a combination of imaging, biopsy, and other diagnostic tests to provide a complete picture of the tumor and its characteristics.",
    "vicuna-13b_fact_raw": "1. Triple negative gliomas lack expression of the progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) genes.\n2. Triple negative gliomas are typically more aggressive and have a worse prognosis than other types of gliomas.\n3. The characterization of triple negative gliomas involves imaging studies, such as magnetic resonance imaging (MRI).\n4. A biopsy is used in the process of characterizing triple negative gliomas, where a small sample of the tumor is examined microscopically.\n5. Other diagnostic tests for triple negative gliomas may include blood tests and genetic tests.",
    "vicuna-13b_fact": [
      "Triple negative gliomas lack expression of the progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) genes.",
      "Triple negative gliomas are typically more aggressive and have a worse prognosis than other types of gliomas.",
      "The characterization of triple negative gliomas involves imaging studies, such as magnetic resonance imaging (MRI).",
      "A biopsy is used in the process of characterizing triple negative gliomas, where a small sample of the tumor is examined microscopically.",
      "Other diagnostic tests for triple negative gliomas may include blood tests and genetic tests."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Triple negative refers to breast cancer, not gliomas. Triple negative breast cancers lack expression of the progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2) genes. Gliomas are a type of brain tumor and would not be classified in the same way as breast cancers.\n2. TRUE: While the statement about triple negative gliomas is technically incorrect due to the confusion with breast cancer, it is true that triple negative breast cancers are typically more aggressive and have a worse prognosis than other types of breast cancer. By analogy, if we correct the term to triple negative breast cancer, the statement would be true.\n3. TRUE: For brain tumors like gliomas, imaging studies, such as magnetic resonance imaging (MRI), are indeed used as part of the characterization process. Although the term \"triple negative gliomas\" is incorrect, the usage of MRI would be true for gliomas in general.\n4. TRUE: Biopsies are used to characterize many types of tumors, including gliomas, in which a small sample of the tumor is examined microscopically to determine the tumor's characteristics.\n5. TRUE: For tumors, including gliomas, other diagnostic tests can include blood tests to check for tumor markers and genetic tests to find mutations associated with the tumor. These tests can assist with diagnosis and the tailoring of treatment strategies, even though the term \"triple negative gliomas\" is not accurate.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "vicuna-13b_response": "TOPAZ1 is a cleaning device intended for the cleaning of immunological plates. It is composed of a cleaning device, a discharge block, a cleaning solution vessel, and a wasted liquid collector. The technical parameters of the device have been specified in Document-0.",
    "vicuna-13b_fact_raw": "1. TOPAZ1 is a cleaning device used for cleaning immunological plates.\n2. TOPAZ1 consists of a cleaning device, a discharge block, a cleaning solution vessel, and a wasted liquid collector.\n3. The technical parameters of the TOPAZ1 device are detailed in Document-0.",
    "vicuna-13b_fact": [
      "TOPAZ1 is a cleaning device used for cleaning immunological plates.",
      "TOPAZ1 consists of a cleaning device, a discharge block, a cleaning solution vessel, and a wasted liquid collector.",
      "The technical parameters of the TOPAZ1 device are detailed in Document-0."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout specific context or reference material that verifies these statements about TOPAZ1 and Document-0, it is not possible to determine the truthfulness of these statements.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "vicuna-13b_response": "The gene that controls the expression of GATA-1 isoforms is not specified in the given information. However, the document provides information on the regulation of GATA-1 by its cofactor, friend of GATA-1 (FOG-1), and the mechanisms by which FOG-1 regulates GATA-1 function. The document also suggests that the interaction between GATA-1 and FOG-1 is required for GATA-1 occupancy at some regulatory elements, such as HS2, but is dispensable at others, including the FOG-1-independent GATA-1 target gene EKLF. Additionally, the document indicates that the interaction between GATA-1 and FOG-1 is required for transcriptional inhibition and histone deacetylation at the GATA-2 gene, which is repressed by GATA-1.",
    "vicuna-13b_fact_raw": "1. The expression of GATA-1 isoforms is regulated by its cofactor, friend of GATA-1 (FOG-1).\n2. The interaction between GATA-1 and FOG-1 is necessary for GATA-1 occupancy at certain regulatory elements, such as HS2.\n3. The interaction between GATA-1 and FOG-1 is not required at the FOG-1-independent GATA-1 target gene EKLF.\n4. The interaction between GATA-1 and FOG-1 is essential for transcriptional inhibition and histone deacetylation at the GATA-2 gene.\n5. The GATA-2 gene is repressed by GATA-1.",
    "vicuna-13b_fact": [
      "The expression of GATA-1 isoforms is regulated by its cofactor, friend of GATA-1 (FOG-1).",
      "The interaction between GATA-1 and FOG-1 is necessary for GATA-1 occupancy at certain regulatory elements, such as HS2.",
      "The interaction between GATA-1 and FOG-1 is not required at the FOG-1-independent GATA-1 target gene EKLF.",
      "The interaction between GATA-1 and FOG-1 is essential for transcriptional inhibition and histone deacetylation at the GATA-2 gene.",
      "The GATA-2 gene is repressed by GATA-1."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The interaction between GATA-1 and FOG-1 is not required at the FOG-1-independent GATA-1 target gene EKLF, which may suggest that EKLF can be regulated independently, but without specific context or data, it's hard to confirm the nature of its regulation.\n4. UNKNOWN: While the interaction between GATA-1 and FOG-1 is important for the regulation of some target genes, without specific evidence, we can't definitively say it's essential for transcriptional inhibition and histone deacetylation at the GATA-2 gene.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "vicuna-13b_response": "MIRA-seq is a medical information, retrieval, and archives system developed and implemented at the University Hospital Freiburg. It integrates the Minimum Basic Data Set into the hospital's patient administration system and other information systems. MIRA-seq provides access to medical data of patients treated in all medical departments and buildings since 1986. It is mainly used for readmission cases, scientific purposes, and managerial purposes. The system has privacy-controlled access to central patient data bases, which includes records of 450,000 patients, through 610 online PCs and dialog terminals. MIRA-seq is widely accepted by physicians, nurses, and administrators due to its easy-to-use standard functions and special extensions for different clinical departments.",
    "vicuna-13b_fact_raw": "1. MIRA-seq is a medical information, retrieval, and archives system developed at the University Hospital Freiburg.\n2. The system integrates the Minimum Basic Data Set into the hospital's patient administration system.\n3. MIRA-seq has been providing access to medical data of patients since 1986.\n4. It includes records of 450,000 patients.\n5. The MIRA-seq system can be accessed through 610 online PCs and dialog terminals.",
    "vicuna-13b_fact": [
      "MIRA-seq is a medical information, retrieval, and archives system developed at the University Hospital Freiburg.",
      "The system integrates the Minimum Basic Data Set into the hospital's patient administration system.",
      "MIRA-seq has been providing access to medical data of patients since 1986.",
      "It includes records of 450,000 patients.",
      "The MIRA-seq system can be accessed through 610 online PCs and dialog terminals."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The specific details about MIRA-seq, such as its full name and development location, are not common knowledge and cannot be confirmed without additional context or information.\n2. UNKNOWN: Without further context, it's unclear whether the Minimum Basic Data Set is indeed integrated into the hospital's patient administration system by MIRA-seq or another system.\n3. FALSE [correction]: Without specific knowledge of when MIRA-seq began providing access, an accurate starting date cannot be given; however, \"MIRA-seq\" sounds like a sequencing technology rather than a patient data system, so a clarification on its purpose and start date is needed.\n4. UNKNOWN: The number of patient records included in MIRA-seq cannot be confirmed without additional information.\n5. UNKNOWN: The details regarding system access, such as through how many online PCs and dialog terminals, require specific information that is not provided.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "vicuna-13b_response": "ARC channels, also known as arachidonate-regulated Ca(2+)-selective channels, are a type of highly Ca(2+)-selective channel that are specifically activated by low concentrations of agonist-induced arachidonic acid. This activation occurs in the absence of any depletion of internal Ca(2+) stores, meaning they are 'non-capacitative'. These channels have been demonstrated to provide the predominant pathway for the entry of Ca(2+) seen at low agonist concentrations, where oscillatory [Ca(2+)](i) signals are typically produced. In contrast, activation of the more widely studied store-operated Ca(2+) channels, such as CRAC channels, is only seen at higher agonist concentrations where sustained 'plateau-type'[Ca(2+)](i) responses are observed. ARC channels have been found in both parotid and pancreatic acinar cells and are specifically activated by the low concentrations of appropriate agonists (carbachol in the parotid, and both carbachol and cholecystokinin in the pancreas) that are associated with oscillatory [Ca(2+)](i) signals in these cells. Uncoupling the receptor-mediated activation of cytosolic phospholipase A(2) (cPLA(2)) with isotetrandrine reduces the activation of the ARC channels by carbachol and correspondingly inhibits the [Ca(2+)](i) signals induced by low carbachol concentrations, while those signals seen at high agonist concentrations are essentially unaffected. In the pancreatic acinar cells, activation by cholecystokinin induces a current through the ARC channels that is only approximately 60% of that seen with carbachol, which is consistent with previous reports indicating that carbachol-induced [Ca(2+)](i) signals in these cells are much more dependent on Ca(2+) entry than are the cholecystokinin-induced responses.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "vicuna-13b_response": "The human acrocentric chromosomes involved in Robertsonian translocation are chromosomes 21 and 22. The non-mosaic de novo Robertsonian translocation 21q;21q involves the exchange of the long arms of chromosomes 21, resulting in a rearrangement of genetic material between these two chromosomes. In this specific case, the genotypes indicated a biparental origin, meaning that one 21q was paternal and the other maternal. This suggests that the formation of the rob(21q;21q) occurs in the zygote or in the first few postzygotic mitotic divisions.",
    "vicuna-13b_fact_raw": "1. Chromosomes 21 and 22 are human acrocentric chromosomes involved in Robertsonian translocation.\n2. Robertsonian translocation can involve the exchange of the long arms of chromosomes.\n3. The non-mosaic de novo Robertsonian translocation 21q;21q is an example of such translocation involving chromosome 21.\n4. In the case of Robertsonian translocation 21q;21q, one 21q is paternal and the other is maternal, indicating a biparental origin.\n5. The formation of rob(21q;21q) occurs in the zygote or in the first few postzygotic mitotic divisions.",
    "vicuna-13b_fact": [
      "Chromosomes 21 and 22 are human acrocentric chromosomes involved in Robertsonian translocation.",
      "Robertsonian translocation can involve the exchange of the long arms of chromosomes.",
      "The non-mosaic de novo Robertsonian translocation 21q;21q is an example of such translocation involving chromosome 21.",
      "In the case of Robertsonian translocation 21q;21q, one 21q is paternal and the other is maternal, indicating a biparental origin.",
      "The formation of rob(21q;21q) occurs in the zygote or in the first few postzygotic mitotic divisions."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: In the case of Robertsonian translocation 21q;21q, both arms are maternal or paternal, not biparental, indicating a uniparental origin. This type of translocation is incompatible with life and leads to miscarriage.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "vicuna-13b_response": "An R package that could be used for the identification of pediatric brain tumors is \"brainmrs\". This package provides a set of functions for analyzing in vivo proton magnetic resonance spectroscopy (MRS) data of the brain. It includes functions for processing and analyzing MRS data, as well as functions for calculating various metabolite ratios and comparing them to reference values. The package also includes functions for visualizing the results of the MRS analysis, such as plots of the metabolite ratios over time or between different groups of patients. Additionally, there are also functions for evaluating the diagnostic performance of different metabolite ratios for different types of brain tumors.",
    "vicuna-13b_fact_raw": "1. The R package \"brainmrs\" can be used for the identification of pediatric brain tumors.\n2. The \"brainmrs\" package includes functions for processing and analyzing in vivo proton magnetic resonance spectroscopy (MRS) data of the brain.\n3. \"brainmrs\" provides functions for calculating various metabolite ratios and comparing them to reference values.\n4. The package contains functions for visualizing MRS analysis results, including plots of metabolite ratios.\n5. \"brainmrs\" includes functions for evaluating the diagnostic performance of different metabolite ratios for different types of brain tumors.",
    "vicuna-13b_fact": [
      "The R package \"brainmrs\" can be used for the identification of pediatric brain tumors.",
      "The \"brainmrs\" package includes functions for processing and analyzing in vivo proton magnetic resonance spectroscopy (MRS) data of the brain.",
      "\"brainmrs\" provides functions for calculating various metabolite ratios and comparing them to reference values.",
      "The package contains functions for visualizing MRS analysis results, including plots of metabolite ratios.",
      "\"brainmrs\" includes functions for evaluating the diagnostic performance of different metabolite ratios for different types of brain tumors."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or access to the documentation or description of the \"brainmrs\" R package, it is not possible to reliably confirm or correct these statements. They pertain to specific features of a specialized software package, and determining their accuracy would require consulting the package's documentation or having domain expertise in magnetic resonance spectroscopy data analysis.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "vicuna-13b_response": "Based on the provided information, NEMO (NF-kappaB essential modulator) is a regulatory protein that plays a crucial role in the canonical NF-kappaB signaling pathway, which is involved in immune and inflammatory responses, apoptosis, and oncogenesis. The document also states that the zinc finger (ZF) motif located in the regulatory C-terminal half of NEMO forms a specific complex with ubiquitin. The authors of the document have investigated the NEMO ZF-ubiquitin interaction and proposed a structural model of the complex based on NMR, fluorescence, and mutagenesis data, as well as on the sequence homology with the polymerase eta ubiquitin-binding zinc finger involved in DNA repair.\nFunctional complementation assays and in vivo pull-down experiments further show that ZF residues involved in ubiquitin binding are functionally important and required for NF-kappaB signaling in response to tumor necrosis factor-alpha. Therefore, the document concludes that NEMOZF is a bona fide ubiquitin-binding domain of the ubiquitin-binding zinc finger type.\nBased on the information provided in the document, it can be inferred that NEMO is a zinc finger protein that binds to ubiquitin.",
    "vicuna-13b_fact_raw": "1. NEMO (NF-kappaB essential modulator) is involved in the canonical NF-kappaB signaling pathway.\n2. The canonical NF-kappaB signaling pathway is associated with immune and inflammatory responses, apoptosis, and oncogenesis.\n3. The zinc finger (ZF) motif in NEMO is located in the regulatory C-terminal half of the protein.\n4. NEMO's zinc finger motif forms a complex with ubiquitin.\n5. The zinc finger residues in NEMO that are involved in ubiquitin binding are functionally important for NF-kappaB signaling in response to tumor necrosis factor-alpha.",
    "vicuna-13b_fact": [
      "NEMO (NF-kappaB essential modulator) is involved in the canonical NF-kappaB signaling pathway.",
      "The canonical NF-kappaB signaling pathway is associated with immune and inflammatory responses, apoptosis, and oncogenesis.",
      "The zinc finger (ZF) motif in NEMO is located in the regulatory C-terminal half of the protein.",
      "NEMO's zinc finger motif forms a complex with ubiquitin.",
      "The zinc finger residues in NEMO that are involved in ubiquitin binding are functionally important for NF-kappaB signaling in response to tumor necrosis factor-alpha."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The zinc finger (ZF) motif in NEMO is not located in the regulatory C-terminal half of the protein, but is actually found in the N-terminal region, specifically at the NEMO UBAN (Ubiquitin binding in ABIN and NEMO) domain.\n4. FALSE [correction]: The UBAN domain, not the zinc finger motif, in NEMO forms a complex with ubiquitin.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "vicuna-13b_response": "Based on the provided document, TFIIS can affect nucleosome positioning. The document states that TFIIS stimulates RNA cleavage by RNA polymerase II and promotes the resolution of backtracking events, and it acts in the chromatin context. The document also mentions that co-transcriptional chromatin alterations include subtle changes in nucleosome positioning, which are elusive to detect, and that the most popular method to map nucleosomes involves intensive chromatin digestion by micrococcal nuclease (MNase), which misses any MNase-sensitive nucleosomes caused by transcription. The document also mentions that a systematic way of correcting this bias for massively parallel sequencing experiments is still missing. The document then goes on to describe a refined nucleosome-mapping method in Saccharomyces cerevisiae that is based on partial MNase digestion and a sequence-bias correction derived from naked DNA cleavage, which can efficiently map nucleosomes in promoter regions rich in MNase-sensitive structures, and with this improved method, the authors analyzed the global nucleosomal changes caused by lack of TFIIS and detected a general increase in nucleosomal fuzziness and more restricted changes in nucleosome occupancy, which concentrated in some gene categories. The document concludes that the detected chromatin alterations correlated with functional defects in nascent transcription, as revealed by genomic run-on experiments, and that TFIIS generally contributed to nucleosome positioning in both gene promoters and bodies, and the independent effect of lack of TFIIS on nucleosome occupancy and fuzziness supports the existence of alternative chromatin dynamics during transcription elongation.",
    "vicuna-13b_fact_raw": "1. TFIIS stimulates RNA cleavage by RNA polymerase II and promotes the resolution of backtracking events.\n2. Co-transcriptional chromatin alterations include subtle changes in nucleosome positioning, which are difficult to detect.\n3. The most popular method to map nucleosomes involves chromatin digestion by micrococcal nuclease (MNase).\n4. A refined nucleosome-mapping method in Saccharomyces cerevisiae utilizes partial MNase digestion and a sequence-bias correction derived from naked DNA cleavage.\n5. Lack of TFIIS causes a general increase in nucleosomal fuzziness and changes in nucleosome occupancy in specific gene categories.",
    "vicuna-13b_fact": [
      "TFIIS stimulates RNA cleavage by RNA polymerase II and promotes the resolution of backtracking events.",
      "Co-transcriptional chromatin alterations include subtle changes in nucleosome positioning, which are difficult to detect.",
      "The most popular method to map nucleosomes involves chromatin digestion by micrococcal nuclease (MNase).",
      "A refined nucleosome-mapping method in Saccharomyces cerevisiae utilizes partial MNase digestion and a sequence-bias correction derived from naked DNA cleavage.",
      "Lack of TFIIS causes a general increase in nucleosomal fuzziness and changes in nucleosome occupancy in specific gene categories."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements correspond with general knowledge on the topic. TFIIS is indeed known to stimulate RNA cleavage by RNA polymerase II, chromatin changes can be subtle during transcription, chromatin digestion by MNase is a common nucleosome mapping method, and a refined nucleosome-mapping method involving partial MNase digestion and sequence-bias correction from naked DNA is a known technique in yeast. \n\nThe fifth statement about the lack of TFIIS and its effects is more specific and would depend on the results of particular studies or experiments that are not part of common knowledge and are not indicated within the context provided, making it difficult to verify without additional information.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "vicuna-13b_response": "Based on the information provided in the document, it appears that origins of replication that are close to yeast centromeres fire late, not early. The study identified a stretch of 200 bp that was sufficient to compel nearby origins to fire late, and all origins that fire in very late S phase were located close to a cluster of LCS elements. This suggests that the default firing time of origins of replication in yeast is early in S phase, and that origins can be forced to fire later by proximity to certain cis-acting sequences, such as the LCS elements identified in the study.",
    "vicuna-13b_fact_raw": "1. Origins of replication close to yeast centromeres fire late.\n2. A 200 bp stretch was identified that can compel nearby origins to fire late.\n3. Origins that fire in very late S phase are located close to a cluster of LCS (Late Conserved Sequence) elements.\n4. The default firing time of origins of replication in yeast is early in S phase.\n5. The timing of origin firing can be altered by proximity to certain cis-acting sequences like LCS elements.",
    "vicuna-13b_fact": [
      "Origins of replication close to yeast centromeres fire late.",
      "A 200 bp stretch was identified that can compel nearby origins to fire late.",
      "Origins that fire in very late S phase are located close to a cluster of LCS (Late Conserved Sequence) elements.",
      "The default firing time of origins of replication in yeast is early in S phase.",
      "The timing of origin firing can be altered by proximity to certain cis-acting sequences like LCS elements."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Origins of replication close to yeast centromeres are generally known to fire late in the S phase of the cell cycle.\n2. UNKNOWN: Without specific information about the research paper or experimental data that identified a 200 bp stretch, it's unclear whether this statement is true or false.\n3. TRUE: Origins that fire very late in S phase are often associated with clusters of Late Conserved Sequence (LCS) elements.\n4. TRUE: The default firing time for most origins of replication in yeast is early in S phase, although this timing can be influenced by various factors, including proximity to chromosome structure elements like centromeres.\n5. TRUE: The timing of origin firing can indeed be influenced by proximity to certain cis-acting sequences, including LCS elements. These sequences can act as regulatory elements for the timing of replication initiation.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "vicuna-13b_response": "The properties of mammalian GA-sequences are as follows:\n1. They are longer than 50 bases and consist exclusively of G's and A's.\n2. Their frequency of incidence should be 10(-16) or smaller.\n3. They are ubiquitously located along the chromosomes with a species-dependent density, reaching sizes of up to 1300 b.\n4. They are unique individuals and contain several repeated short GA-containing motifs.\n5. They share a common hexa-nucleotide spectrum.\n6. At most 2% of the human GA-sequences were transcribed into mRNAs; all others were not coding for proteins.\n7. They contain many times fewer point mutations than one should expect from the genome at large.\n8. There are approximately as many pure TC-sequences as pure GA-sequences, but many fewer pure AC-, TA, and TG-sequences.\n9. There are practically no pure GC-sequences.\n10. The functions of pure GA-sequences are not known, but they may serve as genomic sign posts which may help guide polymerases and transcription factors to their proper targets, and/or as spatial linkers that help generate the 3-dimensional organization of chromatin.\nIt is worth noting that this information is based on a specific article and may not be generalizable to all mammalian genomes.",
    "vicuna-13b_fact_raw": "1. Mammalian GA-sequences are longer than 50 bases and consist exclusively of G's and A's.\n2. The frequency of incidence of mammalian GA-sequences is 10(-16) or smaller.\n3. Mammalian GA-sequences can reach sizes of up to 1300 bases.\n4. At most 2% of the human GA-sequences were transcribed into mRNAs.\n5. There are approximately as many pure TC-sequences as pure GA-sequences in the human genome.",
    "vicuna-13b_fact": [
      "Mammalian GA-sequences are longer than 50 bases and consist exclusively of G's and A's.",
      "The frequency of incidence of mammalian GA-sequences is 10(-16) or smaller.",
      "Mammalian GA-sequences can reach sizes of up to 1300 bases.",
      "At most 2% of the human GA-sequences were transcribed into mRNAs.",
      "There are approximately as many pure TC-sequences as pure GA-sequences in the human genome."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Mammalian GA-sequences do not exclusively consist of G's and A's, as there may be exceptions; additionally, the length of \"longer than 50 bases\" is not enough information to assert the nature of all GA-sequences in mammals.\n2. UNKNOWN: This statement's accuracy cannot be determined without specific scientific references regarding the frequency of incidence of mammalian GA-sequences.\n3. UNKNOWN: Without scientific literature or specific research data, it's not possible to verify the maximum size of mammalian GA-sequences.\n4. UNKNOWN: The exact percentage of human GA-sequences that are transcribed into mRNAs requires empirical data which is not provided.\n5. UNKNOWN: The comparison of frequency between pure TC-sequences and pure GA-sequences in the human genome needs specific genetic data or research findings for verification.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "vicuna-13b_response": "Based on the information provided in Document-0, at least four Groucho-related genes (GRG) are contained in the mouse genome. The Groucho protein interacts with Hairy-related transcription factors to regulate segmentation, neurogenesis, and sex determination in Drosophila, and it is expected that murine Grg proteins may interact with mammalian Hairy and E(spl) homologues (Hes proteins) and take part in a signalling pathway downstream of murine Notch. The authors have isolated murine Grg4 cDNAs and examined Grg4 expression during embryogenesis, and transcripts of Grg4 were detected in proliferating epithelial tissues undergoing mesenchymal induction, overlapping with Grg3, Notch1, and Hes1 expression. Grg4 was also expressed in the central nervous system and somites, but in cells adjacent to Grg3-, Notch1-, and Hes1-expressing cells. This distinct pattern of expression suggests a role for Grg4 in later stages of cell differentiation than for the other mouse neurogenic gene homologues.",
    "vicuna-13b_fact_raw": "1. The mouse genome contains at least four Groucho-related genes (GRG).\n2. Groucho protein in Drosophila regulates segmentation, neurogenesis, and sex determination.\n3. Murine Grg proteins are expected to interact with mammalian Hairy and E(spl) homologues (Hes proteins).\n4. Grg4 expression in mice was detected in proliferating epithelial tissues undergoing mesenchymal induction.\n5. Murine Grg4 was expressed in the central nervous system and somites, with a distinct pattern suggesting a role in later stages of cell differentiation.",
    "vicuna-13b_fact": [
      "The mouse genome contains at least four Groucho-related genes (GRG).",
      "Groucho protein in Drosophila regulates segmentation, neurogenesis, and sex determination.",
      "Murine Grg proteins are expected to interact with mammalian Hairy and E(spl) homologues (Hes proteins).",
      "Grg4 expression in mice was detected in proliferating epithelial tissues undergoing mesenchymal induction.",
      "Murine Grg4 was expressed in the central nervous system and somites, with a distinct pattern suggesting a role in later stages of cell differentiation."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The mouse genome does contain multiple Groucho-related genes, which are homologous to the Drosophila Groucho gene.\n2. TRUE: In Drosophila, the Groucho protein is known to regulate segmentation, neurogenesis, sex determination, and other developmental processes.\n3. TRUE: It is plausible that murine Grg proteins (the mammalian homologs of Groucho) interact with mammalian homologues of Hairy and E(spl) proteins, which are known as Hes proteins.\n4. TRUE: Grg4 expression in mice can be detected in various tissues, including proliferating epithelial tissues that are undergoing mesenchymal induction, which is consistent with the known roles of Groucho-related genes in development.\n5. TRUE: Murine Grg4 is expressed in the central nervous system and somites, and the distinct pattern of expression does suggest a role in later stages of cell differentiation, in alignment with its potential regulatory functions similar to its Drosophila counterpart.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "vicuna-13b_response": "The RNA polymerase II subunit that carries RNA cleavage activity is the largest subunit of RNAP II. The C-terminal domain (CTD) of this subunit was found to be responsible for the pre-mRNA polyadenylation cleavage reaction in vitro. The cleavage activity was found to reside in the heptapeptides of the CTD, specifically in the vicinity of amino acids 30 to 37. The non-consensus heptads of the CTD contribute only 20% of the wild-type cleavage activity, while the remaining 80% directly correlates with the length of the CTD, requiring approximately 26 or more repeats for significant activity. These results suggest that the RNAP II CTD functions as a scaffold for the pre-mRNA cleavage reaction.",
    "vicuna-13b_fact_raw": "1. The largest subunit of RNA polymerase II contains RNA cleavage activity.\n2. The cleavage activity for pre-mRNA polyadenylation is attributable to the C-terminal domain (CTD) of the largest subunit.\n3. The cleavage activity localizes in the vicinity of amino acids 30 to 37 of the heptapeptides in the CTD.\n4. Non-consensus heptads of the CTD contribute 20% of the wild-type cleavage activity.\n5. Approximately 26 or more repeats of the CTD are required for significant cleavage activity.",
    "vicuna-13b_fact": [
      "The largest subunit of RNA polymerase II contains RNA cleavage activity.",
      "The cleavage activity for pre-mRNA polyadenylation is attributable to the C-terminal domain (CTD) of the largest subunit.",
      "The cleavage activity localizes in the vicinity of amino acids 30 to 37 of the heptapeptides in the CTD.",
      "Non-consensus heptads of the CTD contribute 20% of the wild-type cleavage activity.",
      "Approximately 26 or more repeats of the CTD are required for significant cleavage activity."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The largest subunit of RNA polymerase II does not contain RNA cleavage activity. The cleavage activity for pre-mRNA processing is carried out by a different set of proteins that form the cleavage and polyadenylation specificity factor (CPSF) and other associated factors.\n2. FALSE [correction]: The cleavage activity for pre-mRNA polyadenylation is not attributable to the C-terminal domain (CTD) of the largest subunit of RNA polymerase II. The CTD is involved in the process of transcription and processing of pre-mRNA by serving as a binding site for various proteins, but the actual cleavage activity is performed by specific cleavage factors.\n3. FALSE [correction]: Since the cleavage activity is not attributable to the CTD, it is incorrect to say that the cleavage activity localizes in the vicinity of amino acids 30 to 37 of the heptapeptides in the CTD. The cleavage activity occurs in a complex of proteins that includes CPSF, not within the CTD heptapeptides.\n4. FALSE [correction]: As the CTD of RNA polymerase II does not contain the RNA cleavage activity, it is not correct to attribute a percentage of cleavage activity to non-consensus heptads of the CTD. The wild-type cleavage activity is associated with the cleavage factors that process pre-mRNA.\n5. UNKNOWN: This statement appears to be about the CTD and its repeats. While it is known that the CTD of RNA polymerase II contains multiple tandem repeats that are important for transcription and processing events, the exact number of repeats required for significant cleavage activity is not stated, as cleavage activity is executed by different proteins. The necessity of a specific number of repeats for significant cleavage activity in relation to this context is not clear or universally established to provide a true or false judgement.",
    "vicuna-13b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "vicuna-13b_response": "Answer: The genetic basis of Ohdo syndrome is not known. The condition is characterized by a wide range of dysmorphic features and congenital abnormalities, including blepharophimosis, ptosis, dental hypoplasia, hearing impairment, and intellectual disability. A review of the literature suggests that all cases with the severe phenotype have been sporadic, and subtelomeric FISH studies of all chromosome arms have not revealed any abnormality. While some cases have been reported, there is currently no known genetic test for Ohdo syndrome. Further research is needed to determine the underlying genetic causes of this condition.",
    "vicuna-13b_fact_raw": "1. Ohdo syndrome is characterized by dysmorphic features and congenital abnormalities, including blepharophimosis, ptosis, dental hypoplasia, hearing impairment, and intellectual disability.\n2. All cases with the severe phenotype of Ohdo syndrome have been reported to be sporadic.\n3. Subtelomeric FISH studies of all chromosome arms have not revealed any abnormalities in individuals with Ohdo syndrome.\n4. There is currently no known genetic test for Ohdo syndrome.\n5. Further research is needed to determine the underlying genetic causes of Ohdo syndrome.",
    "vicuna-13b_fact": [
      "Ohdo syndrome is characterized by dysmorphic features and congenital abnormalities, including blepharophimosis, ptosis, dental hypoplasia, hearing impairment, and intellectual disability.",
      "All cases with the severe phenotype of Ohdo syndrome have been reported to be sporadic.",
      "Subtelomeric FISH studies of all chromosome arms have not revealed any abnormalities in individuals with Ohdo syndrome.",
      "There is currently no known genetic test for Ohdo syndrome.",
      "Further research is needed to determine the underlying genetic causes of Ohdo syndrome."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: Not all cases with the severe phenotype of Ohdo syndrome have been reported to be sporadic; some cases have been found to have a genetic basis.\n3. TRUE  Based on the wording \"have not revealed any abnormalities,\" this could be accurate; however, the lack of abnormalities in subtelomeric FISH studies does not rule out other genetic abnormalities that could be detected using different methods or in other regions of the genome.\n4. FALSE [correction]: There are known genetic tests for Ohdo syndrome, such as sequencing genes known to be associated with the condition, like KAT6B and MED12.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "vicuna-13b_response": "The R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is not specified in the given information. However, the information provides a solution to integrate chemical-gene or chemical-disease relationships into R/Bioconductor analysis pipelines through a package called CTDquerier. CTDquerier is a flexible and easy-to-use Bioconductor package that provides novel hypotheses about the relationships between chemicals and diseases by allowing users to easily download CTD data and integrate it into the R/Bioconductor framework. The package also contains functions for visualizing CTD data and performing enrichment analyses. CTDquerier is available through Bioconductor and its development version at <https://github.com/isglobal-brge/CTDquerier>. Supplementary data are available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. CTDquerier is a Bioconductor package that integrates chemical-gene or chemical-disease relationships into R/Bioconductor analysis pipelines.\n2. CTDquerier allows users to download CTD data for use with R/Bioconductor.\n3. CTDquerier contains functions for visualizing CTD data.\n4. CTDquerier also includes functions for performing enrichment analyses.\n5. The development version of CTDquerier can be found at <https://github.com/isglobal-brge/CTDquerier>.",
    "vicuna-13b_fact": [
      "CTDquerier is a Bioconductor package that integrates chemical-gene or chemical-disease relationships into R/Bioconductor analysis pipelines.",
      "CTDquerier allows users to download CTD data for use with R/Bioconductor.",
      "CTDquerier contains functions for visualizing CTD data.",
      "CTDquerier also includes functions for performing enrichment analyses.",
      "The development version of CTDquerier can be found at <https://github.com/isglobal-brge/CTDquerier>."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "vicuna-13b_response": "The \"swirl sign\" is a radiological finding observed on non-contrast computed tomography (CT) scans of patients with head trauma who have developed extradural hematomas. It is characterized by two components: a hyperacute component, which indicates ongoing active intracranial bleeding, and an acute component, which consists of surrounding hyperattenuated clotted blood. Early identification of this sign by surgeons is crucial, as it suggests the presence of expanding extradural hematoma with ongoing active bleeding, requiring aggressive surgical management. Failure to recognize and promptly treat the swirl sign has been associated with poor outcomes and decreased survival rates. Two clinical scenarios are provided to emphasize the importance of the swirl sign in the management of intracranial hemorrhage.",
    "vicuna-13b_fact_raw": "1. The \"swirl sign\" is a radiological finding seen on non-contrast CT scans.\n2. It is associated with patients who have head trauma and developed extradural hematomas.\n3. The \"swirl sign\" includes a hyperacute component indicating ongoing active intracranial bleeding.\n4. The \"swirl sign\" also includes an acute component consisting of surrounding hyperattenuated clotted blood.\n5. Early identification of the \"swirl sign\" suggests the need for aggressive surgical management.",
    "vicuna-13b_fact": [
      "The \"swirl sign\" is a radiological finding seen on non-contrast CT scans.",
      "It is associated with patients who have head trauma and developed extradural hematomas.",
      "The \"swirl sign\" includes a hyperacute component indicating ongoing active intracranial bleeding.",
      "The \"swirl sign\" also includes an acute component consisting of surrounding hyperattenuated clotted blood.",
      "Early identification of the \"swirl sign\" suggests the need for aggressive surgical management."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "vicuna-13b_response": "Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase and a member of the FKBP (FK506 binding protein) family. ROF1 expression is induced by heat stress and developmentally regulated. In this study, it was found that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain, and localizes in the cytoplasm under normal conditions. Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent upon the presence of the transcription factor HsfA2, which interacts with HSP90.1 but not with ROF1. Nuclear localization of ROF1 was not detected in Arabidopsis HSP90.1 and HsfA2 knockout mutants. The rof1 knockout plants exhibited collapse when 24-48 h passed between acclimation at 37 degrees C and exposure to 45 degrees C. Transgenic ROF1 over-expressors showed better survival in response to exposure to 45 degrees C than wild-type plants did. In rof1 knockout mutants, the level of expression of small HSPs regulated by HsfA2 was dramatically reduced after exposure to 37 degrees C and recovery for 24-48 h, and correlates well with the mutant phenotype. The study suggests a role for ROF1 in prolongation of thermotolerance by sustaining the levels of small HSPs that are essential for survival at high temperatures.",
    "vicuna-13b_fact_raw": "1. Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase part of the FKBP family.\n2. ROF1 expression in Arabidopsis is induced by heat stress.\n3. The ROF1-HSP90.1 complex exhibits induced nuclear localization under heat stress and requires the transcription factor HsfA2.\n4. Arabidopsis HSP90.1 and HsfA2 knockout mutants do not show nuclear localization of ROF1.\n5. Transgenic ROF1 over-expressors in Arabidopsis have better survival rates at 45 degrees Celsius compared to wild-type plants.",
    "vicuna-13b_fact": [
      "Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase part of the FKBP family.",
      "ROF1 expression in Arabidopsis is induced by heat stress.",
      "The ROF1-HSP90.1 complex exhibits induced nuclear localization under heat stress and requires the transcription factor HsfA2.",
      "Arabidopsis HSP90.1 and HsfA2 knockout mutants do not show nuclear localization of ROF1.",
      "Transgenic ROF1 over-expressors in Arabidopsis have better survival rates at 45 degrees Celsius compared to wild-type plants."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThese statements require specific knowledge of the biological research surrounding Arabidopsis thaliana, ROF1, and heat stress responses. Up until my knowledge cutoff date in 2023, these statements are consistent with scientific findings regarding the heat stress response of Arabidopsis and the involvement of ROF1, HSP90.1, HsfA2, and their interactions and functions.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "vicuna-13b_response": "The most common cause of hereditary renal amyloidosis is a variant fibrinogen alpha-chain, as demonstrated in a family with three members who died from renal amyloidosis and were found to share a single nucleotide substitution in the fibrinogen alpha-chain gene. The specific mutation identified in this case is the arginine to leucine mutation (Arg554Leu). This is the first reported case of hereditary amyloidosis associated with a variant fibrinogen alpha-chain. Variants of circulating fibrinogen may be the cause of a number of systemic amyloidoses with primarily renal involvement.",
    "vicuna-13b_fact_raw": "1. A variant fibrinogen alpha-chain is the most common cause of hereditary renal amyloidosis.\n2. A family with hereditary renal amyloidosis was found to share a single nucleotide substitution in the fibrinogen alpha-chain gene.\n3. The specific mutation identified in the case of hereditary renal amyloidosis is an arginine to leucine mutation (Arg554Leu).\n4. The arginine to leucine mutation in the fibrinogen alpha-chain gene was the first reported case of hereditary amyloidosis associated with a variant fibrinogen alpha-chain.\n5. Variants of circulating fibrinogen may cause systemic amyloidoses with primarily renal involvement.",
    "vicuna-13b_fact": [
      "A variant fibrinogen alpha-chain is the most common cause of hereditary renal amyloidosis.",
      "A family with hereditary renal amyloidosis was found to share a single nucleotide substitution in the fibrinogen alpha-chain gene.",
      "The specific mutation identified in the case of hereditary renal amyloidosis is an arginine to leucine mutation (Arg554Leu).",
      "The arginine to leucine mutation in the fibrinogen alpha-chain gene was the first reported case of hereditary amyloidosis associated with a variant fibrinogen alpha-chain.",
      "Variants of circulating fibrinogen may cause systemic amyloidoses with primarily renal involvement."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The most common cause of hereditary renal amyloidosis is a variant in the protein transthyretin (TTR), not the fibrinogen alpha-chain.\n2. TRUE - This statement is consistent with the genetic basis of hereditary diseases, where a mutation is passed down within a family.\n3. TRUE - The Arg554Leu mutation in the fibrinogen alpha-chain gene is indeed associated with familial renal amyloidosis.\n4. UNKNOWN - Without further context, it cannot be confirmed whether the Arg554Leu mutation was the first reported case of this kind.\n5. TRUE - Variants of circulating fibrinogen can indeed cause systemic amyloidoses, including those with primary renal involvement.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it appears that the proteome of mice hippocampus has not been extensively analyzed. While there have been proteomic studies on the hippocampus of other species, such as human and rat, no extensive analysis has been carried out in mice. However, the document goes on to describe a proteomic study that was conducted on the hippocampus of five different mouse strains, which identified 469 individual proteins expressed in the mouse hippocampus. This study was conducted using a 2-DE coupled to MS (MALDI-TOF/TOF) approach and provides a comprehensive reference database of proteins expressed in the mouse hippocampus. The study may provide insight into the characteristics of proteins serving the highly sophisticated function of the hippocampus in neuronal information processing and storage.",
    "vicuna-13b_fact_raw": "1. Proteomic studies on the hippocampus have been conducted on species such as human and rat.\n2. There has been no extensive analysis of the proteome of mice hippocampus.\n3. A study that was conducted on the hippocampus of five different mouse strains identified 469 individual proteins expressed in the mouse hippocampus.\n4. The aforementioned proteomic study used a 2-DE coupled to MS (MALDI-TOF/TOF) approach.\n5. The study on mouse hippocampus proteins provides a comprehensive reference database for proteins expressed in the mouse hippocampus.",
    "vicuna-13b_fact": [
      "Proteomic studies on the hippocampus have been conducted on species such as human and rat.",
      "There has been no extensive analysis of the proteome of mice hippocampus.",
      "A study that was conducted on the hippocampus of five different mouse strains identified 469 individual proteins expressed in the mouse hippocampus.",
      "The aforementioned proteomic study used a 2-DE coupled to MS (MALDI-TOF/TOF) approach.",
      "The study on mouse hippocampus proteins provides a comprehensive reference database for proteins expressed in the mouse hippocampus."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: There has been extensive analysis of the proteome of mice hippocampus, including the study mentioned in the third statement.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the answer to the question \"Are mouse chromosomes acrocentric?\" is no. The document states that all of the chromosomes in the mouse karyotype are morphologically very similar, and that the only acrocentric chromosomes are chromosomes 19 and the sex chromosomes. The rest of the chromosomes are metacentric, including nine pairs of metacentric Robertsonian translocation (Rb) chromosomes containing chromosomes 1 to 18. The presence of these metacentric chromosomes indicates that mouse chromosomes are not acrocentric.",
    "vicuna-13b_fact_raw": "1. All of the chromosomes in the mouse karyotype are morphologically very similar.\n2. In mice, only chromosome 19 and the sex chromosomes are acrocentric.\n3. The rest of the mouse chromosomes are metacentric.\n4. There are nine pairs of metacentric Robertsonian translocation (Rb) chromosomes containing chromosomes 1 to 18 in mice.",
    "vicuna-13b_fact": [
      "All of the chromosomes in the mouse karyotype are morphologically very similar.",
      "In mice, only chromosome 19 and the sex chromosomes are acrocentric.",
      "The rest of the mouse chromosomes are metacentric.",
      "There are nine pairs of metacentric Robertsonian translocation (Rb) chromosomes containing chromosomes 1 to 18 in mice."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Not all of the chromosomes in the mouse karyotype are morphologically very similar; there are both metacentric and acrocentric chromosomes.\n2. FALSE [correction]: In mice, multiple chromosomes are acrocentric, not only chromosome 19 and the sex chromosomes. \n3. FALSE [correction]: While many mouse chromosomes are metacentric, it is not accurate to say that all non-acrocentric chromosomes are metacentric without specifying which ones.\n4. UNKNOWN",
    "vicuna-13b_judge": [
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "vicuna-13b_response": "Based on the given information, it appears that a siRNA-based drug is being investigated for the treatment of pancreatic cancer. Specifically, the study aimed to investigate the impact of k-ras oncogene silencing on pancreatic tumor growth and the therapeutic potential of combining k-ras siRNA with gemcitabine. The results of the study showed that targeting mutant k-ras through specific siRNA was effective for k-ras oncogene silencing and tumor growth inhibition. Additionally, the combination of k-ras siRNA and gemcitabine resulted in strong growth inhibition of orthotopic pancreatic tumors and prolonged survival. Therefore, it can be concluded that the siRNA-based drug being investigated has potential as a treatment for pancreatic cancer.",
    "vicuna-13b_fact_raw": "1. A siRNA-based drug is under investigation for the treatment of pancreatic cancer.\n2. The study focused on the impact of silencing the k-ras oncogene on pancreatic tumor growth.\n3. Targeting the mutant k-ras with specific siRNA was found to be effective for silencing the gene and inhibiting tumor growth.\n4. Combining k-ras siRNA with gemcitabine led to a significant inhibition of tumor growth in orthotopic pancreatic tumors.\n5. The combination of k-ras siRNA and gemcitabine prolonged the survival in the context of the study.",
    "vicuna-13b_fact": [
      "A siRNA-based drug is under investigation for the treatment of pancreatic cancer.",
      "The study focused on the impact of silencing the k-ras oncogene on pancreatic tumor growth.",
      "Targeting the mutant k-ras with specific siRNA was found to be effective for silencing the gene and inhibiting tumor growth.",
      "Combining k-ras siRNA with gemcitabine led to a significant inhibition of tumor growth in orthotopic pancreatic tumors.",
      "The combination of k-ras siRNA and gemcitabine prolonged the survival in the context of the study."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Small interfering RNA (siRNA) based drugs are an emerging area of research and could feasibly be under investigation for various forms of cancer, including pancreatic cancer.\n2. TRUE: Given the context of pancreatic cancer and siRNA, it is plausible that the study focused on silencing the k-ras oncogene, which is known to be commonly mutated in pancreatic cancer.\n3. TRUE: If the context mentions an investigation of siRNA for treating pancreatic cancer by targeting k-ras, and since k-ras is a well-known target in such research, it is reasonable to assume that the statement about the effectiveness of siRNA for silencing the gene and inhibiting tumor growth is true.\n4. TRUE: The statement logically follows from the previous points, suggesting that the study may have investigated the combined effect of k-ras siRNA with an established chemotherapy drug, gemcitabine, which is commonly used to treat pancreatic cancer.\n5. TRUE: If combining k-ras siRNA with gemcitabine led to significant inhibition of tumor growth, it is a reasonable conclusion that this could have extended survival in the context of the study. However, it's worth noting that the statement would require specific results from the study to be factual, and without access to the actual results, this response is based on the context provided.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "vicuna-13b_response": "The HPG pore refers to a type of pore structure in a dosage form, specifically in tablets, that is formed by the compacting of a heterodisperse polysaccharide (HP) based granule. The study mentioned in Document-0 aimed to investigate the release-controlling action of HP-based materials in relation to the initial pore structure of the formulations. The study found that the pore volume and pore size distribution of HP-based tablets produced using matrix tablets were substantially different and that the release of a water-soluble model compound, benzamide, from swollen matrices was not affected by the total porosity or median pore diameter of the initial dry matrix. The study also found that when HP-based formulations containing either diclofenac sodium or propranolol HCl were contained within hard gelatin capsules in the form of uncompacted granules, it produced a dosage form with a high intraparticulate porosity in the dry state. The in vitro release profiles from matrix tablets compacted from any of the formulations did not differ significantly from release profiles obtained when the same materials were contained uncompacted in hard gelatin capsules.",
    "vicuna-13b_fact_raw": "1. The HPG pore refers to a type of pore structure that is formed by the compacting of a heterodisperse polysaccharide based granule.\n2. A study investigated the release-controlling action of heterodisperse polysaccharide-based materials in relation to the initial pore structure of tablet formulations.\n3. The study found that the pore volume and size distribution of heterodisperse polysaccharide-based tablets were substantially different when using matrix tablets.\n4. In the study, the release of benzamide from swollen matrices was not affected by the total porosity or median pore diameter of the initial dry matrix.\n5. When formulations containing diclofenac sodium or propranolol HCl were contained within hard gelatin capsules as uncompacted granules, they produced a dosage form with a high intraparticulate porosity in the dry state.",
    "vicuna-13b_fact": [
      "The HPG pore refers to a type of pore structure that is formed by the compacting of a heterodisperse polysaccharide based granule.",
      "A study investigated the release-controlling action of heterodisperse polysaccharide-based materials in relation to the initial pore structure of tablet formulations.",
      "The study found that the pore volume and size distribution of heterodisperse polysaccharide-based tablets were substantially different when using matrix tablets.",
      "In the study, the release of benzamide from swollen matrices was not affected by the total porosity or median pore diameter of the initial dry matrix.",
      "When formulations containing diclofenac sodium or propranolol HCl were contained within hard gelatin capsules as uncompacted granules, they produced a dosage form with a high intraparticulate porosity in the dry state."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The release of benzamide from swollen matrices was likely affected by the total porosity or median pore diameter of the initial dry matrix, since these parameters are important factors influencing drug release from hydrophilic matrix tablets.\n5. TRUE",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "vicuna-13b_response": "The 959 Nematode Genomes initiative is a community-curated semantic wiki that aims to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda. The wiki is based on the same platform that runs Wikipedia and allows users to track the status of their favorite worm by querying the site with machine- and human-readable metadata. The main goal of the wiki is to track sequencing projects that have been proposed, are in progress, or have been completed. The wiki also provides a way to track and share preliminary data if those data are not polished enough to be submitted to the official sequence repositories. The initiative has already fostered new international collaborations and attracted newcomers to the enthusiastic community of nematode genomicists. The website for the initiative is [www.nematodegenomes.org](http://www.nematodegenomes.org).",
    "vicuna-13b_fact_raw": "1. The 959 Nematode Genomes initiative is a project aiming to coordinate the sequencing of 959 genomes within the phylum Nematoda.\n2. It is a community-curated semantic wiki platform.\n3. The platform used for the 959 Nematode Genomes initiative is the same as the one running Wikipedia.\n4. Users can track the status of worm sequencing projects using machine- and human-readable metadata through the wiki.\n5. The initiative's website is located at www.nematodegenomes.org.",
    "vicuna-13b_fact": [
      "The 959 Nematode Genomes initiative is a project aiming to coordinate the sequencing of 959 genomes within the phylum Nematoda.",
      "It is a community-curated semantic wiki platform.",
      "The platform used for the 959 Nematode Genomes initiative is the same as the one running Wikipedia.",
      "Users can track the status of worm sequencing projects using machine- and human-readable metadata through the wiki.",
      "The initiative's website is located at www.nematodegenomes.org."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: While the specific platform used for the 959 Nematode Genomes initiative isn't stated, Wikipedia runs on the MediaWiki software, which is a specific platform often used for collaborative wiki projects. Without additional context, we cannot determine that the platform used for the initiative is the same as Wikipedia's.\n4. UNKNOWN\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "vicuna-13b_response": "The R package for analyzing Non-invasive prenatal testing (NIPT) data is NIPTmer. It is a software package developed for detecting fetal aneuploidies from next-generation low-coverage whole genome sequencing data. NIPTmer is based on counting pre-defined per-chromosome sets of unique k-mers from raw sequencing data and applying linear regression model on the counts. The processing time of one sample is less than 10 CPU-minutes on a high-end workstation. NIPTmer was validated on a cohort of 583 NIPT samples and it correctly predicted 37 non-mosaic fetal aneuploidies. NIPTmer has the potential to reduce significantly the time and complexity of NIPT post-sequencing analysis compared to mapping-based methods. It is freely available for non-commercial users at <http://bioinfo.ut.ee/NIPTMer/>.",
    "vicuna-13b_fact_raw": "1. NIPTmer is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. NIPTmer is designed to detect fetal aneuploidies from next-generation low-coverage whole genome sequencing data.\n3. NIPTmer operates by counting unique k-mers from raw sequencing data and applying a linear regression model on the counts.\n4. The processing time for one sample with NIPTmer is under 10 CPU-minutes on a high-end workstation.\n5. NIPTmer was validated with 583 NIPT samples and correctly predicted 37 non-mosaic fetal aneuploidies.",
    "vicuna-13b_fact": [
      "NIPTmer is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "NIPTmer is designed to detect fetal aneuploidies from next-generation low-coverage whole genome sequencing data.",
      "NIPTmer operates by counting unique k-mers from raw sequencing data and applying a linear regression model on the counts.",
      "The processing time for one sample with NIPTmer is under 10 CPU-minutes on a high-end workstation.",
      "NIPTmer was validated with 583 NIPT samples and correctly predicted 37 non-mosaic fetal aneuploidies."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nRationale:\n1. NIPTmer is indeed an R package developed for analyzing Non-Invasive Prenatal Testing (NIPT) data.\n2. It is true that NIPTmer is designed to detect fetal aneuploidies from next-generation low-coverage whole genome sequencing data.\n3. NIPTmer operates by counting unique k-mers from raw sequencing data and applies a statistical model to these counts, which can include linear regression among other methods.\n4. The processing time can vary based on different factors such as the sequencing depth, the efficiency of the implementation, and the actual specifications of the workstation. Therefore, without specific data, it is difficult to ascertain the accuracy of this statement.\n5. Without having access to the validation study or specific publication, one cannot determine the truthfulness of the validation result mentioned.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbachs syndrome.",
    "vicuna-13b_response": "Achenbach's syndrome is a rare clinical entity characterized by the presence of spontaneous or mechanically induced hematomas on the volar aspects of fingers, often accompanied by burning pain and swelling of the digits. The condition is named after the German physician, Friedrich Achenbach, who first described it in 1902.\nThe exact cause of Achenbach's syndrome is not well understood, but it is thought to be related to abnormalities in the small blood vessels that supply the fingers. The condition typically affects middle-aged women, and the onset is often sudden and without any apparent trigger.\nThe diagnosis of Achenbach's syndrome is typically made based on the patient's symptoms and physical examination findings. The presence of a painful, swollen finger with a visible hematoma on the volar aspect is a classic sign of the condition. Imaging studies such as X-ray or ultrasound may also be used to confirm the diagnosis and rule out other potential causes of the symptoms.\nTreatment of Achenbach's syndrome typically involves supportive care, such as rest, ice, and nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce pain and inflammation. In some cases, surgical intervention may be necessary to remove the hematoma or repair damaged blood vessels.\nIn summary, Achenbach's syndrome is a rare condition characterized by spontaneous or mechanically induced hematomas on the volar aspects of fingers, often accompanied by burning pain and swelling of the digits. The condition is typically treated with supportive care, and surgical intervention may be necessary in some cases.",
    "vicuna-13b_fact_raw": "1. Achenbach's syndrome is characterized by spontaneous or mechanically induced hematomas on the volar aspects of fingers.\n2. Friedrich Achenbach, a German physician, first described Achenbach's syndrome in 1902.\n3. Achenbach's syndrome is more commonly seen in middle-aged women.\n4. The diagnosis of Achenbach's syndrome is based on symptoms and physical examination, and can involve imaging studies to confirm.\n5. Treatment for Achenbach's syndrome can include rest, ice, NSAIDs, and possibly surgical intervention.",
    "vicuna-13b_fact": [
      "Achenbach's syndrome is characterized by spontaneous or mechanically induced hematomas on the volar aspects of fingers.",
      "Friedrich Achenbach, a German physician, first described Achenbach's syndrome in 1902.",
      "Achenbach's syndrome is more commonly seen in middle-aged women.",
      "The diagnosis of Achenbach's syndrome is based on symptoms and physical examination, and can involve imaging studies to confirm.",
      "Treatment for Achenbach's syndrome can include rest, ice, NSAIDs, and possibly surgical intervention."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: Friedrich Achenbach, a German physician, first described Achenbach's syndrome in 1958.\n3. TRUE\n4. TRUE\n5. TRUE, although surgical intervention is rare and typically not necessary.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "vicuna-13b_response": "The document-0 describes the use of the repeat expansion detection (RED) method for detecting trinucleotide repeat expansions of unknown chromosomal location. The method uses 8-mer oligonucleotides and has been assessed in 30 samples from patients with spinocerebellar ataxia type 1 (SCA1), Huntington's disease (HD), and Machado Joseph's disease (MJD). The correlation between the number of repeats detected by sequencing and those identified by RED was good, but in 17% of samples, the RED gave additional fragments for ligation products of different size than the CAG/CTG repeat expansion detected in the sample by sequencing. The same was observed in a group of control subjects (n = 78) without known clinical abnormalities in which products of more than 40 repeats were detected in 27% of them, indicating that CAG/CTG repeat expansions are common in the general population. The document suggests that the presence of additional fragments may indicate unidentified loci with expansions.\nIt is not specified in the document which algorithm is used for detection of long repeat expansions.",
    "vicuna-13b_fact_raw": "1. The document-0 describes using the repeat expansion detection (RED) method for detecting trinucleotide repeat expansions.\n2. The RED method was assessed in 30 patient samples from individuals with spinocerebellar ataxia type 1 (SCA1), Huntington's disease (HD), and Machado Joseph's disease (MJD).\n3. A correlation between the number of repeats detected by sequencing and those identified by RED was observed.\n4. In 17% of samples, the RED method gave additional fragments for ligation products of different sizes than the CAG/CTG repeat expansion detected by sequencing.\n5. In a control group of 78 subjects without known clinical abnormalities, products of more than 40 repeats were detected in 27% of them.",
    "vicuna-13b_fact": [
      "The document-0 describes using the repeat expansion detection (RED) method for detecting trinucleotide repeat expansions.",
      "The RED method was assessed in 30 patient samples from individuals with spinocerebellar ataxia type 1 (SCA1), Huntington's disease (HD), and Machado Joseph's disease (MJD).",
      "A correlation between the number of repeats detected by sequencing and those identified by RED was observed.",
      "In 17% of samples, the RED method gave additional fragments for ligation products of different sizes than the CAG/CTG repeat expansion detected by sequencing.",
      "In a control group of 78 subjects without known clinical abnormalities, products of more than 40 repeats were detected in 27% of them."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There is not enough information provided to verify the percentage of samples in which the RED method gave additional fragments. Therefore, without this specificity, the statement's accuracy cannot be confirmed.\n5. FALSE [correction]: There is not enough information provided to verify the percentage of subjects in the control group where products of more than 40 repeats were detected. Therefore, without this specificity, the statement's accuracy cannot be confirmed.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "vicuna-13b_response": "Based on the information provided in Document-0, neuroligin-3 does not appear to be directly related to the promotion of brain tumors. Instead, the document describes the discovery of a compound called PF403, which inhibits the Hedgehog (Hh) signaling pathway and displays significant in vivo efficacy against medulloblastoma (MB) and glioblastoma (GBM) brain tumors. The mechanism of action of PF403 is to interrupt the Hh signaling pathway by directly binding or enhancing the interaction of the Smoothened (Smo) receptor with the repressor Ptch1, repressing Gli1 nuclear accumulation and transcription by promoting Sufu-Gli1 and PKA-Gli1 interactions. Therefore, the answer to the question is that PF403, not neuroligin-3, promotes the inhibition of Hh-driven MB and GBM brain tumors.",
    "vicuna-13b_fact_raw": "1. PF403 is a compound that inhibits the Hedgehog (Hh) signaling pathway.\n2. PF403 displays significant in vivo efficacy against medulloblastoma (MB) and glioblastoma (GBM) brain tumors.\n3. PF403 works by interrupting the Hh signaling pathway.\n4. The mechanism of PF403 includes directly binding or enhancing the interaction of the Smoothened (Smo) receptor with the repressor Ptch1.\n5. PF403 represses Gli1 nuclear accumulation and transcription by promoting interactions between Sufu-Gli1 and PKA-Gli1.",
    "vicuna-13b_fact": [
      "PF403 is a compound that inhibits the Hedgehog (Hh) signaling pathway.",
      "PF403 displays significant in vivo efficacy against medulloblastoma (MB) and glioblastoma (GBM) brain tumors.",
      "PF403 works by interrupting the Hh signaling pathway.",
      "The mechanism of PF403 includes directly binding or enhancing the interaction of the Smoothened (Smo) receptor with the repressor Ptch1.",
      "PF403 represses Gli1 nuclear accumulation and transcription by promoting interactions between Sufu-Gli1 and PKA-Gli1."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The correct mechanism for PF403 or any compound that inhibits the Hedgehog (Hh) signaling pathway would involve inhibiting the Hh signaling components, but not necessarily by enhancing the interaction between Smo and Ptch1, as Ptch1 is a repressor of Smo in the absence of Hh ligands. Instead, compounds typically inhibit the pathway by antagonizing the activity of Smo or affecting downstream components.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "vicuna-13b_response": "The approximate size of gas vesicles in the diatom Microcyclus aquaticus is around 100 nm in diameter, as determined by electron microscopy observations. The size of the vesicles increases over time, and they are synthesized in two distinct stages, with the initiation of smaller vesicles resulting in a doubling of the number of vesicles per cell by 90 minutes. The assembly of gas vesicles requires protein and ribonucleic acid synthesis, and inhibition of these processes results in a loss of extant gas vesicles. Deoxyribonucleic acid synthesis is not required for gas vesicle assembly or stability.",
    "vicuna-13b_fact_raw": "1. Gas vesicles in the diatom Microcyclus aquaticus are approximately 100 nm in diameter.\n2. The size of the vesicles in Microcyclus aquaticus increases over time.\n3. The initial assembly of gas vesicles leads to a doubling of the number of vesicles per cell by 90 minutes.\n4. The assembly of gas vesicles in Microcyclus aquaticus requires protein and ribonucleic acid (RNA) synthesis.\n5. Inhibition of protein and RNA synthesis results in a loss of extant gas vesicles in Microcyclus aquaticus.",
    "vicuna-13b_fact": [
      "Gas vesicles in the diatom Microcyclus aquaticus are approximately 100 nm in diameter.",
      "The size of the vesicles in Microcyclus aquaticus increases over time.",
      "The initial assembly of gas vesicles leads to a doubling of the number of vesicles per cell by 90 minutes.",
      "The assembly of gas vesicles in Microcyclus aquaticus requires protein and ribonucleic acid (RNA) synthesis.",
      "Inhibition of protein and RNA synthesis results in a loss of extant gas vesicles in Microcyclus aquaticus."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe given statements pertain to very specific scientific claims about the diatom Microcyclus aquaticus, and determining their accuracy would require access to specialized scientific research or empirical data on the organism. Without such data or a reference to a specific scientific study, it is not possible to ascertain the veracity of these claims.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "vicuna-13b_response": "The Bromodomain and extra-terminal (BET) family proteins are epigenetic \"readers\" that play a key role in the regulation of gene transcription. These proteins, including BRD2, BRD3, BRD4, and the testis-specific BRDT member, are considered attractive therapeutic targets for cancer and other human diseases. Recently, heterobifunctional small-molecule BET degraders have been designed based on the proteolysis targeting chimera (PROTAC) concept to induce BET protein degradation. The document presents the design, synthesis, and evaluation of a new class of PROTAC BET degraders. One of the most promising compounds, 23, effectively degrades the BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line and achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth. In addition, it induces rapid tumor regression in vivo against RS4;11 xenograft tumors. These data establish that compound 23 (BETd-260/ZBC260) is a highly potent and efficacious BET degrader.",
    "vicuna-13b_fact_raw": "1. The BET family proteins include BRD2, BRD3, BRD4, and BRDT.\n2. BET proteins are considered therapeutic targets for cancer and other human diseases.\n3. Heterobifunctional small-molecule BET degraders have been designed based on the PROTAC concept.\n4. Compound 23, also known as BETd-260 or ZBC260, effectively degrades the BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line.\n5. Compound 23 achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors.",
    "vicuna-13b_fact": [
      "The BET family proteins include BRD2, BRD3, BRD4, and BRDT.",
      "BET proteins are considered therapeutic targets for cancer and other human diseases.",
      "Heterobifunctional small-molecule BET degraders have been designed based on the PROTAC concept.",
      "Compound 23, also known as BETd-260 or ZBC260, effectively degrades the BRD4 protein at concentrations as low as 30 pM in the RS4;11 leukemia cell line.",
      "Compound 23 achieves an IC50 value of 51 pM in inhibition of RS4;11 cell growth and induces rapid tumor regression in vivo against RS4;11 xenograft tumors."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe correctness of the statements about the specific effects of Compound 23, its potency, and efficacy in the RS4;11 leukemia cell line, and tumor regression in vivo would require up-to-date and specific scientific study data that is not available as common knowledge. Therefore, without access to the source material that provides this information, I can only categorize these statements as UNKNOWN.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "vicuna-13b_response": "Answer: The algorithm that has been developed for prediction of protein subcellular localization using deep learning is not specified in the given document. However, it mentions a comprehensive system that integrates protein sequence-derived data and text-based information, which outperforms previously reported results for a wide range of eukaryotic subcellular localizations.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "vicuna-13b_response": "MULTOVL is a software application suite designed to detect and statistically analyze multiple overlaps of genomic regions. The package is capable of detecting a variety of overlaps, including multiple region intersections, unions, and \"solitary\" genomic regions. The software uses an empirical null distribution approach to estimate the significance of observed overlaps by comparing them with random shufflings of the input regions. This allows MULTOVL to identify meaningful overlaps that are unlikely to occur by chance. The package is designed to be fast and efficient, making it a useful tool for analyzing large genomic datasets.",
    "vicuna-13b_fact_raw": "1. MULTOVL is a software application suite for detecting and analyzing multiple overlaps of genomic regions.\n2. It can detect various types of overlaps, including intersections, unions, and \"solitary\" genomic regions.\n3. MULTOVL employs an empirical null distribution approach to estimate the significance of overlaps.\n4. The software compares observed overlaps with random shufflings of the input regions to identify statistically significant overlaps.\n5. MULTOVL is designed for fast and efficient analysis of large genomic datasets.",
    "vicuna-13b_fact": [
      "MULTOVL is a software application suite for detecting and analyzing multiple overlaps of genomic regions.",
      "It can detect various types of overlaps, including intersections, unions, and \"solitary\" genomic regions.",
      "MULTOVL employs an empirical null distribution approach to estimate the significance of overlaps.",
      "The software compares observed overlaps with random shufflings of the input regions to identify statistically significant overlaps.",
      "MULTOVL is designed for fast and efficient analysis of large genomic datasets."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: MULTOVL does not employ an empirical null distribution; it uses various heuristic algorithms to analyze overlaps without explicit statistical modeling of significance.\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "vicuna-13b_response": "Based on the information provided, it appears that GDF15 may be a potential biomarker for metformin treatment. The document states that GDF15 is elevated in people receiving metformin treatment and that an analysis of data from the SUMMIT cohort (n = 1438) found that major cardiovascular risk factors, with the exception of gender and cholesterol, increased similarly and linearly across GDF-15 quartiles. The document also states that the independent variables associated with GDF-15 in participants with and without diabetes were age, plasma creatinine, N-terminal pro-brain natriuretic peptide, diuretic use, smoking exposure, and glycated haemoglobin. Additionally, the document states that in participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 level, which was independent of the other major factors and largely explained their elevated GDF-15 levels. The document suggests that the relatively high GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin. Therefore, based on this information, it appears that GDF15 may be a potential biomarker for metformin treatment.",
    "vicuna-13b_fact_raw": "1. GDF15 levels are elevated in individuals receiving metformin treatment.\n2. An analysis of the SUMMIT cohort with 1438 participants found that cardiovascular risk factors increased across GDF-15 quartiles, with the exception of gender and cholesterol.\n3. The independent variables associated with GDF-15 in individuals with and without diabetes include age, plasma creatinine, N-terminal pro-brain natriuretic peptide, diuretic use, smoking exposure, and glycated haemoglobin.\n4. In participants with diabetes, metformin treatment is associated with a 40% increase in GDF-15 level.\n5. The elevation of GDF-15 levels in diabetic participants treated with metformin is independent of other major factors.",
    "vicuna-13b_fact": [
      "GDF15 levels are elevated in individuals receiving metformin treatment.",
      "An analysis of the SUMMIT cohort with 1438 participants found that cardiovascular risk factors increased across GDF-15 quartiles, with the exception of gender and cholesterol.",
      "The independent variables associated with GDF-15 in individuals with and without diabetes include age, plasma creatinine, N-terminal pro-brain natriuretic peptide, diuretic use, smoking exposure, and glycated haemoglobin.",
      "In participants with diabetes, metformin treatment is associated with a 40% increase in GDF-15 level.",
      "The elevation of GDF-15 levels in diabetic participants treated with metformin is independent of other major factors."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: It has been reported in scientific studies that GDF15 levels are elevated in individuals receiving metformin treatment.\n2. UNKNOWN: The correctness of this statement depends on the specific findings from the SUMMIT cohort analysis. Without access to the original study data, the effect of cardiovascular risk factors across GDF-15 quartiles cannot be confirmed.\n3. UNKNOWN: The specific independent variables associated with GDF-15 could vary depending on the cohort and study analyzed. Without the original study data or evidence, the association of these variables with GDF-15 cannot be confirmed.\n4. UNKNOWN: The specific percentage increase in GDF-15 level associated with metformin treatment in participants with diabetes would require validation against empirical data from clinical studies. Without such data, the exact figure cannot be confirmed.\n5. UNKNOWN: The independence of the elevation of GDF-15 levels in diabetic participants treated with metformin from other major factors would require analysis of multivariable models controlling for potential confounders. Without access to the specific study and its results, this statement cannot be confirmed.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it can be inferred that recursive splicing is more common in short introns. The document states that recursive splicing has been observed in a small subset of Drosophila melanogaster introns, and that it requires observation of splicing intermediates that are inherently unstable, making it difficult to study. Furthermore, the document states that recursive sites occur in most very long (> 40 kb) fly introns, including many genes involved in morphogenesis and development, and tend to occur near the midpoints of introns. This suggests that recursive splicing is more common in longer introns, and that it may have a function in accurately splicing these introns.",
    "vicuna-13b_fact_raw": "1. Recursive splicing has been observed in a small subset of Drosophila melanogaster introns.\n2. Recursive splicing requires observation of splicing intermediates that are inherently unstable.\n3. Recursive sites occur in most very long (> 40 kb) fly introns.\n4. Genes involved in morphogenesis and development in Drosophila melanogaster often contain long introns with recursive sites.\n5. Recursive sites tend to occur near the midpoints of introns in Drosophila melanogaster.",
    "vicuna-13b_fact": [
      "Recursive splicing has been observed in a small subset of Drosophila melanogaster introns.",
      "Recursive splicing requires observation of splicing intermediates that are inherently unstable.",
      "Recursive sites occur in most very long (> 40 kb) fly introns.",
      "Genes involved in morphogenesis and development in Drosophila melanogaster often contain long introns with recursive sites.",
      "Recursive sites tend to occur near the midpoints of introns in Drosophila melanogaster."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nAccording to current scientific knowledge, recursive splicing is a mechanism observed in a small number of genes within organisms such as Drosophila melanogaster. It often involves the recognition of unstable splicing intermediates. Very long introns, such as those over 40 kb, in Drosophila are known to contain recursive splicing sites. These genes indeed can be related to morphogenesis and development and often have long introns that facilitate the need for recursive splicing, and such recursive sites can occur near the midpoints of the introns.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "vicuna-13b_response": "The TALE-iD method is used for genome editing and gene regulation applications. It involves the use of recombinant transcription activator-like effectors (TALEs) which can be tailored to specifically target almost any user-defined DNA sequences. This is achieved through the use of a liquid phase high-throughput TALE synthesis platform called fairyTALE, which is capable of producing TALE-nucleases, activators, and repressors that recognize DNA sequences between 14 and 31 bp. The platform features a highly efficient reaction scheme, a flexible functionalization platform, and fully automated robotic liquid handling, enabling the production of hundreds of expression-ready TALEs within a single day with over 98% assembly efficiency at a material cost of just $5 per TALE. The proof of concept for the method involved the synthesis and testing of 90 TALEs, each recognizing 27 bp, without restrictions on their sequence composition. 96% of these TALEs were found to be functional, while sequencing confirmation revealed that the nonfunctional constructs were all correctly assembled.",
    "vicuna-13b_fact_raw": "1. The TALE-iD method is used for genome editing and gene regulation applications.\n2. TALE-iD uses transcription activator-like effectors (TALEs) that can target almost any user-defined DNA sequences.\n3. The fairyTALE platform facilitates the production of TALE-nucleases, activators, and repressors that recognize DNA sequences between 14 and 31 base pairs.\n4. The fairyTALE platform can produce expression-ready TALEs within a single day with over 98% assembly efficiency.\n5. A proof of concept for the TALE-iD method involved the synthesis and testing of 90 TALEs, each recognizing 27 base pairs, with a functionality rate of 96%.",
    "vicuna-13b_fact": [
      "The TALE-iD method is used for genome editing and gene regulation applications.",
      "TALE-iD uses transcription activator-like effectors (TALEs) that can target almost any user-defined DNA sequences.",
      "The fairyTALE platform facilitates the production of TALE-nucleases, activators, and repressors that recognize DNA sequences between 14 and 31 base pairs.",
      "The fairyTALE platform can produce expression-ready TALEs within a single day with over 98% assembly efficiency.",
      "A proof of concept for the TALE-iD method involved the synthesis and testing of 90 TALEs, each recognizing 27 base pairs, with a functionality rate of 96%."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The fairyTALE platform can produce expression-ready TALEs within a single day but the assembly efficiency percentage is unknown without specific reference to supporting data.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "vicuna-13b_response": "The Lisp framework for image processing is FunImageJ. It is built upon the ImageJ software ecosystem and provides a natural functional-style for programming while accounting for the performance requirements necessary in big data processing commonly encountered in biological image analysis. It is freely available as a plugin to Fiji, and installation and use instructions can be found at the Imagej.net website. The contact for more information is kharrington@uidaho.edu. Supplementary data are also available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. FunImageJ is a Lisp framework developed for image processing.\n2. FunImageJ is built upon the ImageJ software ecosystem.\n3. FunImageJ is available as a plugin to Fiji.\n4. Installation and use instructions for FunImageJ can be found on the Imagej.net website.\n5. Supplementary data for FunImageJ are available at Bioinformatics online.",
    "vicuna-13b_fact": [
      "FunImageJ is a Lisp framework developed for image processing.",
      "FunImageJ is built upon the ImageJ software ecosystem.",
      "FunImageJ is available as a plugin to Fiji.",
      "Installation and use instructions for FunImageJ can be found on the Imagej.net website.",
      "Supplementary data for FunImageJ are available at Bioinformatics online."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWithout a specific reference to the supplementary data location for FunImageJ, the claim about the availability of supplementary data at Bioinformatics online cannot be confirmed or denied with the information provided.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it is stated that the ancient whole genome duplication in Saccharomyces cerevisiae resulted in the loss of most of the duplicated genes (approximately 85%) before speciation. Only a small amount of paralogous gene loss (4-6%) occurred after speciation. Additionally, it is mentioned that S. castellii appears to have lost several hundred genes that were not retained as duplicated paralogs, which could be related to genomic rearrangements that reduced the number of chromosomes from 16 to 9. Therefore, the number of genes in S. cerevisiae that are the result of an ancient whole genome duplication is not specified in the document.",
    "vicuna-13b_fact_raw": "1. The ancient whole genome duplication in Saccharomyces cerevisiae resulted in the initial duplication of its genes.\n2. Approximately 85% of the duplicated genes were lost before speciation of S. cerevisiae.\n3. Between 4-6% of paralogous gene loss in S. cerevisiae occurred after speciation.\n4. S. castellii lost several hundred genes that were not retained as duplicated paralogs.\n5. S. castellii underwent genomic rearrangements that reduced its number of chromosomes from 16 to 9.",
    "vicuna-13b_fact": [
      "The ancient whole genome duplication in Saccharomyces cerevisiae resulted in the initial duplication of its genes.",
      "Approximately 85% of the duplicated genes were lost before speciation of S. cerevisiae.",
      "Between 4-6% of paralogous gene loss in S. cerevisiae occurred after speciation.",
      "S. castellii lost several hundred genes that were not retained as duplicated paralogs.",
      "S. castellii underwent genomic rearrangements that reduced its number of chromosomes from 16 to 9."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Approximately 90-95% of the duplicated genes, not 4-6%, were lost after speciation of S. cerevisiae, assuming the numbers provided are intended to refer to the initial percentage of duplicated genes lost.\n4. TRUE\n5. FALSE [correction]: It is S. cerevisiae that is typically characterized by having 16 chromosomes. S. castellii (also known as Naumovozyma castellii), does have fewer chromosomes, but the information given about the specific reduction from 16 to 9 is incorrect or incomplete without further context. The precise number of chromosomes in S. castellii and the genomic rearrangements it may have undergone need to be verified with specific scientific literature.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "vicuna-13b_response": "The complex bound by estrogen-related receptor  (Esrrb) is not specified in the given information. The information provided is about the synthesis of selective estrogen receptor modulators, such as 17-estradiol derivatives bound to metal complexes, which are used as targeted probes for the diagnosis and treatment of breast cancer. The information also provides the detailed 3D structure of the estrogen receptor ligand-binding domain (ER-LBD) bound with a novel estradiol-derived metal complex, estradiol-pyridine tetra acetate europium(III), at 2.6  resolution. This structure provides important information pertinent to the design of novel functional ER-targeted probes for clinical applications.",
    "vicuna-13b_fact_raw": "1. Selective estrogen receptor modulators, such as 17-estradiol derivatives, are bound to metal complexes.\n2. These metal complexes are used as targeted probes for the diagnosis and treatment of breast cancer.\n3. There is a detailed 3D structure of the estrogen receptor ligand-binding domain (ER-LBD) available.\n4. The estrogen receptor ligand-binding domain (ER-LBD) has been mapped with a novel estradiol-derived metal complex, estradiol-pyridine tetra acetate europium(III).\n5. The resolution of the 3D structure of ER-LBD bound with estradiol-pyridine tetra acetate europium(III) is at 2.6 .",
    "vicuna-13b_fact": [
      "Selective estrogen receptor modulators, such as 17-estradiol derivatives, are bound to metal complexes.",
      "These metal complexes are used as targeted probes for the diagnosis and treatment of breast cancer.",
      "There is a detailed 3D structure of the estrogen receptor ligand-binding domain (ER-LBD) available.",
      "The estrogen receptor ligand-binding domain (ER-LBD) has been mapped with a novel estradiol-derived metal complex, estradiol-pyridine tetra acetate europium(III).",
      "The resolution of the 3D structure of ER-LBD bound with estradiol-pyridine tetra acetate europium(III) is at 2.6 ."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe given context is highly specialized and requires specific knowledge in biochemistry and medicinal chemistry. The statements about selective estrogen receptor modulators (SERMs) and metal complexes being used in diagnosis and treatment of breast cancer are plausible as this area of research is continually evolving. The availability of a detailed 3D structure of the ER-LBD is very likely true since the study of hormone receptors, including the estrogen receptor, is common in structural biology. However, without precise references to the scientific literature that presents these specific metal complexes or the resolution of the mentioned 3D structure, it's not possible to verify the accuracy of statements 4 and 5. They require specialized knowledge or evidence that is not provided in the context given.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the role of ZCCHC17 is not mentioned. The document only discusses the NMR spectral assignment of the zinc knuckle region of ZCCHC9 and its potential use in performing NMR structural and RNA-binding studies to investigate its role in RNA quality control in human. It does not provide any information about the role of ZCCHC17.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "vicuna-13b_response": "The proteins that form the nuclear pore basket in human cells are not specifically mentioned in the given document. However, it is mentioned that the nuclear pore complexes are composed of approximately 30 different proteins, each present at the pore in multiple copies, and these proteins create specialized channels that convey cargo between the cytoplasm and the nuclear interior. The document also mentions that specific individual pore proteins and protein cofactors have been probed for their role in the assembly process, as well as certain kinases that add a layer of regulation via the phosphorylation status of nucleoporins. Additionally, other posttranslational modifications are candidates for coordinating events of pore assembly.",
    "vicuna-13b_fact_raw": "1. The nuclear pore complexes are composed of approximately 30 different proteins.\n2. These proteins create specialized channels that convey cargo between the cytoplasm and the nuclear interior.\n3. Specific individual pore proteins and protein cofactors have been studied for their role in the assembly process of nuclear pores.\n4. Certain kinases are involved in the regulation of nuclear pores through the phosphorylation status of nucleoporins.\n5. Posttranslational modifications may be involved in coordinating events of nuclear pore assembly.",
    "vicuna-13b_fact": [
      "The nuclear pore complexes are composed of approximately 30 different proteins.",
      "These proteins create specialized channels that convey cargo between the cytoplasm and the nuclear interior.",
      "Specific individual pore proteins and protein cofactors have been studied for their role in the assembly process of nuclear pores.",
      "Certain kinases are involved in the regulation of nuclear pores through the phosphorylation status of nucleoporins.",
      "Posttranslational modifications may be involved in coordinating events of nuclear pore assembly."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The nuclear pore complexes are composed of approximately 30 different proteins, known as nucleoporins, or nups.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "vicuna-13b_response": "Gepotidacin is a type IIA topoisomerase inhibitor. It is a novel triazaacenaphthylene antibacterial agent that is active against many biothreat and conventional pathogens, including Neisseria gonorrhoeae. The reference organism for clinical studies of gepotidacin to treat gonorrhea is N. gonorrhoeae ATCC 49226. A multilaboratory quality assurance investigation determined the reference organism (N. gonorrhoeae ATCC 49226) quality control MIC range to be 0.25 to 1 g/mL (88.8% of gepotidacin MIC results at the 0.5 g/mL mode).",
    "vicuna-13b_fact_raw": "1. Gepotidacin is a type IIA topoisomerase inhibitor.\n2. Gepotidacin is a novel triazaacenaphthylene antibacterial agent.\n3. Gepotidacin is active against biothreat and conventional pathogens, including Neisseria gonorrhoeae.\n4. N. gonorrhoeae ATCC 49226 is the reference organism for clinical studies of gepotidacin to treat gonorrhea.\n5. The quality control MIC range for N. gonorrhoeae ATCC 49226 is 0.25 to 1 g/mL when tested with gepotidacin.",
    "vicuna-13b_fact": [
      "Gepotidacin is a type IIA topoisomerase inhibitor.",
      "Gepotidacin is a novel triazaacenaphthylene antibacterial agent.",
      "Gepotidacin is active against biothreat and conventional pathogens, including Neisseria gonorrhoeae.",
      "N. gonorrhoeae ATCC 49226 is the reference organism for clinical studies of gepotidacin to treat gonorrhea.",
      "The quality control MIC range for N. gonorrhoeae ATCC 49226 is 0.25 to 1 g/mL when tested with gepotidacin."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with known information about gepotidacin up to my knowledge cutoff date. Gepotidacin is indeed classified as a type IIA topoisomerase inhibitor and is a novel antibacterial agent, which is active against various pathogens including Neisseria gonorrhoeae. N. gonorrhoeae ATCC 49226 is commonly used as a reference strain in clinical microbiology. However, without specific and up-to-date reference data or guidelines, I cannot verify the accuracy of the statement regarding the exact quality control MIC range for N. gonorrhoeae ATCC 49226 when tested with gepotidacin, hence it is marked as UNKNOWN.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "vicuna-13b_response": "Canvas SPW is a tool for identifying inherited and de novo copy number variants from pedigree sequencing data. It was developed to address the challenge of joint variant calling in pedigrees due to the complexity of consensus breakpoint alignment across samples within an arbitrary pedigree structure. Canvas SPW supports various family structures and provides options for scoring and filtering to automate and streamline the identification of de novo variants. It is available for download from the GitHub repository and interested users can contact sivakhno@illumina.com for more information. Supplementary data are also available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. Canvas SPW is a tool for identifying inherited and de novo copy number variants from pedigree sequencing data.\n2. The tool was developed to address the challenge of joint variant calling in pedigrees with complex consensus breakpoint alignment.\n3. Canvas SPW is designed to support various family structures.\n4. The tool offers options for scoring and filtering to identify de novo variants.\n5. Canvas SPW is available for download from the GitHub repository.",
    "vicuna-13b_fact": [
      "Canvas SPW is a tool for identifying inherited and de novo copy number variants from pedigree sequencing data.",
      "The tool was developed to address the challenge of joint variant calling in pedigrees with complex consensus breakpoint alignment.",
      "Canvas SPW is designed to support various family structures.",
      "The tool offers options for scoring and filtering to identify de novo variants.",
      "Canvas SPW is available for download from the GitHub repository."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "vicuna-13b_response": "Based on the given information, it appears that the patient was stung by a Great Weever fish (Echiichthys draco) and experienced a severe reaction with symptoms such as swelling, pain, dizziness, and chill. The pain symptoms were only slightly reduced even under morphine therapy.\nIn addition, the patient developed an erythema with scaling at the sting site, reduced bending capacity of the forefinger, and permanent numbness in the region. Raynaud's phenomenon also developed limited to the right forefinger after 4 months.\nIt is important to note that Great Weever fishes are the most venomous fishes in European waters, and while life-threatening sting reactions are rare, they can occur in exceptional cases. Therefore, it is recommended to seek medical attention if a sting occurs.\nAs there is no commercial antiserum available, the therapy is mainly empiric, with general measures of first aid and emergency medicine being applied, such as thoroughly washing the wound. Patients should also be informed that reduced motion ability, swelling, or Raynaud's phenomenon can persist for several months.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "vicuna-13b_response": "SLIC-CAGE is a type of electronic portal imaging device that uses a scanning liquid-filled ionization chamber (SLIC) to measure portal doses in radiation therapy. The dosimetric characteristics of this system have been investigated, and it has been found that the response of the imaging system is dependent on the incident radiation intensity and can be described accurately using a square root function. The SLIC has been shown to be capable of measuring portal doses to within 3% of the ionization chamber results for homogeneous material. For two-dimensional dosimetry applications, the system is calibrated with a 10 cm Perspex block used as a beam flattening material on the detector cassette to correct for variations in individual ion chamber sensitivity and the effect of nonuniform beam profiles produced by the flattening filter. The SLIC has been shown to agree with ion chamber measured profiles to within 3.5% accuracy for open and wedged dose profiles. Overall, the SLIC-CAGE is a reliable and accurate system for measuring portal doses in radiation therapy.",
    "vicuna-13b_fact_raw": "1. SLIC-CAGE is an electronic portal imaging device used in radiation therapy.\n2. The dosimetric characteristics of the SLIC-CAGE system are dependent on the incident radiation intensity.\n3. The SLIC-CAGE system's response can be described accurately using a square root function.\n4. The SLIC-CAGE is capable of measuring portal doses to within 3% of ionization chamber results for homogeneous material.\n5. The SLIC-CAGE agrees with ion chamber measured profiles to within 3.5% accuracy for open and wedged dose profiles.",
    "vicuna-13b_fact": [
      "SLIC-CAGE is an electronic portal imaging device used in radiation therapy.",
      "The dosimetric characteristics of the SLIC-CAGE system are dependent on the incident radiation intensity.",
      "The SLIC-CAGE system's response can be described accurately using a square root function.",
      "The SLIC-CAGE is capable of measuring portal doses to within 3% of ionization chamber results for homogeneous material.",
      "The SLIC-CAGE agrees with ion chamber measured profiles to within 3.5% accuracy for open and wedged dose profiles."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: There is no widely recognized electronic portal imaging device by the name \"SLIC-CAGE\" used in radiation therapy. The statement seems to refer to a fictional or incorrect term. EPIDs commonly used in radiation therapy are devices like amorphous silicon panels.\n2. TRUE: The dosimetric characteristics of electronic portal imaging devices (though \"SLIC-CAGE\" seems to be a fictional or incorrect name) are indeed dependent on the incident radiation intensity.\n3. UNKNOWN: Without specific details on the characteristics and behavior of the \"SLIC-CAGE\" system (which appears to be a fictitious or incorrect term), it is not possible to confirm or refute the claim about its response being accurately described by a square root function.\n4. UNKNOWN: As the \"SLIC-CAGE\" is not a recognized name for an electronic portal imaging device, it is not possible to confirm the accuracy of its measurements relative to ionization chambers. However, it should be noted that in general, EPIDs are capable of portal dose measurements with varying degrees of accuracy when compared to ionization chambers.\n5. UNKNOWN: Similar to the previous statement, without validation of the existence of the \"SLIC-CAGE,\" the comparison to ion chamber measured profiles is not confirmable. In general EPIDs are used to compare measured dose profiles to within certain accuracy thresholds for treatment verification in radiation therapy, but the specific percentages can vary.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "vicuna-13b_response": "Based on the given information, it appears that the role of LEM-3 in AcMNPV is to transport the large DNA-binding protein P143 into the nucleus. This is suggested by the fact that when LEF-3 is expressed in transfected cells on its own from a plasmid expression vector, it localizes to the nucleus, while P143 requires LEF-3 to enter the nucleus. Additionally, when the N-terminal 56 amino acid residues of LEF-3 were fused with either the green fluorescent protein reporter gene or P143, it was able to direct these proteins to the nucleus.\nHowever, it is important to note that while LEF-3 is essential for DNA replication in transient assays, fusing the LEF-3 nuclear localization signal domain to P143 did not alter the function of P143 in supporting DNA replication but was not sufficient to substitute for whole LEF-3. This suggests that while LEF-3 plays an important role in transporting P143 to the nucleus, it performs other essential replication functions once inside the nucleus.",
    "vicuna-13b_fact_raw": "1. LEM-3 is suggested to have the role of transporting the large DNA-binding protein P143 into the nucleus in AcMNPV.\n2. LEF-3, when expressed from a plasmid expression vector, localizes to the nucleus.\n3. P143 requires LEF-3 to enter the nucleus.\n4. The N-terminal 56 amino acid residues of LEF-3 fused with other proteins can direct those proteins to the nucleus.\n5. Fusing the LEF-3 nuclear localization signal domain to P143 does not alter the function of P143 in supporting DNA replication.",
    "vicuna-13b_fact": [
      "LEM-3 is suggested to have the role of transporting the large DNA-binding protein P143 into the nucleus in AcMNPV.",
      "LEF-3, when expressed from a plasmid expression vector, localizes to the nucleus.",
      "P143 requires LEF-3 to enter the nucleus.",
      "The N-terminal 56 amino acid residues of LEF-3 fused with other proteins can direct those proteins to the nucleus.",
      "Fusing the LEF-3 nuclear localization signal domain to P143 does not alter the function of P143 in supporting DNA replication."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without additional context, it is not possible to verify the role of LEM-3 in transporting the P143 protein into the nucleus in AcMNPV (Autographa californica multiple nucleopolyhedrovirus).\n \n2. TRUE: Generally, the statement that LEF-3 localizes to the nucleus when expressed from a plasmid expression vector is consistent with the behavior of Nuclear Localization Signals (NLS) containing proteins. LEF-3 is known to have an NLS which can direct its localization to the nucleus.\n\n3. UNKNOWN: The necessity of LEF-3 for P143 to enter the nucleus is not something that can be confirmed without specific experimental evidence from the given context.\n\n4. UNKNOWN: Whether the N-terminal 56 amino acids of LEF-3 are sufficient to direct other proteins to the nucleus requires experimental evidence which is not provided in the context.\n\n5. UNKNOWN: The functional impact of fusing the LEF-3 nuclear localization signal domain to P143 on the function of P143 in supporting DNA replication would require experimental evidence to verify. Without that information, this statement cannot be validated.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "vicuna-13b_response": "Based on the information provided in Document-0, the releases of tmVar were studied using photo-cross-linked poly(propylene fumarate)/poly(N-vinyl pyrrolidone) (PPF/PNVP) matrices. The hydrophilicity of the solid PPF/PNVP matrices was increased by adding various amounts of poly(ethylene glycol) (PEG) or by increasing the amount of N-vinyl pyrrolidone (NVP) in the polymer mixture prior to cross-linking. The in vitro release studies utilizing high-performance liquid chromatography for quantification revealed highly accelerated drug release from the matrices with increasing contents of the hydrophilic modifier. The study found that the release of acetazolamide (AZ) was accelerated with the addition of 5% PEG in the matrices, and the release duration of timolol maleate (TM) was shortened by one-third with the addition of 1% PEG. The study also revealed that increasing the NVP content in the PPF-NVP mixture also accelerated the drug release. The study showed that hydrophilic matrix modifications of PPF/PNVP matrices accelerate the drug release of two ophthalmic drugs and represent a suitable tool to adjust drug-release rates from PPF-based matrices for different therapeutic needs.",
    "vicuna-13b_fact_raw": "1. In vitro release studies of tmVar used high-performance liquid chromatography for quantification.\n2. The hydrophilicity of PPF/PNVP matrices was modified by adding poly(ethylene glycol) (PEG) or increasing the N-vinyl pyrrolidone (NVP) amount.\n3. Drug release from the matrices was accelerated with increasing contents of hydrophilic modifiers.\n4. With the addition of 5% PEG, the release of acetazolamide (AZ) was notably accelerated.\n5. The release duration of timolol maleate (TM) was shortened by one-third when 1% PEG was added to the matrix.",
    "vicuna-13b_fact": [
      "In vitro release studies of tmVar used high-performance liquid chromatography for quantification.",
      "The hydrophilicity of PPF/PNVP matrices was modified by adding poly(ethylene glycol) (PEG) or increasing the N-vinyl pyrrolidone (NVP) amount.",
      "Drug release from the matrices was accelerated with increasing contents of hydrophilic modifiers.",
      "With the addition of 5% PEG, the release of acetazolamide (AZ) was notably accelerated.",
      "The release duration of timolol maleate (TM) was shortened by one-third when 1% PEG was added to the matrix."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific technical details that would require access to the original passage or research findings to verify. As the statements are not common knowledge and no context or reference material is provided to validate them, their truth value cannot be determined without additional information.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "vicuna-13b_response": "The database of somatic mutations in normal cells is the NIST reference material NA12878 genome. This genome has been well-characterized with publicly available high-confidence genotype calls and can be used to simulate tumors by introducing somatic small variants (SNVs and small indels) into homozygous reference or wildtype sites. The simulated tumors can vary in sequencing and subsequent mapping error profiles, read length, the number of sub-clones, the VAF, the mutation frequency across the genome and the genomic context. This database, which is a total size of 15 terabytes, can be used to benchmark somatic small variant callers and guide their improvement.",
    "vicuna-13b_fact_raw": "1. The NIST reference material NA12878 genome is a database of somatic mutations in normal cells.\n2. The NA12878 genome includes publicly available high-confidence genotype calls.\n3. The NA12878 genome can be used to simulate tumors by introducing somatic small variants into homozygous reference sites.\n4. The database can be used to benchmark somatic small variant callers.\n5. The total size of the database is 15 terabytes.",
    "vicuna-13b_fact": [
      "The NIST reference material NA12878 genome is a database of somatic mutations in normal cells.",
      "The NA12878 genome includes publicly available high-confidence genotype calls.",
      "The NA12878 genome can be used to simulate tumors by introducing somatic small variants into homozygous reference sites.",
      "The database can be used to benchmark somatic small variant callers.",
      "The total size of the database is 15 terabytes."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The NIST reference material NA12878 genome is not specifically a database of somatic mutations in normal cells; it is a human reference genome that is widely used as a standard for benchmarking human genetic analysis, composed of a genome sequence from a Utah woman with Northern and Western European ancestry from the CEPH collection.\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "vicuna-13b_response": "Yes, there are graph kernel libraries implemented in Java that can be used to measure the similarity of graphs. One such library is the Graph Kernels library, which is a Java implementation of graph kernels. It includes baseline kernels such as label histogram based kernels and classic graph kernels such as random walk based kernels, and the state-of-the-art Weisfeiler-Lehman graph kernel. The core of all graph kernels is implemented in C++ for efficiency. The Graph Kernels library is available for download at <https://github.com/graph-kernels/graph-kernels>.",
    "vicuna-13b_fact_raw": "1. Graph kernel libraries implemented in Java are available for measuring the similarity of graphs.\n2. The Graph Kernels library is a Java implementation of graph kernels.\n3. The Graph Kernels library includes label histogram based kernels.\n4. The library contains classic graph kernels such as random walk based kernels and the Weisfeiler-Lehman graph kernel.\n5. The core of all graph kernels in the Graph Kernels library is implemented in C++ for efficiency.",
    "vicuna-13b_fact": [
      "Graph kernel libraries implemented in Java are available for measuring the similarity of graphs.",
      "The Graph Kernels library is a Java implementation of graph kernels.",
      "The Graph Kernels library includes label histogram based kernels.",
      "The library contains classic graph kernels such as random walk based kernels and the Weisfeiler-Lehman graph kernel.",
      "The core of all graph kernels in the Graph Kernels library is implemented in C++ for efficiency."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The statement implies that the Graph Kernels library's core is implemented in C++. Since the earlier statements specified that the libraries are implemented in Java, it is unlikely that the core would be implemented in C++. However, without specific information about a \"Graph Kernels\" library that fits this description, the correctness of the claim about implementation language for the core is undeterminable. Hence, without specific evidence, the provided correction assumes that the library is entirely in Java, as initially stated.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "vicuna-13b_response": "The four advances integrated into the SHERLOCKv2 platform are:\n1. Four-channel single-reaction multiplexing with orthogonal CRISPR enzymes.\n2. Quantitative measurement of input as low as 2 attomolar.\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated enzyme.\n4. Lateral-flow readout.",
    "vicuna-13b_fact_raw": "1. SHERLOCKv2 platform features four-channel single-reaction multiplexing with orthogonal CRISPR enzymes.\n2. SHERLOCKv2 platform has the capability for quantitative measurement of input as low as 2 attomolar.\n3. The platform includes a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated enzyme.\n4. SHERLOCKv2 platform uses a lateral-flow readout.",
    "vicuna-13b_fact": [
      "SHERLOCKv2 platform features four-channel single-reaction multiplexing with orthogonal CRISPR enzymes.",
      "SHERLOCKv2 platform has the capability for quantitative measurement of input as low as 2 attomolar.",
      "The platform includes a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated enzyme.",
      "SHERLOCKv2 platform uses a lateral-flow readout."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nEach of these statements pertains to details of the SHERLOCKv2 platform, which is an updated version of the original SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) technology used for nucleic acid detection. The technology does feature multiplexing capabilities, sensitivity improvements via the combination of CRISPR enzymes like Cas13 with Csm6, and can also facilitate quantitative measurements at very low concentrations. Additionally, SHERLOCK technology is known for employing a lateral-flow readout which is similar to a pregnancy test, allowing for easy visualization of results.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "vicuna-13b_response": "The Bartender algorithm is a new approach to the cocktail party problem that uses a cortronic artificial neural network architecture as the front end of a speech processing system. This algorithm is unique in several ways. First, it utilizes detailed knowledge of the signals that need to be attended to in a cocktail party environment. Second, its goal is to provide preprocessing in advance of a pattern recognition system, rather than separating one or more of the mixed sources explicitly. Third, the neural network model used is more biologically feasible than other approaches to the cocktail party problem. The Bartender algorithm can be applied to other areas of information processing beyond the cocktail party problem.",
    "vicuna-13b_fact_raw": "1. The Bartender algorithm is a new approach to the cocktail party problem.\n2. It utilizes a cortronic artificial neural network architecture.\n3. The algorithm focuses on preprocessing in advance of a pattern recognition system.\n4. The Bartender algorithm does not explicitly separate mixed sources.\n5. It is considered more biologically feasible than other approaches to the cocktail party problem.",
    "vicuna-13b_fact": [
      "The Bartender algorithm is a new approach to the cocktail party problem.",
      "It utilizes a cortronic artificial neural network architecture.",
      "The algorithm focuses on preprocessing in advance of a pattern recognition system.",
      "The Bartender algorithm does not explicitly separate mixed sources.",
      "It is considered more biologically feasible than other approaches to the cocktail party problem."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: It utilizes a \"cortronic\" artificial neural network architecture. The term \"cortronic\" is not standard in the context of artificial neural networks, which makes this statement unclear. The correct term may be \"convolutional\" if referring to a common type of network architecture used in pattern recognition.\n3. UNKNOWN\n4. FALSE [correction]: A core aspect of solving the cocktail party problem with an algorithm would typically include separating mixed audio sources, so it would be unusual for an approach not to do this. However, without specific details about the \"Bartender\" algorithm, it is difficult to provide a precise correction.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "vicuna-13b_response": "There are several web-based pedigree editors available, including:\n1. PedigreeJS: This is an open-source, interactive graphical pedigree editor written in JavaScript. It uses standard pedigree nomenclature and is freely available under the GPL license. It can be easily configured and incorporated into web applications.\n2. GenoPro: This is a web-based genealogy software that allows users to create and share family trees. It includes features such as photos, documents, and events.\n3. Famberry: This is a web-based genealogy software that allows users to create and share family trees. It includes features such as photos, documents, and events.\n4. MyHeritage: This is a web-based genealogy platform that allows users to build and share their family tree, as well as discover and connect with other families.\n5. Ancestry: This is a web-based genealogy platform that allows users to build and share their family tree, as well as discover and connect with other families.\nIt is important to note that these are just a few examples and there may be other web-based pedigree editors available.",
    "vicuna-13b_fact_raw": "1. PedigreeJS is an open-source, interactive graphical pedigree editor written in JavaScript.\n2. PedigreeJS is available under the GPL license.\n3. GenoPro is web-based genealogy software that includes features such as photos, documents, and events.\n4. MyHeritage is a web-based genealogy platform that allows building and sharing family trees.\n5. Ancestry is a web-based genealogy platform that enables users to build, share family trees, and connect with other families.",
    "vicuna-13b_fact": [
      "PedigreeJS is an open-source, interactive graphical pedigree editor written in JavaScript.",
      "PedigreeJS is available under the GPL license.",
      "GenoPro is web-based genealogy software that includes features such as photos, documents, and events.",
      "MyHeritage is a web-based genealogy platform that allows building and sharing family trees.",
      "Ancestry is a web-based genealogy platform that enables users to build, share family trees, and connect with other families."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: GenoPro is not a web-based genealogy software; it is a software application that needs to be downloaded and installed on a user's computer.\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "vicuna-13b_response": "There are several curated databases that exist for spider-venom toxins, including:\n1. The Spider Venom Database (SVD) - a comprehensive database that provides information on the biological activities, molecular structures, and evolutionary relationships of spider venom components.\n2. The Toxin Database - a database that provides information on toxins from various sources, including spider venom.\n3. The Venomous Animals Database (VAD) - a database that provides information on the biology and venomology of venomous animals, including spiders.\n4. The Arachnid Venom Database (AVD) - a database that provides information on the biology and venomology of arachnids, including spiders.\n5. The PeptideAtlas database - a database that provides information on peptides and proteins from various sources, including spider venom.\nThese databases can be used to search for information on spider-venom toxins, including their biological activities, molecular structures, and evolutionary relationships.",
    "vicuna-13b_fact_raw": "1. The Spider Venom Database (SVD) provides information on biological activities, molecular structures, and evolutionary relationships of spider venom components.\n2. The Toxin Database includes information about toxins from various sources, such as spider venom.\n3. The Venomous Animals Database (VAD) contains information on the biology and venomology of venomous animals, including spiders.\n4. The Arachnid Venom Database (AVD) focuses on biology and venomology information of arachnids, including spiders.\n5. The PeptideAtlas database contains information on peptides and proteins from different sources, including those derived from spider venom.",
    "vicuna-13b_fact": [
      "The Spider Venom Database (SVD) provides information on biological activities, molecular structures, and evolutionary relationships of spider venom components.",
      "The Toxin Database includes information about toxins from various sources, such as spider venom.",
      "The Venomous Animals Database (VAD) contains information on the biology and venomology of venomous animals, including spiders.",
      "The Arachnid Venom Database (AVD) focuses on biology and venomology information of arachnids, including spiders.",
      "The PeptideAtlas database contains information on peptides and proteins from different sources, including those derived from spider venom."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN: There is no widely recognized \"Arachnid Venom Database (AVD)\"; thus, it is unclear whether this statement is true. Please note that databases can exist but might not be well-known or publicly accessible.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "vicuna-13b_response": "Based on the provided document, the use of Axitinib in combination with gemcitabine does not improve overall survival in patients with advanced pancreatic cancer. The study found that the median overall survival was 85 months for patients receiving gemcitabine and Axitinib, and 83 months for patients receiving gemcitabine and placebo. The hazard ratio for overall survival was 1.014 with a 95% confidence interval of 0.786-1.309, indicating that the addition of Axitinib did not have a statistically significant impact on overall survival. These results suggest that targeting VEGF signalling with Axitinib is an ineffective strategy for treating advanced pancreatic cancer.",
    "vicuna-13b_fact_raw": "1. Axitinib, when used in combination with gemcitabine, does not improve overall survival in patients with advanced pancreatic cancer according to the study.\n2. The study reported a median overall survival of 85 months for patients treated with gemcitabine and Axitinib.\n3. Patients receiving gemcitabine and a placebo had a median overall survival of 83 months in the study.\n4. The hazard ratio for overall survival with the addition of Axitinib was 1.014 in the study.\n5. The 95% confidence interval for the overall survival hazard ratio when adding Axitinib was 0.786-1.309, which indicates no statistically significant impact.",
    "vicuna-13b_fact": [
      "Axitinib, when used in combination with gemcitabine, does not improve overall survival in patients with advanced pancreatic cancer according to the study.",
      "The study reported a median overall survival of 85 months for patients treated with gemcitabine and Axitinib.",
      "Patients receiving gemcitabine and a placebo had a median overall survival of 83 months in the study.",
      "The hazard ratio for overall survival with the addition of Axitinib was 1.014 in the study.",
      "The 95% confidence interval for the overall survival hazard ratio when adding Axitinib was 0.786-1.309, which indicates no statistically significant impact."
    ],
    "vicuna-13b_judge_raw": "1. TRUE [assuming the study results actually concluded this]\n2. FALSE [correction]: It is unlikely for a study on advanced pancreatic cancer to report a median overall survival of 85 months, as this period is very long for such a condition. Advanced pancreatic cancer typically has a much shorter median overall survival, usually reported in terms of weeks or a few months.\n3. FALSE [correction]: Similar to the above statement, a median overall survival of 83 months for advanced pancreatic cancer patients seems incorrect due to the generally low survival rates associated with this disease.\n4. TRUE [assuming the number 1.014 is correctly reported from the study, it indicates a slight difference and suggests the study's finding]\n5. TRUE [if the 95% confidence interval includes the value 1, it suggests that there is no statistically significant difference in the hazard ratios and thus the addition of Axitinib makes no significant impact]",
    "vicuna-13b_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "vicuna-13b_response": "The muscle LIM protein (MLP) regulates F-actin dynamics through its self-association and actin filament cross-linking. MLP autonomously binds to, stabilizes, and bundles actin filaments independently of calcium and pH. MLP cross-links actin filaments into both unipolar and mixed-polarity bundles, and substantially promotes actin bundling in live myoblasts. Bimolecular fluorescence complementation (BiFC) assays revealed MLP self-association, and complexes mostly localize along actin filament-rich structures, such as stress fibers and sarcomeres, supporting a functional link between MLP self-association and actin cross-linking. MLP self-associates through its N-terminal LIM domain, whereas it binds to AFs through its C-terminal LIM domain. Together, the data suggest that MLP contributes to the maintenance of cardiomyocyte cytoarchitecture by a mechanism involving its self-association and actin filament cross-linking.",
    "vicuna-13b_fact_raw": "1. Muscle LIM protein (MLP) regulates F-actin dynamics through self-association and actin filament cross-linking.\n2. MLP binds to, stabilizes, and bundles actin filaments independently of calcium and pH.\n3. MLP can cross-link actin filaments into unipolar and mixed-polarity bundles.\n4. Bimolecular fluorescence complementation (BiFC) assays have shown that MLP self-associates.\n5. MLP self-associates through its N-terminal LIM domain and binds to actin filaments through its C-terminal LIM domain.",
    "vicuna-13b_fact": [
      "Muscle LIM protein (MLP) regulates F-actin dynamics through self-association and actin filament cross-linking.",
      "MLP binds to, stabilizes, and bundles actin filaments independently of calcium and pH.",
      "MLP can cross-link actin filaments into unipolar and mixed-polarity bundles.",
      "Bimolecular fluorescence complementation (BiFC) assays have shown that MLP self-associates.",
      "MLP self-associates through its N-terminal LIM domain and binds to actin filaments through its C-terminal LIM domain."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Muscle LIM protein (MLP) is known to play a role in the mechanosensory signaling of muscle cells and in the regulation of cardiac gene expression, but it is not specifically known to regulate F-actin dynamics through self-association and actin filament cross-linking. That characteristic is generally attributed to proteins such as filamins, not MLP.\n2. UNKNOWN: Without specific literature or studies cited, it is not possible to confirm the binding specifics of MLP, such as its independence from calcium and pH in stabilizing and bundling actin filaments.\n3. UNKNOWN: The ability of MLP to cross-link actin filaments into unipolar and mixed-polarity bundles is a specific claim that would require supporting evidence from scientific studies or literature to confirm or refute.\n4. TRUE: Bimolecular fluorescence complementation (BiFC) assays are commonly used to demonstrate protein-protein interactions, and if this statement was extracted from a passage where it was mentioned, it is plausible that this technique showed MLP self-association.\n5. UNKNOWN: This statement outlines specific domain functions for MLP regarding self-association and binding to actin filaments, which would require confirmation from specialized biochemical or molecular biology references to be substantiated.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it is mentioned that two types of kinin were released from T-kininogen in rats with carrageenin-induced inflammation. The kinin was identified as Ile-Ser-bradykinin (T-kinin) and a novel kinin, Met-Ile-Ser-bradykinin (Met-T-kinin), from determination of its amino acid composition and its immunoreactivity toward anti-bradykinin antiserum. It is also mentioned that the release of T-kinin and Met-T-kinin from T-kininogen was found to occur by consecutive cleavage by cathepsin D and 72 kDa protease.\nHowever, the question is asking about the number of pseudokinases in the human kinome, which is a different question from the information provided in Document-0. Therefore, I cannot provide an answer to the question based on the given document.\nTo answer this question, additional information about the human kinome and the definition of pseudokinases would be required.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "vicuna-13b_response": "Answer:\nBased on the information provided in Document-0, three apoE mimetics are:\n1. ApoE mimetic peptide: This is a synthetic peptide that mimics the putative receptor binding domain 141-150 (LRKLRKRLLR) of apoE. It is covalently linked to the class A amphipathic helical peptide 18A and has been shown to dramatically reduce plasma cholesterol in dyslipidemic mouse and rabbit models.\n2. Recycling of apoE mimetic peptide: The recycling of apoE mimetic peptide increases the duration of pre-HDL formation, leading to extended anti-inflammatory and atheroprotective properties.\n3. ApoE mimetic peptide (LRKLRKRLLR) conjugated to polyethylene glycol (PEG): This is a modified version of the apoE mimetic peptide in which the peptide is conjugated to PEG. This modification increases the half-life of the peptide in circulation and improves its atheroprotective properties.",
    "vicuna-13b_fact_raw": "1. ApoE mimetic peptide mimics the receptor binding domain 141-150 (LRKLRKRLLR) of apoE and is linked to the amphipathic helical peptide 18A.\n2. The recycling of apoE mimetic peptide enhances pre-HDL formation duration and anti-inflammatory and atheroprotective properties.\n3. A modified apoE mimetic peptide conjugated to polyethylene glycol (PEG) has an increased half-life in circulation and enhanced atheroprotective properties.",
    "vicuna-13b_fact": [
      "ApoE mimetic peptide mimics the receptor binding domain 141-150 (LRKLRKRLLR) of apoE and is linked to the amphipathic helical peptide 18A.",
      "The recycling of apoE mimetic peptide enhances pre-HDL formation duration and anti-inflammatory and atheroprotective properties.",
      "A modified apoE mimetic peptide conjugated to polyethylene glycol (PEG) has an increased half-life in circulation and enhanced atheroprotective properties."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n\nIt's important to note that without the specific context or reference to the particular research and its findings, it's difficult to verify the exact effects of modifications to apoE mimetic peptides like increased pre-HDL formation duration and the improvement of anti-inflammatory and atheroprotective properties, or the effects of conjugation with PEG. These statements generally align with pharmacological strategies aimed at improving the function and pharmacokinetics of therapeutic peptides, but their accuracy would require validation from relevant scientific literature or expert analysis.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "vicuna-13b_response": "Based on the provided document, there are sex differences in the sensitization of the locomotor activity and stereotypy produced by repeated intermittent amphetamine (AMPH) treatment. Female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior than males. Additionally, prior exposure to AMPH was associated with an elevation in resting striatal dihydroxyphenlacetic acid (DOPAC) to DA ratios in female rats, but not male rats, suggesting a sex difference in one neurochemical correlate of sensitization. The document also suggests that there is a sex difference in the responsiveness of brain DA systems to repetitive activation, which contributes to individual variation in the susceptibility to sensitization.",
    "vicuna-13b_fact_raw": "1. Female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior from repeated intermittent amphetamine treatment compared to male rats.\n2. Prior exposure to amphetamine was associated with an increase in resting striatal dihydroxyphenylacetic acid (DOPAC) to dopamine (DA) ratios in female rats, but not in male rats.\n3. There is a sex difference in the neurochemical correlates of sensitization, specifically in the striatal DOPAC to DA ratios.\n4. The responsiveness of brain dopamine systems to repetitive activation differs by sex.\n5. Sex differences contribute to individual variation in the susceptibility to sensitization by amphetamines.",
    "vicuna-13b_fact": [
      "Female rats showed greater and more rapid sensitization of locomotor activity and stereotyped behavior from repeated intermittent amphetamine treatment compared to male rats.",
      "Prior exposure to amphetamine was associated with an increase in resting striatal dihydroxyphenylacetic acid (DOPAC) to dopamine (DA) ratios in female rats, but not in male rats.",
      "There is a sex difference in the neurochemical correlates of sensitization, specifically in the striatal DOPAC to DA ratios.",
      "The responsiveness of brain dopamine systems to repetitive activation differs by sex.",
      "Sex differences contribute to individual variation in the susceptibility to sensitization by amphetamines."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided seem to be scientific in nature, possibly summarizing findings from a research study on the effects of amphetamines on male and female rats. Without the associated study or data, it is impossible to determine the truthfulness of these statements. They are all specific claims that require empirical evidence to verify, and such evidence is not provided here.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "vicuna-13b_response": "Based on the given information, it is not directly stated whether RUNX2 inhibits astrocyte differentiation. The document mentions that RUNX2 is a key regulator of osteogenic and odontoblastic differentiation, and that mutations in RUNX2 can cause Cleidocranial dysplasia, which is characterized by abnormal development of bone and teeth. The document also describes a study that aimed to find out the effect of a specific microRNA, mmu-miR-1963, on the ameloblast differentiation of LS8 cells. The study showed that mmu-miR-1963 suppresses ameloblast differentiation of LS8 cells by targeting Smoc2, and that Smoc2 itself promotes ameloblast differentiation of LS8 cells. However, there is no direct mention of RUNX2 inhibiting astrocyte differentiation in this study.",
    "vicuna-13b_fact_raw": "1. RUNX2 is a key regulator of osteogenic and odontoblastic differentiation.\n2. Mutations in RUNX2 can cause Cleidocranial dysplasia, which is characterized by abnormal development of bone and teeth.\n3. The study mentioned investigated the effect of mmu-miR-1963 on ameloblast differentiation of LS8 cells.\n4. Mmu-miR-1963 was found to suppress ameloblast differentiation of LS8 cells by targeting Smoc2.\n5. Smoc2 promotes ameloblast differentiation of LS8 cells.",
    "vicuna-13b_fact": [
      "RUNX2 is a key regulator of osteogenic and odontoblastic differentiation.",
      "Mutations in RUNX2 can cause Cleidocranial dysplasia, which is characterized by abnormal development of bone and teeth.",
      "The study mentioned investigated the effect of mmu-miR-1963 on ameloblast differentiation of LS8 cells.",
      "Mmu-miR-1963 was found to suppress ameloblast differentiation of LS8 cells by targeting Smoc2.",
      "Smoc2 promotes ameloblast differentiation of LS8 cells."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements pertain to well-known biological functions and genetic associations. RUNX2 is indeed a major transcription factor involved in bone and tooth development, and mutations in this gene are known to cause Cleidocranial dysplasia. However, the last three statements are specific to a certain study and its findings, the details of which are not provided. Without additional context, it is impossible to determine the truthfulness of the claims regarding mmu-miR-1963, Smoc2, and their interactions in ameloblast differentiation.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "vicuna-13b_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure that is performed to treat Cobb syndrome, which is a rare entity that involves concurrent findings of a metameric spinal vascular malformation and a cutaneous vascular malformation within several dermatomes of each other. In the case described in the document, the surgical excision of the spinal arteriovenous malformation was performed to treat the Cobb syndrome and resulted in partial recovery of neurological function. The surgical excision was done after multiple refractory embolizations. The document recommends a multidisciplinary approach for the management of Cobb syndrome, which balances the patient's current neurological function against the risks and potential gains from any interventional and surgical procedure.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "vicuna-13b_response": "Based on the information provided in Document-0, overexpression of LOXL2 can lead to EMT. The accumulation of LOXL2 in the Endoplasmic Reticulum activates the IRE1-XBP1 signalling pathway of the ER-stress response, which in turn induces the expression of several EMT-TFs such as SNAI1, SNAI2, ZEB2, and TCF3. This suggests that the activation of the IRE1-XBP1 pathway by LOXL2 overexpression is a key factor in the induction of EMT.",
    "vicuna-13b_fact_raw": "1. Overexpression of LOXL2 can lead to Epithelial-Mesenchymal Transition (EMT).\n2. Accumulation of LOXL2 in the Endoplasmic Reticulum activates the IRE1-XBP1 signalling pathway.\n3. The IRE1-XBP1 signalling pathway is part of the ER-stress response.\n4. Activation of the IRE1-XBP1 pathway induces the expression of EMT transcription factors like SNAI1, SNAI2, ZEB2, and TCF3.\n5. The activation of the IRE1-XBP1 pathway by LOXL2 overexpression is linked to the induction of EMT.",
    "vicuna-13b_fact": [
      "Overexpression of LOXL2 can lead to Epithelial-Mesenchymal Transition (EMT).",
      "Accumulation of LOXL2 in the Endoplasmic Reticulum activates the IRE1-XBP1 signalling pathway.",
      "The IRE1-XBP1 signalling pathway is part of the ER-stress response.",
      "Activation of the IRE1-XBP1 pathway induces the expression of EMT transcription factors like SNAI1, SNAI2, ZEB2, and TCF3.",
      "The activation of the IRE1-XBP1 pathway by LOXL2 overexpression is linked to the induction of EMT."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Overexpression of LOXL2 has been shown in scientific research to contribute to the process of Epithelial-Mesenchymal Transition (EMT).\n2. UNKNOWN: While LOXL2 is involved in various cellular processes, the specific accumulation of LOXL2 in the Endoplasmic Reticulum and its direct activation of the IRE1-XBP1 signalling pathway is not a well-established fact and would need a specific reference to a study or scientific article to confirm its accuracy.\n3. TRUE: The IRE1-XBP1 signalling pathway is indeed part of the endoplasmic reticulum (ER) stress response, also known as the unfolded protein response (UPR).\n4. UNKNOWN: While activation of the IRE1-XBP1 pathway does induce the expression of genes that respond to ER stress, the specific induction of EMT transcription factors such as SNAI1, SNAI2, ZEB2, and TCF3 would require a citation from scientific literature as it is not a universally recognized fact.\n5. UNKNOWN: The linkage between the activation of the IRE1-XBP1 pathway by LOXL2 overexpression and the induction of EMT would need evidence from specific scientific studies to verify the statement.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "vicuna-13b_response": "Based on the provided document, the T-UCR \"uc.306\" has been implicated in lung cancer. The document states that the uc.306 was upregulated in M1 cells and was predicted to be involved in the Wnt pathway. Additionally, the document states that the uc.306 had a lower expression in the HCC tissues than in para-tumor tissues, and that low expression of uc.306 was significantly associated with a shorter overall survival. However, it is important to note that the document specifically mentions that it is evaluating the role of uc.306 in the prognosis of hepatitis B (HBV)-related hepatocellular carcinoma (HCC) and not lung cancer.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "vicuna-13b_response": "GPR151, also known as Nociceptin receptor, is an orphan G protein-coupled receptor that is expressed in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion. Its restricted pattern of expression and homology with the galanin family of receptors suggest a role in nociception. A study investigated the role of GPR151 in neuropathic pain using a spared nerve injury model in mice. Real-time quantitative RT-PCR demonstrated a significant increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after the injury. However, measures of acute, inflammatory, and neuropathic pain behaviors were not significantly different in GPR151 loss-of-function mutant mice and wild-type controls. Additionally, galanin did not induce calcium signaling responses in ND7/23 cells transfected with GPR151. The study suggests that despite the large upregulation of GPR151 in the dorsal root ganglion after a nerve injury model of neuropathic pain, GPR151 does not appear to be involved in the modulation of pain-related behaviors, and galanin is unlikely to be an endogenous ligand for GPR151.",
    "vicuna-13b_fact_raw": "1. GPR151 is an orphan G protein-coupled receptor.\n2. GPR151 is expressed in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion.\n3. A study using a spared nerve injury model in mice suggested that GPR151 might be involved in nociception.\n4. Real-time quantitative RT-PCR demonstrated an increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after nerve injury.\n5. GPR151 loss-of-function mutant mice did not show significant differences in acute, inflammatory, and neuropathic pain behaviors compared to wild-type controls.",
    "vicuna-13b_fact": [
      "GPR151 is an orphan G protein-coupled receptor.",
      "GPR151 is expressed in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion.",
      "A study using a spared nerve injury model in mice suggested that GPR151 might be involved in nociception.",
      "Real-time quantitative RT-PCR demonstrated an increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after nerve injury.",
      "GPR151 loss-of-function mutant mice did not show significant differences in acute, inflammatory, and neuropathic pain behaviors compared to wild-type controls."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nExplanation:\n1. GPR151 indeed is an orphan G protein-coupled receptor, which means its endogenous ligand has not been clearly defined.\n2. GPR151 expression in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion is consistent with scientific reports about its localization.\n3. Studies that use models like the spared nerve injury model in mice often aim to explore the involvement of genetic factors or proteins in processes such as nociception, which is the sensory perception of pain, so this statement can be true.\n4. Real-time quantitative RT-PCR is a commonly used method to evaluate changes in mRNA expression. The statement about the specific increase in expression of GPR151 mRNA in the dorsal root ganglion after nerve injury aligns with the type of results such experiments might find.\n5. The outcome of the loss-of-function mutation and its impact on pain behaviors would depend on the results of the specific study. Without the actual data or reference to the study, we cannot confirm if this statement is true or false; thus, the response is UNKNOWN.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "vicuna-13b_response": "Based on the information provided in Document-0, the Fluzone intradermal quadrivalent vaccine contains live attenuated viruses. The study showed that the attenuation index of the vaccine was equal to or slightly better than 1.0, which is attributed to the 'reference' attenuated A/Hong Kong/68 strain of Beare and Bynoe. The attenuation index is measured in vitro on ferret tracheal rings and is expressed as the ratio of the time required for ciliary activity inhibition of 50% of the rings by the tested candidate vaccine strain and the 'reference' attenuated strain. The study also showed that the vaccine induced heterologous antibodies. It is worth noting that the study also mentioned that oral administration of underattenuated preparations did not cause severe reactions when the same vaccine was administered intranasally.",
    "vicuna-13b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains live attenuated viruses.\n2. The attenuation index of the vaccine was equal to or slightly better than 1.0.\n3. The 'reference' attenuated strain mentioned in the vaccine's context is A/Hong Kong/68 strain of Beare and Bynoe.\n4. The attenuation index is measured on ferret tracheal rings.\n5. The vaccine induced heterologous antibodies according to the study mentioned.",
    "vicuna-13b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains live attenuated viruses.",
      "The attenuation index of the vaccine was equal to or slightly better than 1.0.",
      "The 'reference' attenuated strain mentioned in the vaccine's context is A/Hong Kong/68 strain of Beare and Bynoe.",
      "The attenuation index is measured on ferret tracheal rings.",
      "The vaccine induced heterologous antibodies according to the study mentioned."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not live attenuated viruses.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific data from the passage on attenuation indexes, the reference strain, and the method of measuring attenuation indexes, and information regarding the induction of heterologous antibodies, it is not possible to determine the veracity of statements 2 through 5.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "vicuna-13b_response": "The study suggests that a specific part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus (SLE). The study used restriction fragment length polymorphism (RFLP) to compare the frequency of a 5.5 kb NcoI fragment in SLE patients and normal individuals. The frequency of this fragment was found to be significantly higher in SLE patients, indicating that the polymorphic TNF genes may be involved in the pathogenesis of SLE.",
    "vicuna-13b_fact_raw": "1. A specific part of the TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. The study used restriction fragment length polymorphism (RFLP) to analyze the TNFR2 gene in the context of SLE.\n3. A 5.5 kb NcoI fragment frequency was compared between SLE patients and normal individuals.\n4. The 5.5 kb NcoI fragment was found at a higher frequency in patients with SLE.\n5. The polymorphic TNF genes may be involved in the pathogenesis of Systemic Lupus Erythematosus.",
    "vicuna-13b_fact": [
      "A specific part of the TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "The study used restriction fragment length polymorphism (RFLP) to analyze the TNFR2 gene in the context of SLE.",
      "A 5.5 kb NcoI fragment frequency was compared between SLE patients and normal individuals.",
      "The 5.5 kb NcoI fragment was found at a higher frequency in patients with SLE.",
      "The polymorphic TNF genes may be involved in the pathogenesis of Systemic Lupus Erythematosus."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Certain regions of the TNFR2 (tumor necrosis factor receptor 2) gene have been associated with the risk of developing autoimmune diseases like Systemic Lupus Erythematosus (SLE), as implicated in various genetic studies.\n\n2. UNKNOWN: The use of restriction fragment length polymorphism (RFLP) to analyze the TNFR2 gene in the context of SLE may have been the method used in a particular study, but without specific reference to that study, we cannot confirm the truth of this statement.\n\n3. UNKNOWN: The comparison of a 5.5 kb NcoI fragment frequency between SLE patients and normal individuals sounds like a specific finding from a research study. Without specific reference to this study, its not possible to confirm the accuracy of this statement.\n\n4. UNKNOWN: The statement concerning the higher frequency of a 5.5 kb NcoI fragment in patients with SLE seems to draw from specific research findings. Since the source or study is not mentioned, the validity of this statement cannot be confirmed here.\n\n5. TRUE: It's widely recognized that polymorphisms in genes coding for cytokines, such as tumor necrosis factor (TNF), can influence susceptibility to autoimmune diseases like SLE, potentially being involved in their pathogenesis.",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "vicuna-13b_response": "Based on the information provided in Document-0, there is currently no vaccine available for peanut allergy. The study evaluated the potential application of poly(anhydride) nanoparticles as immunoadjuvants for peanut oral immunotherapy, but the results showed that oral immunization with poly(anhydride) NPs led to a pro-T(H)1 immune response, which means it did not provide a vaccine for peanut allergy.",
    "vicuna-13b_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. A study evaluated poly(anhydride) nanoparticles as possible immunoadjuvants for peanut oral immunotherapy.\n3. Oral immunization with poly(anhydride) nanoparticles led to a pro-T(H)1 immune response.",
    "vicuna-13b_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "A study evaluated poly(anhydride) nanoparticles as possible immunoadjuvants for peanut oral immunotherapy.",
      "Oral immunization with poly(anhydride) nanoparticles led to a pro-T(H)1 immune response."
    ],
    "vicuna-13b_judge_raw": "1. TRUE (As of my knowledge cutoff in 2023, there is no commercially available vaccine for peanut allergy, although research in the area is ongoing.)\n2. UNKNOWN (Without specific context or a reference, it's not possible to confirm the accuracy of the statement regarding a study evaluating poly(anhydride) nanoparticles. It is plausible as nanoparticles are being explored in immunotherapy research.)\n3. UNKNOWN (The outcome of immunization with poly(anhydride) nanoparticles leading to a pro-T(H)1 immune response is specific to the outcome of a study that cannot be confirmed without additional information.)",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "vicuna-13b_response": "The mouse Fxy gene is located on the minute short arm of the mouse Y chromosome. This information is derived from a study that used a combination of in situ mapping and DNA analysis with recombinant DNA probes specific for the Sxr region of the mouse Y chromosome. The study found that both the gene(s) controlling primary sex determination and the expression of the male-specific antigen H-Y (Tdy and Hya respectively) are also located on the same region. Additionally, the study proposed that the H-Y- variant of Sxr (Sxr') arose by a partial deletion within the Sxr region and suggested an alternative model for the generation of the original Sxr region.",
    "vicuna-13b_fact_raw": "1. The mouse Fxy gene is located on the short arm of the mouse Y chromosome.\n2. The study found that the gene(s) controlling primary sex determination are located on the same region as the Fxy gene.\n3. The male-specific antigen H-Y, also known as Tdy and Hya, is located on the same region of the Y chromosome.\n4. The H-Y- variant of Sxr (Sxr') is proposed to have arisen by a partial deletion within the Sxr region.\n5. The study suggested an alternative model for the generation of the original Sxr region.",
    "vicuna-13b_fact": [
      "The mouse Fxy gene is located on the short arm of the mouse Y chromosome.",
      "The study found that the gene(s) controlling primary sex determination are located on the same region as the Fxy gene.",
      "The male-specific antigen H-Y, also known as Tdy and Hya, is located on the same region of the Y chromosome.",
      "The H-Y- variant of Sxr (Sxr') is proposed to have arisen by a partial deletion within the Sxr region.",
      "The study suggested an alternative model for the generation of the original Sxr region."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: The Fxy gene, also known as Sry in mice, is indeed located on the Y chromosome, specifically on the short arm. It is a key gene involved in sex determination.\n2. TRUE: The gene(s) responsible for primary sex determination in mammals, including the Sry gene in mice (equivalent to the Fxy gene mentioned), is indeed located in this region of the Y chromosome.\n3. FALSE [correction]: The male-specific antigen H-Y is not a gene but an antigenic determinant, and while it is linked to sex determination, its exact genetic location can be more complex. \"Tdy\" is actually \"Tdy\" in some literature, which represents \"testis-determining Y\" and refers to the Sry gene. \"Hya\" is an antigen associated with Sry, but not a gene itself.\n4. TRUE: The H-Y- variant of Sxr (sex-reversed), known as Sxr', is believed to have arisen due to a mutation such as a partial deletion within the Sxr region on the Y chromosome.\n5. UNKNOWN: Without knowing the specifics of the study or its conclusions, it is impossible to verify whether the study suggested an alternative model for the generation of the original Sxr region.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "vicuna-13b_response": "The basis of the methidiumpropyl-EDTA (MPE) sequencing method is endonuclease protection or \"footprinting\" analysis. This technique is used to identify the nucleotides involved in a protein-DNA interaction by employing the synthetic DNA intercalator MPE, which cleaves DNA in the presence of ferrous ion and oxygen. Unlike DNase I, MPE exhibits no sequence specificity in its cleavage, making it better suited for protection analysis. The method involves using a crude nuclear extract to identify the nucleotides of a specific DNA-protein complex that binds to the octameric sequence ATGCAAAT. The results obtained using MPE protection analysis were compared to those obtained using DNase I.",
    "vicuna-13b_fact_raw": "1. Methidiumpropyl-EDTA (MPE) sequencing method is based on endonuclease protection or \"footprinting\" analysis.\n2. The synthetic DNA intercalator MPE cleaves DNA in the presence of ferrous ion and oxygen.\n3. MPE exhibits no sequence specificity in its cleavage, unlike DNase I.\n4. The MPE sequencing method uses a crude nuclear extract to identify nucleotides of a specific DNA-protein complex.\n5. The specific DNA-protein complex binds to the octameric sequence ATGCAAAT in the context of MPE protection analysis.",
    "vicuna-13b_fact": [
      "Methidiumpropyl-EDTA (MPE) sequencing method is based on endonuclease protection or \"footprinting\" analysis.",
      "The synthetic DNA intercalator MPE cleaves DNA in the presence of ferrous ion and oxygen.",
      "MPE exhibits no sequence specificity in its cleavage, unlike DNase I.",
      "The MPE sequencing method uses a crude nuclear extract to identify nucleotides of a specific DNA-protein complex.",
      "The specific DNA-protein complex binds to the octameric sequence ATGCAAAT in the context of MPE protection analysis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Methidiumpropyl-EDTA (MPE) sequencing method is indeed based on endonuclease protection or \"footprinting\" analysis which is designed to determine the DNA sequences that proteins specifically recognize and bind to.\n2. TRUE: The intercalating agent methidiumpropyl-EDTA (MPE) cleaves DNA when coupled with ferrous ion (Fe2+) and oxygen, as this triggers the production of reactive species that can break the DNA strands.\n3. FALSE [correction]: MPE exhibits some sequence preference, cleaving most efficiently at sequences rich in adenine and thymine, in contrast to DNase I that cleaves phosphodiester bonds close to any exposed base with preference at certain sequences.\n4. FALSE [correction]: The MPE sequencing method uses purified DNA and does not necessarily require crude nuclear extract. The purpose of the method is to identify the nucleotides in a specific DNA-protein complex, but this is achieved typically by treating the DNA-protein complex with MPE, not by using a crude nuclear extract.\n5. UNKNOWN: Without further context, it is not possible to confirm whether the specific DNA-protein complex indeed binds to the octameric sequence ATGCAAAT. Specificity of binding would depend on the protein in question and its recognition sequence.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "vicuna-13b_response": "Based on the given information, it is not explicitly mentioned which programming language has been used for implementing GWAR. The document mentions the use of modern programming language concepts and object relational mapper and meta programming, but does not specify the programming language used.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "vicuna-13b_response": "Based on the provided information, it appears that xaliproden is a drug with neurotrophic effects that was studied in two randomized, double-blind, placebo-controlled, multi-center, multi-national studies to assess its efficacy and safety in patients with clinically probable or definite ALS of more than 6 months and less than 5 years duration. The primary endpoints of the studies were time to death, tracheostomy, or permanent assisted ventilation (DTP), and time to vital capacity (VC) <50% or DTP before and after adjustment using a Cox proportional hazard model for prespecified prognostic factors.\nIn Study 1, the primary outcome measures did not reach statistical significance, but for the 2 mg group, a significant 30% reduction in the risk of reaching VC <50% was observed (95% confidence interval [CI]: 8.46, P=0.009). In Study 2, no significant results were obtained, but there was a trend in favor of add-on 1 mg dose xaliproden vs. placebo for time to VC <50% (RRR 15% [-6.31, ns] and RRR 12% [CI: -6.27, ns]). Adjusted RR ratios were consistently more favorable for the xaliproden groups.\nThe tolerability of xaliproden was good, and dose-dependent side effects were largely associated with the serotonergic properties of xaliproden. An effect of xaliproden on functional parameters, especially VC, was noted, although this effect did not reach statistical significance. The study suggests that xaliproden has a small effect on clinically noteworthy aspects of disease progression in ALS.\nTherefore, based on the available evidence, it cannot be concluded whether xaliproden improves the prognosis of ALS. Further research is needed to determine the efficacy and safety of xaliproden in the treatment of ALS.",
    "vicuna-13b_fact_raw": "1. Xaliproden is a drug studied for its efficacy and safety in patients with clinically probable or definite amyotrophic lateral sclerosis (ALS) of more than 6 months and less than 5 years duration.\n2. The primary endpoints of the studies on xaliproden included time to death, tracheostomy, or permanent assisted ventilation, and time to vital capacity less than 50%.\n3. In one of the studies, there was a significant 30% reduction in the risk of reaching vital capacity less than 50% for the 2 mg xaliproden group.\n4. Adjusted Relative Risk (RR) ratios were more favorable for the xaliproden groups in the studies, although not all results reached statistical significance.\n5. The tolerability of xaliproden was considered good, with dose-dependent side effects largely associated with its serotonergic properties.",
    "vicuna-13b_fact": [
      "Xaliproden is a drug studied for its efficacy and safety in patients with clinically probable or definite amyotrophic lateral sclerosis (ALS) of more than 6 months and less than 5 years duration.",
      "The primary endpoints of the studies on xaliproden included time to death, tracheostomy, or permanent assisted ventilation, and time to vital capacity less than 50%.",
      "In one of the studies, there was a significant 30% reduction in the risk of reaching vital capacity less than 50% for the 2 mg xaliproden group.",
      "Adjusted Relative Risk (RR) ratios were more favorable for the xaliproden groups in the studies, although not all results reached statistical significance.",
      "The tolerability of xaliproden was considered good, with dose-dependent side effects largely associated with its serotonergic properties."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The particular efficacy and safety parameters, including the length of ALS duration among patients, require specific source verification that is not provided here.\n2. UNKNOWN: Without direct access to the study or studies in question, I cannot verify the primary endpoints.\n3. UNKNOWN: Without specific source data, the claim of a significant 30% reduction in the risk is not verifiable.\n4. UNKNOWN: The value or interpretation of Adjusted Relative Risk (RR) ratios in the context of these studies cannot be confirmed without additional information.\n5. UNKNOWN: Without data from the studies, the tolerability and side effect profile cannot be accurately assessed.\n\nNote: The context provided is insufficient to verify the accuracy of these statements regarding xaliproden, as they all reference specific studies and data that are not provided here. To assess these claims, the actual studies would need to be reviewed.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the transgenes were inserted in the LiPS-A3S line on chromosome 3. Specifically, the insertion was located in the 86B4/6 interband region of chromosome 3.",
    "vicuna-13b_fact_raw": "1. Transgenes were inserted in the LiPS-A3S line on chromosome 3.\n2. The specific location of the insertion was the 86B4/6 interband region of chromosome 3.",
    "vicuna-13b_fact": [
      "Transgenes were inserted in the LiPS-A3S line on chromosome 3.",
      "The specific location of the insertion was the 86B4/6 interband region of chromosome 3."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n\nWithout additional context or specific information regarding the genetic modification referred to, the veracity of these statements cannot be determined. These details are generally found in specialized scientific literature or experimental documentation.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "vicuna-13b_response": "DeepSynergy is a tool that uses deep learning to predict drug synergy. It was developed to address the challenge of identifying novel synergistic drug combinations, which is difficult due to the large combinatorial space. DeepSynergy takes chemical and genomic information as input and uses a normalization strategy and conical layers to model drug synergies. The tool was compared to other machine learning methods such as Gradient Boosting Machines, Random Forests, Support Vector Machines, and Elastic Nets on the largest publicly available synergy dataset. DeepSynergy significantly outperformed the other methods, with an improvement of 7.2% over the second best method at predicting novel drug combinations within the space of explored drugs and cell lines. The tool also had a high predictive performance of an AUC of 0.90 for classifying these novel drug combinations. DeepSynergy is available via the website [www.bioinf.jku.at/software/DeepSynergy](http://www.bioinf.jku.at/software/DeepSynergy) and can be contacted at klambauer@bioinf.jku.at. Supplementary data are also available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. DeepSynergy uses deep learning to predict drug synergies.\n2. DeepSynergy's input includes chemical and genomic information.\n3. DeepSynergy employs a normalization strategy and conical layers in its modeling process.\n4. In a comparative study, DeepSynergy outperformed other machine learning methods like Gradient Boosting Machines, Random Forests, Support Vector Machines, and Elastic Nets.\n5. DeepSynergy achieved an AUC (Area Under the Curve) of 0.90 for classifying novel drug combinations.",
    "vicuna-13b_fact": [
      "DeepSynergy uses deep learning to predict drug synergies.",
      "DeepSynergy's input includes chemical and genomic information.",
      "DeepSynergy employs a normalization strategy and conical layers in its modeling process.",
      "In a comparative study, DeepSynergy outperformed other machine learning methods like Gradient Boosting Machines, Random Forests, Support Vector Machines, and Elastic Nets.",
      "DeepSynergy achieved an AUC (Area Under the Curve) of 0.90 for classifying novel drug combinations."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: DeepSynergy employs a normalization strategy and convolutional layers in its modeling process.\n4. TRUE\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "vicuna-13b_response": "The cloud-based platform for comparing GWAS is called GWAtoolbox. It is an R package that standardizes and accelerates the handling of data from genome-wide association studies (GWAS), particularly in the context of large-scale GWAS meta-analyses. GWAtoolbox has the ability to perform quality control (QC) on any number of files in a matter of minutes. The implemented workflow checks three particular data quality aspects: data formatting, quality of the GWAS results, and data consistency across studies. The output consists of an extensive list of quality statistics and plots which allow inspection of individual files and between-study comparison to identify systematic bias. GWAtoolbox is available at the website <http://www.eurac.edu/GWAtoolbox> and contact information for further inquiries is provided as [cfuchsb@umich.edu; daniel.taliun@eurac.edu](mailto:cfuchsb@umich.edu; daniel.taliun@eurac.edu). Supplementary data are also available at Bioinformatics online.",
    "vicuna-13b_fact_raw": "1. GWAtoolbox is a cloud-based platform developed for comparing GWAS (genome-wide association studies).\n2. GWAtoolbox is an R package designed to standardize and accelerate the handling of GWAS data, especially for large-scale GWAS meta-analyses.\n3. The platform can perform quality control on any number of files in a matter of minutes.\n4. GWAtoolbox checks for data formatting, quality of the GWAS results, and data consistency across studies.\n5. The website for GWAtoolbox is <http://www.eurac.edu/GWAtoolbox>.",
    "vicuna-13b_fact": [
      "GWAtoolbox is a cloud-based platform developed for comparing GWAS (genome-wide association studies).",
      "GWAtoolbox is an R package designed to standardize and accelerate the handling of GWAS data, especially for large-scale GWAS meta-analyses.",
      "The platform can perform quality control on any number of files in a matter of minutes.",
      "GWAtoolbox checks for data formatting, quality of the GWAS results, and data consistency across studies.",
      "The website for GWAtoolbox is <http://www.eurac.edu/GWAtoolbox>."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without specific and current information about a platform named \"GWAtoolbox\", it is not possible to verify whether it is cloud-based or if it is developed for comparing GWAS.\n2. UNKNOWN: Again, without specific and current information about \"GWAtoolbox\", it cannot be verified if it is an R package designed for the claimed purpose.\n3. UNKNOWN: The ability of \"GWAtoolbox\" to perform quality control on any number of files within a specific time frame cannot be confirmed without additional information.\n4. UNKNOWN: It is unclear whether \"GWAtoolbox\" performs checks for data formatting, quality of GWAS results, and data consistency across studies without further context or a source to verify these capabilities.\n5. FALSE [correction]: The website provided (<http://www.eurac.edu/GWAtoolbox>) does not seem to be a valid link. A quick search does not lead to a functioning website for a tool called \"GWAtoolbox\". However, if \"GWAtoolbox\" is real, the correct URL should be provided by a credible source.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it appears that ZIMET 3164 has been shown to have some effectiveness against certain types of sarcomas, specifically sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma. However, the drug was not able to significantly prolong the survival time of mice bearing Ehrlich ascites carcinoma or the leukaemias L 1210 and LAJ I. Additionally, the drug appears to exert its maximum effect when given on days 2 to +2 relative to an antigenic stimulus, and administration of the drug exclusively prior to immunization induced only moderate immunosuppression, while injection afterwards failed to affect the primary response at all. This suggests that ZIMET 3164 may interfere with the afferent limb of the immune response.\nIt is important to note that the effectiveness of a drug against a specific type of cancer can depend on a variety of factors, including the specific strain of the cancer, the dosage and method of administration, and the individual patient's characteristics and medical history. Therefore, the results of animal studies may not necessarily translate to the same effectiveness in humans.\nBased on the information provided in Document-0, it cannot be definitively stated whether CMB305 (the active ingredient in ZIMET 3164) can be used against sarcomas. Further research and clinical trials would be necessary to determine the effectiveness of CMB305 against sarcomas in humans.",
    "vicuna-13b_fact_raw": "1. ZIMET 3164 has shown effectiveness against certain types of sarcomas, specifically sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma.\n2. ZIMET 3164 was not able to significantly prolong the survival time of mice bearing Ehrlich ascites carcinoma.\n3. ZIMET 3164 does not significantly affect the survival time of mice with the leukaemias L 1210 and LAJI.\n4. The maximum effect of ZIMET 3164 is exerted when given on days 2 to +2 relative to an antigenic stimulus.\n5. Administration of ZIMET 3164 exclusively prior to immunization induces only moderate immunosuppression.",
    "vicuna-13b_fact": [
      "ZIMET 3164 has shown effectiveness against certain types of sarcomas, specifically sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma.",
      "ZIMET 3164 was not able to significantly prolong the survival time of mice bearing Ehrlich ascites carcinoma.",
      "ZIMET 3164 does not significantly affect the survival time of mice with the leukaemias L 1210 and LAJI.",
      "The maximum effect of ZIMET 3164 is exerted when given on days 2 to +2 relative to an antigenic stimulus.",
      "Administration of ZIMET 3164 exclusively prior to immunization induces only moderate immunosuppression."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided involve specific effects of a compound named ZIMET 3164 on certain types of cancers and its timing of administration related to immunosuppression. Without source material or additional context that details experimental results or scientific findings, it's not possible to determine the truthfulness of these statements. Access to relevant scientific research or data would be necessary to verify these claims.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "vicuna-13b_response": "The manifestations of the Saint's Triad are a group of three pathologies that are commonly found together in patients. The three pathologies that constitute Saint's Triad are cholelithiasis, diverticulosis, and hiatus hernia. The research conducted on 684 patients revealed that the incidence of Saint's Triad was 1.02%, which is four times higher than expected. The investigation also revealed that there were 7 cases of Saint's Triad and 86 cases of bifocal associations, with the most common combinations being cholelithiasis + diverticulosis and cholelithiasis + hiatus hernia. These findings suggest that Saint's Triad is a real condition that is worth considering in the assessment of patients undergoing radiological examinations.",
    "vicuna-13b_fact_raw": "1. The Saint's Triad consists of cholelithiasis, diverticulosis, and hiatus hernia.\n2. A research study on 684 patients found the incidence of Saint's Triad to be 1.02%.\n3. The same study reported 7 cases of Saint's Triad.\n4. The study also identified 86 cases of bifocal associations among the patients.\n5. The most common combinations in bifocal associations were cholelithiasis + diverticulosis and cholelithiasis + hiatus hernia.",
    "vicuna-13b_fact": [
      "The Saint's Triad consists of cholelithiasis, diverticulosis, and hiatus hernia.",
      "A research study on 684 patients found the incidence of Saint's Triad to be 1.02%.",
      "The same study reported 7 cases of Saint's Triad.",
      "The study also identified 86 cases of bifocal associations among the patients.",
      "The most common combinations in bifocal associations were cholelithiasis + diverticulosis and cholelithiasis + hiatus hernia."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. UNKNOWN (without the actual research data or the title of the study to verify this statistic, this statement can't be confirmed as true or false)\n3. FALSE [correction]: If we assume the incidence of Saint's Triad to be true as 1.02% for the 684 patients, then the number of cases should be approximately 7, but 1.02% of 684 is approximately 6.98 cases, which doesn't translate well into a whole number of cases. Without rounding, the number could not be exactly 7. However, since the percentage is given to two decimal places, it suggests that the actual number has been rounded, potentially leading to the 7 cases reported.\n4. UNKNOWN (without the actual research data or the title of the study to verify this statistic, this statement can't be confirmed as true or false)\n5. UNKNOWN (although the statement seems plausible, without the actual research data to confirm the frequency of these combinations, this statement can't be confirmed as true or false)",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "vicuna-13b_response": "Based on the information provided in Document-0, the overexpression of LY6K is associated with poor prognosis for small cell lung cancer (SCLC) patients. The study found that the PLK1 protein, which is a crucial mitotic regulator, is expressed at higher levels in SCLC tumor samples than in normal lung tissue samples. The selective PLK1 inhibitor BI 6727 significantly induced the inhibition of proliferation and apoptosis in a dose-dependent manner in SCLC cell lines. The inhibition of PLK1 resulted in an increase in the population of cells in the G2/M phase, followed by DNA damage and the consequent activation of the ataxia telangiectasia and Rad3-related (ATR)/ataxia telangiectasia mutated (ATM)-Chk1/Chk2 checkpoint pathway. Additionally, BI 6727 treatment resulted in clearly attenuated growth and apoptosis in NCI-H446 xenografts. The level of histone H2AX phosphorylation at serine-139 was markedly increased both in vitro and in vivo, indicating that BI 6727 has therapeutic potential for SCLC patients.\nTherefore, based on this information, it can be inferred that overexpression of LY6K is associated with poor prognosis for SCLC patients.",
    "vicuna-13b_fact_raw": "1. Overexpression of LY6K is associated with poor prognosis for small cell lung cancer (SCLC) patients.\n2. The PLK1 protein is expressed at higher levels in SCLC tumor samples than in normal lung tissue samples.\n3. The selective PLK1 inhibitor BI 6727 induces inhibition of proliferation and apoptosis in a dose-dependent manner in SCLC cell lines.\n4. Inhibition of PLK1 increases the population of cells in the G2/M phase and subsequently leads to DNA damage and checkpoint pathway activation involving ATR/ATM-Chk1/Chk2.\n5. Treatment with BI 6727 results in attenuated growth and increased apoptosis in NCI-H446 xenografts, with an increase in histone H2AX phosphorylation at serine-139.",
    "vicuna-13b_fact": [
      "Overexpression of LY6K is associated with poor prognosis for small cell lung cancer (SCLC) patients.",
      "The PLK1 protein is expressed at higher levels in SCLC tumor samples than in normal lung tissue samples.",
      "The selective PLK1 inhibitor BI 6727 induces inhibition of proliferation and apoptosis in a dose-dependent manner in SCLC cell lines.",
      "Inhibition of PLK1 increases the population of cells in the G2/M phase and subsequently leads to DNA damage and checkpoint pathway activation involving ATR/ATM-Chk1/Chk2.",
      "Treatment with BI 6727 results in attenuated growth and increased apoptosis in NCI-H446 xenografts, with an increase in histone H2AX phosphorylation at serine-139."
    ],
    "vicuna-13b_judge_raw": "1. TRUE (Assuming this statement is based on scientific research that suggests such a correlation.)\n2. TRUE (Again, assuming this from the context where this statement is implying there is scientific evidence for increased PLK1 protein levels in SCLC tumors.)\n3. TRUE (Based on the specificity of the statement, it seems to report findings from a scientific experiment or study involving the drug BI 6727 on SCLC cell lines.)\n4. TRUE (This is a specific statement likely based on scientific data regarding the biological effects of PLK1 inhibition, which is consistent with known effects on the cell cycle and DNA damage response pathways.)\n5. TRUE (The statement appears to summarize the findings from an experimental therapeutic study using NCI-H446 xenografts and observing the biological markers like histone H2AX phosphorylation, which is a marker for DNA damage. Assuming it's based on specific research findings.)",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "vicuna-13b_response": "Based on the provided document, the following are the Cdk targets that are dephosphorylated during cytokinesis:\n1. Aip1\n2. Ede1\n3. Inn1\nThese proteins are identified as cytokinetic regulators, and their dephosphorylation is required for cytokinesis to occur. The results suggest that the coordination between the master cell cycle regulator Cdk and its counteracting phosphatase Cdc14 is crucial for the execution of cytokinesis and that the dephosphorylation of multiple Cdk targets is involved in the process.",
    "vicuna-13b_fact_raw": "1. Aip1 is a Cdk target that is dephosphorylated during cytokinesis.\n2. Ede1 is a Cdk target that is dephosphorylated during cytokinesis.\n3. Inn1 is a Cdk target that is dephosphorylated during cytokinesis.\n4. Dephosphorylation of Cdk targets is required for cytokinesis to occur.\n5. The coordination between Cdk and its counteracting phosphatase Cdc14 is crucial for the execution of cytokinesis.",
    "vicuna-13b_fact": [
      "Aip1 is a Cdk target that is dephosphorylated during cytokinesis.",
      "Ede1 is a Cdk target that is dephosphorylated during cytokinesis.",
      "Inn1 is a Cdk target that is dephosphorylated during cytokinesis.",
      "Dephosphorylation of Cdk targets is required for cytokinesis to occur.",
      "The coordination between Cdk and its counteracting phosphatase Cdc14 is crucial for the execution of cytokinesis."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nThe statements regarding Aip1, Ede1, and Inn1 as Cdk targets that are dephosphorylated during cytokinesis cannot be confirmed as true or false without more specific scientific context or references. These are specific claims that require detailed knowledge or a specific literature source to verify. The general role of Cdk (Cyclin-dependent kinases) in cell cycle regulation and the requirement for dephosphorylation of Cdk targets for cytokinesis (Statement 4) is true, as Cdk activity is known to be crucial for cell cycle progression and its downregulation is necessary for cytokinesis to occur. Statement 5 is also true; the interplay between kinase and phosphatase activities, such as Cdk and Cdc14, is indeed critical for the regulation of various stages during the cell cycle, including cytokinesis.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "vicuna-13b_response": "Xanamem is not a known drug or compound. It is possible that it is a misspelling or a different name for Alprazolam, which is a benzodiazepine tranquilizer that was first marketed in 1981 under the trade name Xanax. It is commonly used to treat anxiety and panic disorders and is known to be addictive and habit-forming. The drug works by increasing the activity of a neurotransmitter called GABA, which has a calming effect on the brain. It is also known to have a potential for abuse and dependence, and it is classified as a Schedule IV controlled substance in the United States.",
    "vicuna-13b_fact_raw": "1. Alprazolam is a benzodiazepine tranquilizer.\n2. Alprazolam was first marketed in 1981 under the trade name Xanax.\n3. Alprazolam is commonly used to treat anxiety and panic disorders.\n4. Alprazolam increases the activity of the neurotransmitter GABA.\n5. Alprazolam is classified as a Schedule IV controlled substance in the United States.",
    "vicuna-13b_fact": [
      "Alprazolam is a benzodiazepine tranquilizer.",
      "Alprazolam was first marketed in 1981 under the trade name Xanax.",
      "Alprazolam is commonly used to treat anxiety and panic disorders.",
      "Alprazolam increases the activity of the neurotransmitter GABA.",
      "Alprazolam is classified as a Schedule IV controlled substance in the United States."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "vicuna-13b_response": "The Hof1-Cyk3 interaction plays a role in yeast cytokinesis, which is the process by which a cell divides into two daughter cells. In budding yeast, there are two pathways for cytokinesis: one that is dependent on the contractile actomyosin ring and another that is dependent on an SH3 domain protein called Hof1/Cyk2. Hof1 forms a ring at the bud neck during cell division and this zone is active in septum deposition. The Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) ortholog, verprolin/Vrp1/End5, interacts with Hof1 and facilitates Hof1 recruitment to the bud neck. A Vrp1 fragment that is unable to interact with yeast WASP (Las17/Bee1) localizes to the actin cytoskeleton and functions in the polarization of the cortical actin cytoskeleton, but still retains function in Hof1 recruitment and cytokinesis. The ability of this Vrp1 fragment to bind the Hof1 SH3 domain via its Hof one trap (HOT) domain is critical for cytokinesis. The Vrp1 HOT domain consists of three tandem proline-rich motifs flanked by serines. Unexpectedly, the Hof1 SH3 domain itself is not required for cytokinesis and indeed appears to negatively regulate cytokinesis. The Vrp1 HOT domain promotes cytokinesis by binding to the Hof1 SH3 domain and counteracting its inhibitory effect.",
    "vicuna-13b_fact_raw": "1. The Hof1-Cyk3 interaction is involved in the process of cytokinesis in yeast cells.\n2. There are two pathways for cytokinesis in budding yeast: one involving the contractile actomyosin ring and the other dependent on an SH3 domain protein, Hof1/Cyk2.\n3. Hof1 forms a ring at the bud neck during yeast cell division and is active in septum deposition.\n4. The Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) ortholog, verprolin/Vrp1/End5, is involved in Hof1 recruitment to the bud neck in yeast.\n5. The Vrp1 HOT domain, which consists of three tandem proline-rich motifs flanked by serines, is necessary for promoting cytokinesis by binding to the Hof1 SH3 domain.",
    "vicuna-13b_fact": [
      "The Hof1-Cyk3 interaction is involved in the process of cytokinesis in yeast cells.",
      "There are two pathways for cytokinesis in budding yeast: one involving the contractile actomyosin ring and the other dependent on an SH3 domain protein, Hof1/Cyk2.",
      "Hof1 forms a ring at the bud neck during yeast cell division and is active in septum deposition.",
      "The Wiskott-Aldrich syndrome protein (WASP)-interacting protein (WIP) ortholog, verprolin/Vrp1/End5, is involved in Hof1 recruitment to the bud neck in yeast.",
      "The Vrp1 HOT domain, which consists of three tandem proline-rich motifs flanked by serines, is necessary for promoting cytokinesis by binding to the Hof1 SH3 domain."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: There are two pathways for cytokinesis in budding yeast: one involving the contractile actomyosin ring and the other dependent on an SH3 domain protein, Hof1/Cyk3 (not Cyk2).\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The Vrp1 HOT domain is involved in the process, but the description of the HOT domain provided is inaccurate. Instead of specifying details about the HOT domain and its interaction with Hof1's SH3 domain, it would be more accurate to state that Vrp1, through its proline-rich motifs and interaction with other proteins, plays a role in Hof1 recruitment for cytokinesis. The specifics of the Vrp1 domain necessary for binding to the Hof1 SH3 domain should be checked in scientific literature for accuracy.",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "vicuna-13b_response": "The T-UCRs (Tumor-UCRs) that have been implicated in gastric cancer are UCH-L1 (Ubiquitin C-terminal hydrolase L1). In the study, expression of UCH-L1 was evaluated in 196 gastric cardiac adenocarcinoma (GCA) specimens by immunohistochemistry using tissue microarray and its function on gastric cancer cells was measured. UCH-L1 overexpression was found to be tightly correlated with tumor size and overall TNM stage. The study found that UCH-L1 positive is inversely associated with cumulative survival (P<0.001) and multivariate Cox regression model showed that UCH-L1 overexpression is a significant negative predictor in GCA prognosis (Hazard Ratio=0.53, P<0.01), along with advanced TNM stage which is a known negative factor in gastric cancers (Hazard Ratio=0.33, P<0.05). Silencing of UCH-L1 reduced the ability of cell proliferation, colony formation, migration and invasion of gastric cancer cells. The study suggests that UCH-L1 is a promising prognostic biomarker for GCAs and might play an important role in the carcinogenesis of gastric cancer.",
    "vicuna-13b_fact_raw": "1. UCH-L1 (Ubiquitin C-terminal hydrolase L1) has been implicated in gastric cancer, specifically in gastric cardiac adenocarcinoma (GCA).\n2. A study evaluating 196 gastric cardiac adenocarcinoma specimens found a correlation between UCH-L1 overexpression and tumor size and overall TNM stage.\n3. UCH-L1 positivity is inversely associated with cumulative survival in gastric cardiac adenocarcinoma, with a statistical significance (P<0.001).\n4. In the multivariate Cox regression model, UCH-L1 overexpression was indicated as a significant negative predictor in GCA prognosis (Hazard Ratio=0.53, P<0.01).\n5. Silencing of UCH-L1 in gastric cancer cells reduced their proliferation, colony formation, migration, and invasion capabilities.",
    "vicuna-13b_fact": [
      "UCH-L1 (Ubiquitin C-terminal hydrolase L1) has been implicated in gastric cancer, specifically in gastric cardiac adenocarcinoma (GCA).",
      "A study evaluating 196 gastric cardiac adenocarcinoma specimens found a correlation between UCH-L1 overexpression and tumor size and overall TNM stage.",
      "UCH-L1 positivity is inversely associated with cumulative survival in gastric cardiac adenocarcinoma, with a statistical significance (P<0.001).",
      "In the multivariate Cox regression model, UCH-L1 overexpression was indicated as a significant negative predictor in GCA prognosis (Hazard Ratio=0.53, P<0.01).",
      "Silencing of UCH-L1 in gastric cancer cells reduced their proliferation, colony formation, migration, and invasion capabilities."
    ],
    "vicuna-13b_judge_raw": "1. TRUE - UCH-L1 has been implicated in various cancers, including gastric cancer, and its role in gastric cardiac adenocarcinoma (GCA) has been studied and reported in scientific research.\n2. TRUE - This statement aligns with the type of findings that might emerge from such a study, though without the specific reference, the exact numbers cannot be verified. However, the relationship between UCH-L1 overexpression and tumor characteristics like size and stage is a plausible finding in this context.\n3. TRUE - This statement is consistent with scientific findings that could be reported in research, where UCH-L1 positivity (meaning overexpression) could be associated with poorer survival outcomes, indicated by a statistically significant p-value.\n4. FALSE [correction]: If UCH-L1 overexpression was a negative predictor in GCA prognosis, the Hazard Ratio would typically be greater than 1, denoting a higher risk associated with this predictor. A Hazard Ratio of 0.53 would suggest that UCH-L1 overexpression is associated with a better prognosis, which contradicts the statement. Therefore, it is likely that the Hazard Ratio would need to be above 1 to align with the statement as a significant negative predictor.\n5. TRUE - This is consistent with research regarding the effects of gene silencing on cancer cell behaviors. The silencing of a gene associated with cancer progression would be expected to impair tumorigenic properties such as proliferation and migration.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "vicuna-13b_response": "The Lupus Severity Index (LSI) is a measure of the severity of chronic liver disease in patients. It is determined by the distribution of sulfur colloid between the liver and spleen, adjusted for spleen size, as measured by liver-spleen index (LSI). The LSI is calculated by dividing the liver-spleen distribution by the spleen size. The LSI and liver-bone marrow index (LBI) are correlated with each other and the arithmetic mean of both is defined as the severity score. The severity score can be used to evaluate the clinical value of the liver-spleen scan (LSS) as a quantitative test of hepatic function. The study included 329 consecutive patients with adequate LSS and clinical information, of which 27 were considered normal and 220 had chronic liver disease (CLD). The severity score in 27 normals was 102 +/- 5 with all values greater than 85. The severity score correlated with hepatic fibrosis (r = -0.694; P < 0.001) in 109 patients with benign liver disease who had recent biopsies and with the Child-Pugh classification (r = 0.78; P < 0.001) in 220 patients with CLD.",
    "vicuna-13b_fact_raw": "1. The Lupus Severity Index (LSI) is a measure of the severity of chronic liver disease in patients.\n2. The LSI is determined by the distribution of sulfur colloid between the liver and spleen, adjusted for spleen size.\n3. To calculate the LSI, the liver-spleen distribution is divided by the spleen size.\n4. The liver-bone marrow index (LBI) is correlated with the LSI, and the arithmetic mean of both defines the severity score.\n5. The severity score correlated with hepatic fibrosis in patients with benign liver disease and with the Child-Pugh classification in patients with chronic liver disease.",
    "vicuna-13b_fact": [
      "The Lupus Severity Index (LSI) is a measure of the severity of chronic liver disease in patients.",
      "The LSI is determined by the distribution of sulfur colloid between the liver and spleen, adjusted for spleen size.",
      "To calculate the LSI, the liver-spleen distribution is divided by the spleen size.",
      "The liver-bone marrow index (LBI) is correlated with the LSI, and the arithmetic mean of both defines the severity score.",
      "The severity score correlated with hepatic fibrosis in patients with benign liver disease and with the Child-Pugh classification in patients with chronic liver disease."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The Lupus Severity Index (LSI) is not a measure of the severity of chronic liver disease; it is more likely to be associated with the severity of lupus, an autoimmune disease.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe given statements are unclear in that they mix information that might pertain to an instrument measuring lupus severity with that which describes the assessment of liver disease. Without specific, accurate context on what the LSI actually stands for in this passage, evaluations of statements 2-5 are not possible. The term LSI, as provided, does not align with known indices for chronic liver disease, which typically use different types of scoring systems such as the Child-Pugh score or MELD score for liver disease severity. Therefore, corrections for statements 2-5 cannot be made with confidence based on the given statements.",
    "vicuna-13b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "vicuna-13b_response": "Based on the given information, the recurrent de novo nonsense variant (c.2737C>T [p.Arg913Ter]) in the penultimate exon of ZSWIM6 has been found to cause severe-profound intellectual disability and additional central and peripheral nervous system symptoms but an absence of frontonasal or limb malformations. The study suggests that this variant does not trigger nonsense-mediated decay of the ZSWIM6 mRNA in affected individual-derived cells, which supports the existence of a truncated ZSWIM6 protein lacking the Sin3-like domain, which could have a dominant-negative effect. This study builds support for a key role for ZSWIM6 in neuronal development and function, in addition to its putative roles in limb and craniofacial development, and provides a striking example of different variants in the same gene leading to distinct phenotypes.\nBased on this information, it appears that the de novo mutations in ZSWIM6 can cause intellectual disability and other central and peripheral nervous system symptoms, but it is not clear if they are directly responsible for causing any specific disorders. The study specifically mentions acromelic frontonasal dysostosis (AFND) as a disorder that can be caused by a recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6, but it is not clear if the nonsense variant (c.2737C>T [p.Arg913Ter]) in the penultimate exon of ZSWIM6 can cause the same disorder. Further research is needed to determine the specific disorders that can be caused by de novo mutations in ZSWIM6.",
    "vicuna-13b_fact_raw": "1. De novo mutations in the gene ZSWIM6 can cause severe-profound intellectual disability.\n2. These mutations can also cause additional central and peripheral nervous system symptoms.\n3. The recurrent de novo nonsense variant c.2737C>T [p.Arg913Ter] in ZSWIM6 is associated with these symptoms but not with frontonasal or limb malformations.\n4. The study indicates that this de novo nonsense variant does not cause nonsense-mediated decay of ZSWIM6 mRNA in affected individuals.\n5. Variants within the C-terminal Sin3-like domain of ZSWIM6, such as in the case of acromelic frontonasal dysostosis (AFND), are different from the c.2737C>T [p.Arg913Ter] variant associated with intellectual disability and nervous system symptoms.",
    "vicuna-13b_fact": [
      "De novo mutations in the gene ZSWIM6 can cause severe-profound intellectual disability.",
      "These mutations can also cause additional central and peripheral nervous system symptoms.",
      "The recurrent de novo nonsense variant c.2737C>T [p.Arg913Ter] in ZSWIM6 is associated with these symptoms but not with frontonasal or limb malformations.",
      "The study indicates that this de novo nonsense variant does not cause nonsense-mediated decay of ZSWIM6 mRNA in affected individuals.",
      "Variants within the C-terminal Sin3-like domain of ZSWIM6, such as in the case of acromelic frontonasal dysostosis (AFND), are different from the c.2737C>T [p.Arg913Ter] variant associated with intellectual disability and nervous system symptoms."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "vicuna-13b_response": "The Koos Classification is a system for classifying patients with Early Onset Scoliosis (EOS). The study mentioned in the provided document aimed to evaluate the interobserver and intraobserver reliability of the Classification of Early Onset Scoliosis (C-EOS) scheme. The results of the study showed high levels of interobserver and intraobserver agreement of the C-EOS scheme, indicating that it can be used as a reliable tool for classifying EOS patients for clinical communication and research. The C-EOS scheme can be used to classify patients based on etiology, major curve, and kyphosis.",
    "vicuna-13b_fact_raw": "1. The Koos Classification is used for classifying patients with Early Onset Scoliosis (EOS).\n2. A study evaluated the interobserver and intraobserver reliability of the Classification of Early Onset Scoliosis (C-EOS) scheme.\n3. The study found high levels of interobserver and intraobserver agreement for the C-EOS scheme.\n4. The C-EOS scheme is deemed reliable for clinical communication and research purposes.\n5. The C-EOS can classify EOS patients based on etiology, major curve, and kyphosis.",
    "vicuna-13b_fact": [
      "The Koos Classification is used for classifying patients with Early Onset Scoliosis (EOS).",
      "A study evaluated the interobserver and intraobserver reliability of the Classification of Early Onset Scoliosis (C-EOS) scheme.",
      "The study found high levels of interobserver and intraobserver agreement for the C-EOS scheme.",
      "The C-EOS scheme is deemed reliable for clinical communication and research purposes.",
      "The C-EOS can classify EOS patients based on etiology, major curve, and kyphosis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that without specific details on the actual study or studies in question, the veracity of statements 2, 3, and 4 are taken at face value based on what would be expected from a report about a classification scheme's evaluation. Similarly, the fifth statement is presumed true based on general knowledge of how classification schemes are typically designed to provide such distinctions, although the precise variables included in the C-EOS could differ.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "vicuna-13b_response": "Based on the provided document, AZD8601 is a chemically modified mRNA that encodes vascular endothelial growth factor A (VEGF-A). The in vivo effects of AZD8601 have been longitudinally and comprehensively characterized in a mouse model using multi-parametric photoacoustic microscopy. The results show that intradermal injection of AZD8601 formulated in a biocompatible vehicle leads to pronounced, sustained and dose-dependent vasodilation, blood flow upregulation, and neovessel formation. These effects are in contrast to those induced by recombinant human VEGF-A protein and citrate/saline vehicle. Additionally, the bioactivity of AZD8601 has been evaluated in a mouse model of diabetic wound healing in vivo. The results show that sequential dosing of AZD8601 improves vascularization and tissue oxygenation of the wound bed, leading to accelerated re-epithelialization during the early phase of diabetic wound healing. Overall, the results suggest that AZD8601 has potential in cardiovascular medicine and wound healing, and its effects on the microvasculature and bioactivity in disease settings remain to be further explored.",
    "vicuna-13b_fact_raw": "1. AZD8601 is a chemically modified mRNA that encodes vascular endothelial growth factor A (VEGF-A).\n2. In a mouse model, intradermal injection of AZD8601 leads to pronounced, sustained, and dose-dependent vasodilation, blood flow upregulation, and neovessel formation.\n3. The effects of AZD8601 are different from those induced by recombinant human VEGF-A protein.\n4. AZD8601 has been evaluated for its bioactivity in a mouse model of diabetic wound healing in vivo.\n5. Sequential dosing of AZD8601 in a mouse model improves vascularization and tissue oxygenation of the wound bed, leading to accelerated re-epithelialization during the early phase of diabetic wound healing.",
    "vicuna-13b_fact": [
      "AZD8601 is a chemically modified mRNA that encodes vascular endothelial growth factor A (VEGF-A).",
      "In a mouse model, intradermal injection of AZD8601 leads to pronounced, sustained, and dose-dependent vasodilation, blood flow upregulation, and neovessel formation.",
      "The effects of AZD8601 are different from those induced by recombinant human VEGF-A protein.",
      "AZD8601 has been evaluated for its bioactivity in a mouse model of diabetic wound healing in vivo.",
      "Sequential dosing of AZD8601 in a mouse model improves vascularization and tissue oxygenation of the wound bed, leading to accelerated re-epithelialization during the early phase of diabetic wound healing."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "vicuna-13b_response": "SAHFs, or senescence associated heterochromatic foci, are formed through a process called spatial repositioning of the genome. This process occurs based on certain chromatin features that are correlated with, but do not require, the repressive marks histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3. These repressive marks are segregated from each other within SAHFs, forming layered high-order chromatin structures (HOCS). The formation of SAHFs is not fully understood, but it is believed to be influenced by factors such as HMGA proteins and structural components of SAHFs. The recent study used microscopy and ChIP-seq approaches to reveal that SAHFs are formed through the spatial repositioning of the genome, rather than through the spreading of heterochromatin. This process is unique and may provide a model system to study the correlation between HOCS and chromatin types, which are readily visible and regulable.",
    "vicuna-13b_fact_raw": "1. Senescence associated heterochromatic foci (SAHFs) are formed through a process called spatial repositioning of the genome.\n2. The formation of SAHFs is correlated with chromatin features like histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3.\n3. Repressive marks H3K9me3 and H3K27me3 are segregated from each other within SAHFs.\n4. HMGA proteins and structural components of SAHFs are factors believed to influence the formation of SAHFs.\n5. Microscopy and ChIP-seq approaches have been used to study the formation of SAHFs.",
    "vicuna-13b_fact": [
      "Senescence associated heterochromatic foci (SAHFs) are formed through a process called spatial repositioning of the genome.",
      "The formation of SAHFs is correlated with chromatin features like histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3.",
      "Repressive marks H3K9me3 and H3K27me3 are segregated from each other within SAHFs.",
      "HMGA proteins and structural components of SAHFs are factors believed to influence the formation of SAHFs.",
      "Microscopy and ChIP-seq approaches have been used to study the formation of SAHFs."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Senescence associated heterochromatic foci (SAHFs) are indeed formed through various processes including spatial repositioning of the genome.\n2. TRUE: The formation of SAHFs has been correlated with certain chromatin features, including histone marks like histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3.\n3. TRUE: While being associated with SAHFs, the repressive marks H3K9me3 and H3K27me3 are typically segregated from each other within these structures.\n4. TRUE: HMGA proteins, along with other structural components, are factors that have been implicated in the formation of SAHFs.\n5. TRUE: Microscopy allows visualization of SAHF formation while ChIP-seq can be used to analyze the associated chromatin modifications, both of which are approaches used to study SAHFs.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "vicuna-13b_response": "The PDZ domain of SATB1 plays a critical role in the function of SATB1 as a global repressor. The PDZ domain mediates interactions with several chromatin proteins and is responsible for recruiting the interacting partners of SATB1 to its genomic binding sites. Overexpression of the PDZ-like domain of SATB1 results in de-repression of genes regulated by SATB1, indicating that the PDZ-like domain exerts a dominant negative effect on genes regulated by SATB1. The PDZ domain of SATB1 is also responsible for sequestering the interaction partners of SATB1, thereby affecting the global gene regulation by SATB1. Overexpression of the PDZ-like domain results in the upregulation of 600 out of 19000 genes analysed, and these genes are involved in important signalling cascades and cellular functions.",
    "vicuna-13b_fact_raw": "1. The PDZ domain of SATB1 plays a critical role as a global repressor.\n2. It mediates interactions with several chromatin proteins.\n3. The PDZ domain is responsible for recruiting the interacting partners of SATB1 to its genomic binding sites.\n4. Overexpression of the PDZ-like domain of SATB1 results in de-repression of genes regulated by SATB1.\n5. Overexpression of the PDZ-like domain leads to the upregulation of 600 out of 19000 genes analyzed.",
    "vicuna-13b_fact": [
      "The PDZ domain of SATB1 plays a critical role as a global repressor.",
      "It mediates interactions with several chromatin proteins.",
      "The PDZ domain is responsible for recruiting the interacting partners of SATB1 to its genomic binding sites.",
      "Overexpression of the PDZ-like domain of SATB1 results in de-repression of genes regulated by SATB1.",
      "Overexpression of the PDZ-like domain leads to the upregulation of 600 out of 19000 genes analyzed."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\nThe statements pertain to the specific functions of the PDZ domain of a protein known as SATB1, which seems to involve complex molecular interactions. Unless the information is given in a highly specialized text or study, these are not common knowledge facts. Without the specific context or the source of these statements, it's impossible to accurately verify the roles and effects attributed to the PDZ domain of SATB1, such as acting as a global repressor, recruiting interacting partners, or resulting in the de-repression/upregulation of certain genes upon overexpression. Therefore, most statements must be labeled as UNKNOWN. Only the second statement regarding the PDZ domain mediating interactions with several chromatin proteins is marked TRUE, as this generally describes a known function of PDZ domains in proteins. However, even this could be context-specific and may need further verification against a reliable scientific source.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "vicuna-13b_response": "The BLISS technique is a communication aid that uses Blissymbols, a type of symbolic language, to facilitate communication in individuals with aphasia. The technique is based on the use of Blissymbols as a visual support to aid in the expression and comprehension of language. The technique was investigated in a study documented in Document-0, which involved four adult aphasic patients who also exhibited severe verbal apraxia. The study investigated various aspects of the BLISS technique, including the patients' ability to use Blissymbols as a facilitating technique for communication, their capacity for learning Blissymbols, attitudes toward the use of Blissymbols, and the ability to learn Blissymbols in a group setting. The results of the study indicated that candidates with good auditory comprehension, good visual-perceptual skills, and a high level of motivation are more successful in using Blissymbols as a facilitating technique. The study also found that Blissymbols can encourage verbal language and writing skills, even though not stressed, and that the group therapy approach provides needed motivation and proves beneficial.",
    "vicuna-13b_fact_raw": "1. The BLISS technique uses Blissymbols as a symbolic language to facilitate communication in individuals with aphasia.\n2. The technique employs Blissymbols for visual support to assist in the expression and comprehension of language.\n3. A study involving four adult aphasic patients who exhibited severe verbal apraxia investigated the BLISS technique.\n4. The study found that patients with good auditory comprehension, good visual-perceptual skills, and a high level of motivation were more successful in using Blissymbols.\n5. The study indicated that Blissymbols could encourage verbal language and writing skills and that group therapy provides beneficial motivation.",
    "vicuna-13b_fact": [
      "The BLISS technique uses Blissymbols as a symbolic language to facilitate communication in individuals with aphasia.",
      "The technique employs Blissymbols for visual support to assist in the expression and comprehension of language.",
      "A study involving four adult aphasic patients who exhibited severe verbal apraxia investigated the BLISS technique.",
      "The study found that patients with good auditory comprehension, good visual-perceptual skills, and a high level of motivation were more successful in using Blissymbols.",
      "The study indicated that Blissymbols could encourage verbal language and writing skills and that group therapy provides beneficial motivation."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements pertain to the BLISS technique and its use with aphasic patients. While statements 1 and 2 describe general aspects of the technique that are likely to be true, statements 3, 4, and 5 refer to a specific study's findings and characteristics of successful patients that cannot be verified or falsified without the actual study data or additional context.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "vicuna-13b_response": "Based on the information provided in Document-0, the following are three NK3R antagonists:\n1. C3-alkylsulfoxide substituted quinolines\n2. Potent NK3 receptor antagonists\n3. Excellent NK3 functional activity and good selectivity\n4. Good in vitro/in vivo DMPK characteristics and activity in a gerbil locomotor activity model.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "vicuna-13b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is not specified in the given information.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "vicuna-13b_response": "The study conducted by the World Health Organization (WHO) in Guinea between May 20 and October 19, 2012, aimed to estimate the short-term effectiveness of two doses of Shanchol, an oral cholera vaccine, used as part of the integrated response to a cholera outbreak in Africa. The study found that vaccination with two complete doses of Shanchol was associated with significant protection against cholera, with an effectiveness of 86.6% (95% confidence interval, 56.7 to 95.8; P=0.001). These findings support the use of vaccination as part of the response to a cholera outbreak and provide evidence for the establishment of a cholera vaccine stockpile for emergency use.",
    "vicuna-13b_fact_raw": "1. The World Health Organization conducted a study in Guinea between May 20 and October 19, 2012.\n2. The study aimed to estimate the effectiveness of the oral cholera vaccine Shanchol during a cholera outbreak in Africa.\n3. The study reported that two doses of Shanchol provided an effectiveness of 86.6% against cholera.\n4. The study's findings had a 95% confidence interval ranging from 56.7 to 95.8.\n5. The results of the study supported the use of vaccination as part of the response to a cholera outbreak and suggested the establishment of a cholera vaccine stockpile for emergency use.",
    "vicuna-13b_fact": [
      "The World Health Organization conducted a study in Guinea between May 20 and October 19, 2012.",
      "The study aimed to estimate the effectiveness of the oral cholera vaccine Shanchol during a cholera outbreak in Africa.",
      "The study reported that two doses of Shanchol provided an effectiveness of 86.6% against cholera.",
      "The study's findings had a 95% confidence interval ranging from 56.7 to 95.8.",
      "The results of the study supported the use of vaccination as part of the response to a cholera outbreak and suggested the establishment of a cholera vaccine stockpile for emergency use."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that while statements 2, 3, 4, and 5 about the study could be accurate based on similar studies, without access to the specific study, I cannot verify the exact dates, results, and recommendations. Hence, statement 1 is marked as UNKNOWN because the exact timeline of the referenced study is not provided in widely available references as of my knowledge cutoff date. Statements 2 to 5 are plausible and consistent with the types of findings and recommendations that the WHO would make following such a study, but again, without the precise study details, they cannot be independently verified.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "vicuna-13b_response": "The first cholera vaccine approved in the US is Vaxchora, which was approved by the US Food and Drug Administration (FDA) on June 10, 2016. Vaxchora is a single-dose, live oral cholera vaccine that was originally developed in the 1990s by a Swiss company. The vaccine was the first genetically modified organism (GMO) used as a vaccine and was found to be highly effective, with a protective efficacy of 80-100% against moderate to severe cholera, and it acted within 8 days of administration. However, the vaccine's development and approval process was marked by a number of challenges, including strong headwinds from experts in the field, a moratorium on GMOs in the European Union, and low demand for the vaccine. Despite these challenges, Vaxchora was eventually licensed in the US and is now available for use in high-risk populations and travelers.",
    "vicuna-13b_fact_raw": "1. The first cholera vaccine approved in the US is Vaxchora.\n2. The US Food and Drug Administration (FDA) approved Vaxchora on June 10, 2016.\n3. Vaxchora is a single-dose, live oral cholera vaccine.\n4. The vaccine was originally developed in the 1990s by a Swiss company.\n5. Vaxchora has a protective efficacy of 80-100% against moderate to severe cholera and acts within 8 days of administration.",
    "vicuna-13b_fact": [
      "The first cholera vaccine approved in the US is Vaxchora.",
      "The US Food and Drug Administration (FDA) approved Vaxchora on June 10, 2016.",
      "Vaxchora is a single-dose, live oral cholera vaccine.",
      "The vaccine was originally developed in the 1990s by a Swiss company.",
      "Vaxchora has a protective efficacy of 80-100% against moderate to severe cholera and acts within 8 days of administration."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The vaccine known as Vaxchora was developed by a company called PaxVax, which is not Swiss, but an American company based in California.\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "vicuna-13b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is not specified in the given document. CVID is a primary immunodeficiency disorder characterized by decreased serum immunoglobulin levels, recurrent infections, and the occurrence of various autoimmune diseases. The pathogenesis of granulomatous disease in CVID is unclear but may involve monocyte and T-cell abnormalities. The document reports a case of renal granulomatous disease in a CVID patient presenting with subacute renal failure, and partial recovery of renal function after corticosteroid treatment and intravenous immunoglobulin infusions.",
    "vicuna-13b_fact_raw": "1. Common variable immunodeficiency (CVID) is characterized by decreased serum immunoglobulin levels.\n2. CVID patients often experience recurrent infections.\n3. Various autoimmune diseases can occur in CVID patients.\n4. The pathogenesis of granulomatous disease in CVID may involve abnormalities in monocytes and T-cells.\n5. Corticosteroid treatment and intravenous immunoglobulin infusions can partially recover renal function in CVID patients with renal granulomatous disease.",
    "vicuna-13b_fact": [
      "Common variable immunodeficiency (CVID) is characterized by decreased serum immunoglobulin levels.",
      "CVID patients often experience recurrent infections.",
      "Various autoimmune diseases can occur in CVID patients.",
      "The pathogenesis of granulomatous disease in CVID may involve abnormalities in monocytes and T-cells.",
      "Corticosteroid treatment and intravenous immunoglobulin infusions can partially recover renal function in CVID patients with renal granulomatous disease."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While corticosteroid treatment and intravenous immunoglobulin (IVIG) infusions are common treatments for CVID, they do not necessarily \"recover renal function\" but are used to prevent and treat infections or manage autoimmune complications in CVID patients. The specific treatment response for renal granulomatous disease in CVID patients could be variable, and there is no standard treatment guaranteed to recover renal function.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "vicuna-13b_response": "The IFIT1 gene is not mentioned in the given document. The document discusses the association between the IFNG (+874) gene polymorphism and Systemic Lupus Erythematosus (SLE) in a population-based case-control study of 154 SLE patients and 154 healthy control subjects with similar ethnic backgrounds. The study found that the allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects, but there was a significant association between the A dominance model of inheritance with arthritis and SLE susceptibility with arthritis in the Thai population.",
    "vicuna-13b_fact_raw": "1. The document mentions an association between the IFNG (+874) gene polymorphism and Systemic Lupus Erythematosus (SLE).\n2. A case-control study involved 154 SLE patients and 154 healthy control subjects who have similar ethnic backgrounds.\n3. The study indicated that allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects.\n4. There was a significant association between the A dominance model of inheritance with arthritis and SLE susceptibility with arthritis in the Thai population.",
    "vicuna-13b_fact": [
      "The document mentions an association between the IFNG (+874) gene polymorphism and Systemic Lupus Erythematosus (SLE).",
      "A case-control study involved 154 SLE patients and 154 healthy control subjects who have similar ethnic backgrounds.",
      "The study indicated that allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects.",
      "There was a significant association between the A dominance model of inheritance with arthritis and SLE susceptibility with arthritis in the Thai population."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN  Without additional context, the veracity of the statement cannot be determined.\n2. UNKNOWN  Similarly, without further information, it cannot be confirmed if this specific study involved 154 SLE patients and the same number of control subjects.\n3. UNKNOWN  The outcome of the allele frequency analysis in the study is not provided, so the truthfulness of this statement is indeterminable.\n4. UNKNOWN  Without details on the results of the study, it is not possible to ascertain the validity of the claim regarding the A dominance model of inheritance, arthritis, and SLE susceptibility in the Thai population.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "vicuna-13b_response": "The Liverpool Elbow Score (LES) is a validated scoring system used for the assessment of outcome after total elbow arthroplasty. It consists of a patient-answered questionnaire (PAQ) and a clinical assessment. The PAQ portion of the LES can be used independently as a postal questionnaire for the assessment of outcome after total elbow arthroplasty. The study showed an excellent response rate to the postal questionnaire (98%) and good correlation between the LES and the Mayo Elbow Performance Score (MEPS) (Spearman correlation coefficient, 0.84; P < .001) and between the PAQ portion of the LES and the MEPS (Spearman correlation coefficient, 0.76; P < .001). This suggests that outcome assessment is possible by postal questionnaire.",
    "vicuna-13b_fact_raw": "1. The Liverpool Elbow Score (LES) is used for the assessment of outcome after total elbow arthroplasty.\n2. The LES includes a patient-answered questionnaire (PAQ) and a clinical assessment.\n3. The patient-answered questionnaire part of the LES can be used independently as a postal questionnaire.\n4. The response rate to the postal questionnaire part of the LES was reported to be 98%.\n5. There is a good correlation between the LES and the Mayo Elbow Performance Score (MEPS) with Spearman correlation coefficients of 0.84 and 0.76 for LES and the PAQ portion of LES, respectively.",
    "vicuna-13b_fact": [
      "The Liverpool Elbow Score (LES) is used for the assessment of outcome after total elbow arthroplasty.",
      "The LES includes a patient-answered questionnaire (PAQ) and a clinical assessment.",
      "The patient-answered questionnaire part of the LES can be used independently as a postal questionnaire.",
      "The response rate to the postal questionnaire part of the LES was reported to be 98%.",
      "There is a good correlation between the LES and the Mayo Elbow Performance Score (MEPS) with Spearman correlation coefficients of 0.84 and 0.76 for LES and the PAQ portion of LES, respectively."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe Liverpool Elbow Score is indeed used for assessing outcomes after total elbow arthroplasty, it consists of both a patient-answered questionnaire and a clinical assessment, and the patient-answered questionnaire can be used independently for postal surveys. However, without specific study results or additional information, the response rate to the postal questionnaire and the correlation coefficients with the Mayo Elbow Performance Score are not possible to verify as true or false; thus, they are unknown.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "vicuna-13b_response": "The 100,000 Genomes Project is a large-scale research initiative that aims to catalog human genetic variation and develop new methods for characterizing and analyzing genetic data. The project was launched in 2012 and has since collected and made publicly available a vast amount of genetic data from over 100,000 participants. This data includes whole-genome sequences, exomes, and transcriptomes, and is available to researchers and the public through various online platforms.\nAs part of the project, researchers have developed and deployed several tools to facilitate data access and analysis. These tools include the Variant Effect Predictor (VEP), which is a computational tool that predicts the effects of genetic variations on protein function, and the Genome Analysis Toolkit (GATK), which is a suite of software tools for analyzing and interpreting genetic data.\nIn terms of sarcoma specifically, the 100,000 Genomes Project has likely contributed to our understanding of the genetic basis of this disease. By analyzing the genomic data of individuals with sarcoma, researchers have been able to identify genetic variations that may contribute to the development and progression of the disease. For example, a study published in the journal Nature Genetics in 2019 analyzed whole-genome sequences from over 1,000 sarcoma patients and identified several new genetic variants associated with the disease.\nOverall, the 100,000 Genomes Project has provided a valuable resource for researchers studying sarcoma and other genetic diseases, and the tools and data developed through the project are likely to continue to drive progress in this field.",
    "vicuna-13b_fact_raw": "1. The 100,000 Genomes Project was launched in 2012.\n2. The project has collected and made publicly available genetic data from over 100,000 participants.\n3. The data from the 100,000 Genomes Project includes whole-genome sequences, exomes, and transcriptomes.\n4. The Variant Effect Predictor (VEP) is a computational tool developed as part of the project to predict the effects of genetic variations on protein function.\n5. A study published in Nature Genetics in 2019 analyzed whole-genome sequences from over 1,000 sarcoma patients and identified new genetic variants associated with the disease.",
    "vicuna-13b_fact": [
      "The 100,000 Genomes Project was launched in 2012.",
      "The project has collected and made publicly available genetic data from over 100,000 participants.",
      "The data from the 100,000 Genomes Project includes whole-genome sequences, exomes, and transcriptomes.",
      "The Variant Effect Predictor (VEP) is a computational tool developed as part of the project to predict the effects of genetic variations on protein function.",
      "A study published in Nature Genetics in 2019 analyzed whole-genome sequences from over 1,000 sarcoma patients and identified new genetic variants associated with the disease."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in 2013.\n2. TRUE\n3. FALSE [correction]: The 100,000 Genomes Project is focused specifically on whole-genome sequencing, not exomes or transcriptomes.\n4. FALSE [correction]: The Variant Effect Predictor (VEP) was not developed as part of the 100,000 Genomes Project; it is a separate tool developed by the Ensembl project.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it can be inferred that the protein ALEX1 contains armadillo repeats. The protein is classified as an armadillo repeat protein due to its possession of two armadillo repeat domains. The armadillo repeat family of proteins is known to play an important role in the tumorigenesis and maintenance of tissue integrity. The protein ALEX1 is expressed differently in normal and carcinoma tissues, and its expression is significantly increased in cervical cancer tissues compared to non-cancerous tissues. These findings suggest that ALEX1 may play a role as an oncogene in cervical cancer and may serve as a potential diagnostic biomarker for identifying cervical cancer.",
    "vicuna-13b_fact_raw": "1. Protein ALEX1 contains two armadillo repeat domains.\n2. The armadillo repeat family of proteins is associated with tumorigenesis and tissue integrity maintenance.\n3. ALEX1 is expressed differently in normal tissues compared to carcinoma tissues.\n4. Expression of ALEX1 is significantly increased in cervical cancer tissues compared to non-cancerous tissues.\n5. ALEX1 may act as an oncogene in cervical cancer and could be a potential diagnostic biomarker for the disease.",
    "vicuna-13b_fact": [
      "Protein ALEX1 contains two armadillo repeat domains.",
      "The armadillo repeat family of proteins is associated with tumorigenesis and tissue integrity maintenance.",
      "ALEX1 is expressed differently in normal tissues compared to carcinoma tissues.",
      "Expression of ALEX1 is significantly increased in cervical cancer tissues compared to non-cancerous tissues.",
      "ALEX1 may act as an oncogene in cervical cancer and could be a potential diagnostic biomarker for the disease."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Expression of ALEX1 is significantly decreased, not increased, in cervical cancer tissues compared to non-cancerous tissues.\n5. FALSE [correction]: ALEX1 may act as a tumor suppressor in cervical cancer and could be a potential diagnostic biomarker for the disease, not as an oncogene.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "vicuna-13b_response": "Document-1: Histone methyltransferases (HMTs) are enzymes that add methyl groups to the epsilon-amino groups of conserved lysine residues in the amino terminal tail of histones. In humans, there are 18 potential methyltransferase enzymes that are responsible for the addition of methyl groups and maintenance of the equilibrium of lysine methylation on histones. Like most histone modification enzymes, accumulating evidence suggests that many, if not all, HMTs can also modify non-histone proteins. The focus of this article is to provide up-to-date, easy to follow, approaches and techniques specifically for the assay of HMT enzymatic activities.\nBoth HDACs and HMTs are enzymes that play a crucial role in regulating the epigenetic landscape by modifying the histone tails. HDACs remove acetyl groups from histones, leading to a more compact chromatin structure and repressed transcription, while HMTs add methyl groups to histones, leading to a more open chromatin structure and active transcription.\nIn conclusion, some examples of enzymes that remove histone modifications are HDACs, and some examples of enzymes that add histone modifications are HMTs.",
    "vicuna-13b_fact_raw": "1. Histone methyltransferases (HMTs) are enzymes that add methyl groups to the epsilon-amino groups of lysine residues on histone proteins.\n2. There are potentially 18 methyltransferase enzymes in humans responsible for adding methyl groups to histones.\n3. Histone modification enzymes such as HMTs can also modify non-histone proteins.\n4. HDACs (Histone Deacetylases) are enzymes that remove acetyl groups from histones.\n5. The removal of acetyl groups by HDACs leads to a more compact chromatin structure and repressed transcription.",
    "vicuna-13b_fact": [
      "Histone methyltransferases (HMTs) are enzymes that add methyl groups to the epsilon-amino groups of lysine residues on histone proteins.",
      "There are potentially 18 methyltransferase enzymes in humans responsible for adding methyl groups to histones.",
      "Histone modification enzymes such as HMTs can also modify non-histone proteins.",
      "HDACs (Histone Deacetylases) are enzymes that remove acetyl groups from histones.",
      "The removal of acetyl groups by HDACs leads to a more compact chromatin structure and repressed transcription."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: There are more than 50 histone methyltransferase enzymes in humans responsible for adding methyl groups to histones.\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "vicuna-13b_response": "Based on the provided document, it appears that there is an association between paediatric head computed tomography (CT) examination and an increased risk of benign brain tumors. The study found that the overall risk of malignancy and benign brain tumors was not significantly different between the exposed and unexposed cohorts, but the risk of benign brain tumors was significantly higher in the exposed cohort. The frequency of CT examination was also found to be strongly correlated with the subsequent overall risk of malignancy and benign brain tumors. However, the study authors note that a larger, longer-term study is needed to confirm these findings. Therefore, it is unclear whether head CT examination directly increases the risk of brain tumors.",
    "vicuna-13b_fact_raw": "1. There is an association between paediatric head CT examinations and an increased risk of benign brain tumors according to the study mentioned.\n2. The study did not find a significant difference in the overall risk of malignancy and benign brain tumors between exposed and unexposed cohorts.\n3. The risk of benign brain tumors was significantly higher in the cohort exposed to CT examinations.\n4. The frequency of CT examination was strongly correlated with the subsequent overall risk of malignancy and benign brain tumors in the study.\n5. The study authors suggest that a larger, longer-term study is necessary to confirm their findings regarding head CT examinations and brain tumor risks.",
    "vicuna-13b_fact": [
      "There is an association between paediatric head CT examinations and an increased risk of benign brain tumors according to the study mentioned.",
      "The study did not find a significant difference in the overall risk of malignancy and benign brain tumors between exposed and unexposed cohorts.",
      "The risk of benign brain tumors was significantly higher in the cohort exposed to CT examinations.",
      "The frequency of CT examination was strongly correlated with the subsequent overall risk of malignancy and benign brain tumors in the study.",
      "The study authors suggest that a larger, longer-term study is necessary to confirm their findings regarding head CT examinations and brain tumor risks."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The study found a significant difference in the risk of benign brain tumors between exposed and unexposed cohorts but did not find a strong correlation between the frequency of CT examinations and the subsequent overall risk of malignancy and benign brain tumors.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "vicuna-13b_response": "Based on the given document, Otx2 is associated with the primed pluripotency. The document states that \"transition between these two pluripotent states is associated with widespread Oct4 relocalization, mirrored by global rearrangement of enhancer chromatin landscapes\" and \"candidate mediators of primed state-specific Oct4 binding, including Otx2 and Zic2/3\" which suggests that Otx2 is involved in the regulation of primed pluripotency. Additionally, the document also states that \"premature Otx2 overexpression is sufficient to exit the naive state, induce transcription of a substantial subset of primed pluripotency-associated genes, and redirect Oct4 to previously inaccessible enhancer sites\" which further supports the association of Otx2 with the primed pluripotency.",
    "vicuna-13b_fact_raw": "1. Otx2 is associated with primed pluripotency.\n2. The transition between pluripotent states involves widespread Oct4 relocalization and global rearrangement of enhancer chromatin landscapes.\n3. Otx2 is considered a candidate mediator of primed state-specific Oct4 binding.\n4. Premature Otx2 overexpression can cause a cell to exit the naive state.\n5. Premature Otx2 overexpression can induce transcription of genes associated with primed pluripotency.",
    "vicuna-13b_fact": [
      "Otx2 is associated with primed pluripotency.",
      "The transition between pluripotent states involves widespread Oct4 relocalization and global rearrangement of enhancer chromatin landscapes.",
      "Otx2 is considered a candidate mediator of primed state-specific Oct4 binding.",
      "Premature Otx2 overexpression can cause a cell to exit the naive state.",
      "Premature Otx2 overexpression can induce transcription of genes associated with primed pluripotency."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nIt should be noted that the statements provided are quite specific to the field of developmental biology and stem cell research. The assertions made about Otx2 and pluripotency, Oct4 relocalization, and chromatin landscape are consistent with scientific findings in these specialized areas. However, without specific sources or additional context, detailed validation of each statement with current research literature is not possible, but the statements are generally consistent with known concepts in the field as of my last update.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "vicuna-13b_response": "Based on the given information, it is not specified how many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region. The document mentions that DHS are associated with a wide variety of regulatory DNA elements and their locations are helpful for deciphering the function of noncoding genomic regions. It also mentions that a support vector machine based model was proposed to identify DHS by using the pseudo dinucleotide composition, and that the proposed model obtained an accuracy of 83% in a jackknife test. However, it does not provide any information about the specific number of DHS in the murine beta globin locus region.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "vicuna-13b_response": "Based on the given information, here are some European influenza vaccines:\n1. Afluria: Manufactured by Seqirus, Afluria is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n2. Fluarix: Manufactured by GlaxoSmithKline, Fluarix is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n3. FluLaval: Manufactured by Bio-Rad Laboratories, FluLaval is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n4. Fluzone: Manufactured by Sanofi Pasteur, Fluzone is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n5. Influvac: Manufactured by Novartis, Influvac is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n6. Vaxigrip: Manufactured by Sanofi Pasteur, Vaxigrip is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n7. Agrippal: Manufactured by CSL Limited, Agrippal is a trivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), and B viruses.\n8. Fluarix Tetra: Manufactured by GlaxoSmithKline, Fluarix Tetra is a quadrivalent influenza vaccine that provides protection against influenza A(H1N1)pdm09, A(H3N2), B viruses, and an",
    "vicuna-13b_fact_raw": "1. Afluria is a trivalent influenza vaccine manufactured by Seqirus.\n2. Fluarix is a trivalent influenza vaccine manufactured by GlaxoSmithKline.\n3. FluLaval is a trivalent influenza vaccine manufactured by Bio-Rad Laboratories.\n4. Fluzone is a trivalent influenza vaccine manufactured by Sanofi Pasteur.\n5. Influvac is a trivalent influenza vaccine manufactured by Novartis.",
    "vicuna-13b_fact": [
      "Afluria is a trivalent influenza vaccine manufactured by Seqirus.",
      "Fluarix is a trivalent influenza vaccine manufactured by GlaxoSmithKline.",
      "FluLaval is a trivalent influenza vaccine manufactured by Bio-Rad Laboratories.",
      "Fluzone is a trivalent influenza vaccine manufactured by Sanofi Pasteur.",
      "Influvac is a trivalent influenza vaccine manufactured by Novartis."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: FluLaval is a trivalent influenza vaccine manufactured by GlaxoSmithKline.\n4. TRUE\n5. FALSE [correction]: Influvac is a trivalent influenza vaccine manufactured by Mylan (previously by Abbott Laboratories); as of my last update, Novartis had sold their influenza vaccine business.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "vicuna-13b_response": "Yes, the Paramyxovirus genome is segmented, negative-sense RNA. The statement \"Paramyxoviruses belong to the Paramyxoviridae family of the order Mononegavirales. They have a nonsegmented negative-stranded RNA genome\" indicates that Paramyxoviruses are a specific type of virus that belong to the Paramyxoviridae family and have a non-segmented negative-stranded RNA genome. The sentence \"We generated a recombinant Newcastle disease virus (NDV) possessing a two-segmented genome\" implies that the researchers created a modified version of NDV with a segmented genome. The use of the term \"segmented genome\" implies that the genome is not a single continuous piece of RNA, but is instead divided into smaller segments. Additionally, the sentence \"The rescued viruses grew well and were stable in embryonated chicken eggs over multiple passages\" and \"We were able to detect the expression of both reporter genes in the same cell infected with the virus possessing a segmented genome\" suggest that the two-segmented NDV is stable and can express multiple genes, which is a characteristic of negative-sense RNA viruses.",
    "vicuna-13b_fact_raw": "1. Paramyxoviruses belong to the Paramyxoviridae family of the order Mononegavirales.\n2. Paramyxoviruses have a nonsegmented negative-stranded RNA genome.\n3. A recombinant Newcastle disease virus (NDV) with a two-segmented genome was generated by researchers.\n4. The two-segmented NDV was stable in embryonated chicken eggs over multiple passages.\n5. The virus with the segmented genome could express both reporter genes in the same infected cell, characteristic of negative-sense RNA viruses.",
    "vicuna-13b_fact": [
      "Paramyxoviruses belong to the Paramyxoviridae family of the order Mononegavirales.",
      "Paramyxoviruses have a nonsegmented negative-stranded RNA genome.",
      "A recombinant Newcastle disease virus (NDV) with a two-segmented genome was generated by researchers.",
      "The two-segmented NDV was stable in embryonated chicken eggs over multiple passages.",
      "The virus with the segmented genome could express both reporter genes in the same infected cell, characteristic of negative-sense RNA viruses."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE: Researchers have been able to experimentally generate recombinant viruses with modifications such as two-segmented genomes, although this is unconventional for paramyxoviruses as they typically have nonsegmented genomes.\n4. UNKNOWN\n5. FALSE [correction]: The characteristic of expressing both reporter genes in the same infected cell is not specific to negative-sense RNA viruses; rather, this capability is determined by the engineered features of the segmented virus and the regulatory elements controlling gene expression.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "vicuna-13b_response": "Roflumilast Cream is effective in treating cerebral inflammation following subarachnoid hemorrhage (SAH). This is demonstrated in a study where subcutaneous administration of roflumilast (3g/kg) significantly improved neurological deficits in a rat SAH model. Roflumilast treatment also reduced levels of inflammatory cytokines (IL-1, IL-6, and TNF-) and the number of apoptotic neurons in the brain after SAH. Roflumilast is a selective inhibitor for PDE4 and is approved by FDA as an anti-inflammation drug for treatment of chronic obstructive pulmonary disease (COPD).",
    "vicuna-13b_fact_raw": "1. Roflumilast Cream is effective in treating cerebral inflammation following subarachnoid hemorrhage (SAH).\n2. In a study, subcutaneous administration of roflumilast at 3g/kg improved neurological deficits in a rat SAH model.\n3. Roflumilast treatment reduced levels of inflammatory cytokines such as IL-1, IL-6, and TNF- in the brain after SAH.\n4. Roflumilast is a selective inhibitor for phosphodiesterase 4 (PDE4).\n5. The FDA has approved roflumilast as an anti-inflammation drug for the treatment of chronic obstructive pulmonary disease (COPD).",
    "vicuna-13b_fact": [
      "Roflumilast Cream is effective in treating cerebral inflammation following subarachnoid hemorrhage (SAH).",
      "In a study, subcutaneous administration of roflumilast at 3g/kg improved neurological deficits in a rat SAH model.",
      "Roflumilast treatment reduced levels of inflammatory cytokines such as IL-1, IL-6, and TNF- in the brain after SAH.",
      "Roflumilast is a selective inhibitor for phosphodiesterase 4 (PDE4).",
      "The FDA has approved roflumilast as an anti-inflammation drug for the treatment of chronic obstructive pulmonary disease (COPD)."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: The statement is specific, and without access to recent medical research on roflumilast's effectiveness in treating cerebral inflammation following SAH, we cannot verify its accuracy.\n2. UNKNOWN: Specific details about a study involving roflumilast's administration and its dosage/effects on neurological deficits in a rat SAH model require access to the particular study or medical literature for verification.\n3. UNKNOWN: This statement refers to specific scientific results about the effects of roflumilast on inflammatory cytokines. It would require access to the related scientific research data to confirm or deny.\n4. TRUE: Roflumilast is known to be a selective inhibitor of phosphodiesterase 4 (PDE4), which is targeted to treat inflammatory conditions like COPD by reducing inflammation.\n5. TRUE: Roflumilast has been approved by the FDA for the treatment of chronic obstructive pulmonary disease (COPD), specifically to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. However, it is approved as an oral tablet, not a cream, for COPD treatment. Please note, the statement mentions \"anti-inflammation drug\" which is a broader category than COPD treatment, so depending on the interpretation, this might introduce some ambiguity.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "vicuna-13b_response": "Answer: Several tools have been developed for identifying and visualizing ncRNA promoters. These tools include:\n1. RiboGap: This is a database that can be used as a primary tool for finding known ncRNAs and for uncovering simple sequence motifs with regulatory roles. It can also be used to extract intergenic sequences of eubacteria and archaea to find conserved RNA structures upstream of given genes.\n2. Various approaches: The document also describes various approaches for identifying and visualizing ncRNA promoters, such as using the database to extract intergenic sequences of eubacteria and archaea to find conserved RNA structures upstream of given genes, and using the database to choose the best candidate ncRNAs for experimental validation.\nIt is important to note that while these tools can be useful for identifying and visualizing ncRNA promoters, they are not designed to uncover new ncRNAs, or are too slow for conducting analyses on a large scale. Therefore, it is important to use multiple tools and approaches to increase the chances of identifying and validating ncRNA promoters.",
    "vicuna-13b_fact_raw": "1. RiboGap is a database used for finding known ncRNAs and for identifying simple sequence motifs with regulatory roles.\n2. RiboGap can be utilized to extract intergenic sequences of eubacteria and archaea.\n3. The tools mentioned are designed to find conserved RNA structures upstream of given genes.\n4. These tools are not specifically designed to uncover new ncRNAs.\n5. The tools may be too slow to conduct analyses on a large scale.",
    "vicuna-13b_fact": [
      "RiboGap is a database used for finding known ncRNAs and for identifying simple sequence motifs with regulatory roles.",
      "RiboGap can be utilized to extract intergenic sequences of eubacteria and archaea.",
      "The tools mentioned are designed to find conserved RNA structures upstream of given genes.",
      "These tools are not specifically designed to uncover new ncRNAs.",
      "The tools may be too slow to conduct analyses on a large scale."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: RiboGap is not a database but rather a software tool or method used for analyzing ribosomal RNA-depleted RNA sequencing data to identify gaps in coverage that might suggest the presence of non-coding RNAs (ncRNAs).\n2. TRUE\n3. TRUE\n4. FALSE [correction]: These tools, such as RiboGap, are specifically designed to help uncover new non-coding RNAs (ncRNAs) by analyzing gaps in rRNA-depleted transcriptome sequencing data.\n5. UNKNOWN",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "vicuna-13b_response": "Based on the study described in Document-0, some of the genes that the SWIM tool has identified as being down-regulated in glioblastoma include COL3A1, COL5A2, LAMA2, and ALDH1A1. Additionally, the study identified hub proteins in the up-regulated and down-regulated protein-protein interaction networks, such as MYC, FGFR1, HOXA10, and MET, which may be potential targets for diagnosis and treatment of gliomas and glioblastoma.",
    "vicuna-13b_fact_raw": "1. The SWIM tool has identified the gene COL3A1 as being down-regulated in glioblastoma.\n2. The SWIM tool has identified the gene COL5A2 as being down-regulated in glioblastoma.\n3. The SWIM tool has identified the gene LAMA2 as being down-regulated in glioblastoma.\n4. The SWIM tool has identified the gene ALDH1A1 as being down-regulated in glioblastoma.\n5. The study mentioned identified MYC, FGFR1, HOXA10, and MET as hub proteins in the protein-protein interaction networks of glioblastoma.",
    "vicuna-13b_fact": [
      "The SWIM tool has identified the gene COL3A1 as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the gene COL5A2 as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the gene LAMA2 as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the gene ALDH1A1 as being down-regulated in glioblastoma.",
      "The study mentioned identified MYC, FGFR1, HOXA10, and MET as hub proteins in the protein-protein interaction networks of glioblastoma."
    ],
    "vicuna-13b_judge_raw": "UNKNOWN\n\nThe provided statements require specific information about the results of a study using the SWIM tool (Simplified Whole-Internet MappIng) for gene expression analysis in glioblastoma. Without access to the study or publication that contains these findings, we cannot confirm the accuracy of the statements. Therefore, the truthfulness of statements 1-5 cannot be determined without additional context.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "vicuna-13b_response": "The R packages that have been developed for studying TADs (Topological Associated Domains) are:\n1. Risa: This is a package that has been developed to support the ISA format, which is a multi-purpose, pragmatic and accessible format that abstracts away common constructs for describing Investigations, Studies and Assays. The Risa package bridges the gap between metadata collection and curation in an ISA-compliant way and the data analysis using the widely used statistical computing environment R. It offers functionality for parsing ISA-Tab datasets into R objects, augmenting annotation with extra metadata not explicitly stated in the ISA syntax, interfacing with domain specific R packages, suggesting potentially useful R packages available in Bioconductor for subsequent processing of the experimental data described in the ISA format, and saving back to ISA-Tab files augmented with analysis specific metadata from R.\n2. TADtools: This is a package that has been developed to study TADs in the context of single-cell transcriptomics data. It uses a computational framework to infer TADs from genomic distance and correlation between expression of different genomic regions. TADtools can also be used to analyze scATAC-seq, scRNA-seq, and scChIP-seq data to study the organization of chromatin accessibility, transcription factors, and histone modifications within TADs.\n3. TAD-seq: This is a package that has been developed to study TADs in the context of single-cell transcriptomics data. It uses a computational framework to infer TADs from genomic distance and correlation between expression of different genomic regions. TAD-seq can also be used to analyze scATAC-seq, scRNA-seq, and scChIP-seq data to study the organization of chromatin accessibility, transcription factors, and histone modifications within TADs.\n4. TAD-seq-tools: This is a package that has been developed to study TADs in the context of single-cell transcriptomics data. It provides a set of tools for analyzing TAD-seq data, including tools for filtering and normalizing single-cell expression data, identifying differentially expressed genes, and inferring the spatial organization of TADs.\nOverall, these R packages provide a range of tools and functionalities for studying",
    "vicuna-13b_fact_raw": "1. The R package Risa has been developed to support the ISA format for studying TADs (Topological Associated Domains).\n2. TADtools is an R package that infers TADs from genomic distance and correlation between expression of different genomic regions.\n3. TAD-seq is an R package that has been developed for the study of TADs in the context of single-cell transcriptomics data.\n4. TAD-seq-tools is an R package that provides tools for analyzing TAD-seq data, including filtering and normalizing single-cell expression data.\n5. TADtools can be used to analyze scATAC-seq, scRNA-seq, and scChIP-seq data for studying chromatin accessibility, transcription factors, and histone modifications within TADs.",
    "vicuna-13b_fact": [
      "The R package Risa has been developed to support the ISA format for studying TADs (Topological Associated Domains).",
      "TADtools is an R package that infers TADs from genomic distance and correlation between expression of different genomic regions.",
      "TAD-seq is an R package that has been developed for the study of TADs in the context of single-cell transcriptomics data.",
      "TAD-seq-tools is an R package that provides tools for analyzing TAD-seq data, including filtering and normalizing single-cell expression data.",
      "TADtools can be used to analyze scATAC-seq, scRNA-seq, and scChIP-seq data for studying chromatin accessibility, transcription factors, and histone modifications within TADs."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without additional context regarding the R package \"Risa,\" I cannot verify its purpose or its relation to the ISA format and Topological Associated Domains (TADs).\n2. FALSE [correction]: TADtools is an R package for visualizing and analyzing TADs from Hi-C data, not for inferring TADs from genomic distance and correlation between expression of different genomic regions.\n3. FALSE [correction]: There's no indication of an R package specifically named \"TAD-seq\" developed for the study of TADs in single-cell transcriptomics data. TAD-seq generally refers to a sequencing technique rather than an R package.\n4. UNKNOWN: Without additional context or information on \"TAD-seq-tools\" it is not possible to verify if it is indeed an R package or its purported functions.\n5. UNKNOWN: The specificity with which TADtools can be applied to scATAC-seq, scRNA-seq, and scChIP-seq data, and whether it is used to study various genomic features within TADs cannot be verified without additional information.",
    "vicuna-13b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "vicuna-13b_response": "The bioconductor tool that has been developed for accessing bacterial regulatory networks is \"BactoReg\". This tool is a collection of software packages for the analysis of transcriptomic and genomic data from bacteria. It includes tools for the identification of regulatory networks and metabolic pathways, as well as tools for the prediction of gene regulatory interactions. BactoReg is designed to work with a variety of bacterial species, and it is constantly being updated and improved to incorporate new data and methods.",
    "vicuna-13b_fact_raw": "1. BactoReg is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. BactoReg includes software packages for the analysis of transcriptomic and genomic data from bacteria.\n3. The tool provides identification of regulatory networks and metabolic pathways in bacteria.\n4. BactoReg also includes tools for the prediction of gene regulatory interactions.\n5. BactoReg is designed to work with a variety of bacterial species.",
    "vicuna-13b_fact": [
      "BactoReg is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "BactoReg includes software packages for the analysis of transcriptomic and genomic data from bacteria.",
      "The tool provides identification of regulatory networks and metabolic pathways in bacteria.",
      "BactoReg also includes tools for the prediction of gene regulatory interactions.",
      "BactoReg is designed to work with a variety of bacterial species."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on BactoReg, I cannot determine the veracity of these statements. Bioconductor does have a variety of tools for genomic analysis, but without confirmation that BactoReg is one of those tools, these statements cannot be accurately validated.",
    "vicuna-13b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "vicuna-13b_response": "The end products of the shikimate pathway are aromatic amino acids and secondary metabolites. The shikimate pathway is essential in many organisms and has been a subject of extensive research in engineering Saccharomyces cerevisiae to produce shikimate and its derivatives. The yeast Saccharomyces cerevisiae is commonly used for producing compounds with nutraceutical and pharmaceutical applications, but its low precursor availability and complicated regulations in central metabolism have limited production levels. A new platform based on Scheffersomyces stipitis has been developed, which is particularly suited to produce the shikimate group of compounds. The platform produced shikimate at a high level of 3.11 g/L, representing the highest level among shikimate pathway products in yeasts. This work represents a new exploration toward expanding the current collection of microbial factories.",
    "vicuna-13b_fact_raw": "1. Aromatic amino acids and secondary metabolites are the end products of the shikimate pathway.\n2. Saccharomyces cerevisiae has been engineered to produce shikimate and its derivatives.\n3. Saccharomyces cerevisiae is commonly used to produce compounds for nutraceutical and pharmaceutical applications.\n4. Scheffersomyces stipitis-based platform was developed for producing shikimate group of compounds.\n5. The Scheffersomyces stipitis platform produced shikimate at a level of 3.11 g/L, which is the highest level reported for shikimate pathway products in yeasts.",
    "vicuna-13b_fact": [
      "Aromatic amino acids and secondary metabolites are the end products of the shikimate pathway.",
      "Saccharomyces cerevisiae has been engineered to produce shikimate and its derivatives.",
      "Saccharomyces cerevisiae is commonly used to produce compounds for nutraceutical and pharmaceutical applications.",
      "Scheffersomyces stipitis-based platform was developed for producing shikimate group of compounds.",
      "The Scheffersomyces stipitis platform produced shikimate at a level of 3.11 g/L, which is the highest level reported for shikimate pathway products in yeasts."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: Aromatic amino acids and secondary metabolites are indeed end products of the shikimate pathway.\n2. TRUE: Saccharomyces cerevisiae has been engineered to produce shikimate and its derivatives through metabolic engineering.\n3. TRUE: Saccharomyces cerevisiae, also known for its role in baking and brewing, is commonly used in biotechnology for the production of various compounds for nutraceutical and pharmaceutical applications.\n4. TRUE: Scheffersomyces stipitis, a yeast species, has been used as a platform for producing compounds including those from the shikimate pathway.\n5. FALSE [correction]: Without specific reference to the latest research data, we cannot confirm that the Scheffersomyces stipitis platform produced shikimate at the reported level of 3.11 g/L, nor can we validate that it is the highest level reported for shikimate pathway products in yeasts. Such statements can become outdated as new research is published, so it's important to refer to current literature for the most recent findings.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "vicuna-13b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome. In this case report, a patient with Nelson's syndrome, which is a rare condition characterized by the development of a pituitary tumor following bilateral adrenalectomy and pituitary irradiation for Cushing's disease, was treated with cabergoline and experienced normalization of plasma ACTH levels and disappearance of the pituitary tumor. The patient had high plasma ACTH levels (376 ng/l) and a pituitary microadenoma (5 mm) documented at magnetic resonance imaging (MRI) of the pituitary region. After 6 months of cabergoline treatment, given at the dose of 1 mg a week, plasma ACTH levels were significantly decreased (from 376 to 113 ng/l) but they were not normalized. Cabergoline dose was then increased up to 2 mg a week. Six months later plasma ACTH levels were normalized (22 ng/l) and MRI demonstrated the disappearance of the pituitary adenoma. When the treatment was withdrawn, plasma ACTH levels significantly increased (119 ng/l) after 3 months of treatment withdrawal. At the last follow-up, during cabergoline treatment at the dose of 2 mg/week plasma ACTH levels were normalized (40.4 ng/l). This case demonstrated that cabergoline treatment is able to induce the remission of Nelson's syndrome and may be a valid therapeutic alternative in this syndrome.",
    "vicuna-13b_fact_raw": "1. Cabergoline is used for the treatment of Nelson's syndrome.\n2. Nelson's syndrome is characterized by the development of a pituitary tumor following bilateral adrenalectomy and pituitary irradiation for Cushing's disease.\n3. In the mentioned case report, cabergoline treatment led to normalization of plasma ACTH levels.\n4. The case report documented a disappearance of a pituitary tumor after cabergoline treatment, as evidenced by MRI.\n5. The initial dose of cabergoline was 1 mg a week, which was later increased to 2 mg a week for the patient in the case report.",
    "vicuna-13b_fact": [
      "Cabergoline is used for the treatment of Nelson's syndrome.",
      "Nelson's syndrome is characterized by the development of a pituitary tumor following bilateral adrenalectomy and pituitary irradiation for Cushing's disease.",
      "In the mentioned case report, cabergoline treatment led to normalization of plasma ACTH levels.",
      "The case report documented a disappearance of a pituitary tumor after cabergoline treatment, as evidenced by MRI.",
      "The initial dose of cabergoline was 1 mg a week, which was later increased to 2 mg a week for the patient in the case report."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Cabergoline is typically used for the treatment of prolactinomas (prolactin-secreting pituitary tumors) and hyperprolactinemia, not Nelson's syndrome. Nelson's syndrome involves the growth of a pituitary adenoma after the removal of the adrenal glands.\n\n2. TRUE\n\n3. UNKNOWN\n\n4. UNKNOWN\n\n5. UNKNOWN\n\nWithout the specific case report mentioned in the context, it's impossible to confirm the veracity of statements 3, 4, and 5, as they pertain to details not commonly known or established in medical literature. Therefore, a review of the case report would be necessary to confirm these statements.",
    "vicuna-13b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "vicuna-13b_response": "The main manifestation of Liebenberg syndrome is the transformation of the upper limbs to reflect lower limb characteristics. This is characterized by dysplasia of all of the bony components of the elbow joint, abnormalities in the shape of carpal bones, and brachydactyly. The condition is caused by a 275-kb deletion within the cytogenetic band 5q31.1 which contains the H2AFY gene and 190,428bp of its downstream region. The deleted region is upstream to the PITX1 gene, and the radiological features in the upper limbs of all affected members of the family were almost identical to the phenotype in the mouse model with ectopic expression of Pitx1 in the forelimbs.",
    "vicuna-13b_fact_raw": "1. Liebenberg syndrome is characterized by the transformation of the upper limbs to reflect lower limb characteristics.\n2. Dysplasia of all bony components of the elbow joint, abnormalities in the shape of carpal bones, and brachydactyly are manifestations of Liebenberg syndrome.\n3. The condition is caused by a 275-kb deletion within the cytogenetic band 5q31.1.\n4. The deleted region in Liebenberg syndrome affects the H2AFY gene and 190,428bp of its downstream region.\n5. The radiological features in the upper limbs of all affected family members were almost identical to the phenotype observed in the mouse model with ectopic expression of Pitx1 in the forelimbs.",
    "vicuna-13b_fact": [
      "Liebenberg syndrome is characterized by the transformation of the upper limbs to reflect lower limb characteristics.",
      "Dysplasia of all bony components of the elbow joint, abnormalities in the shape of carpal bones, and brachydactyly are manifestations of Liebenberg syndrome.",
      "The condition is caused by a 275-kb deletion within the cytogenetic band 5q31.1.",
      "The deleted region in Liebenberg syndrome affects the H2AFY gene and 190,428bp of its downstream region.",
      "The radiological features in the upper limbs of all affected family members were almost identical to the phenotype observed in the mouse model with ectopic expression of Pitx1 in the forelimbs."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the actual text or passage from which these statements are taken, it is difficult to assess the accuracy of specific genetic details and comparisons to mouse models (statements 3, 4, and 5). Therefore, those have been marked as UNKNOWN. The first two statements are characteristics commonly associated with Liebenberg syndrome, but the precise genetic details would require specialized knowledge or access to the specific source material discussing these aspects.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "vicuna-13b_response": "Answer: Based on the information provided in Document-0, the orally bioavailable MPS1 kinase inhibitors include MPI-0479605, which is a purine-based lead compound that has been optimized for biological activity, novelty, selectivity, and oral bioavailability. The compound has improved Mps1 biochemical activity and cytotoxicity in the HCT-116 cell line, and its on-target activity has been confirmed via a mechanism-based G2/M escape assay. Additionally, the physico-chemical and ADME properties of the compound have been optimized to improve its oral bioavailability in mice.",
    "vicuna-13b_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.\n2. MPI-0479605 is a purine-based lead compound optimized for biological activity.\n3. MPI-0479605 has demonstrated improved Mps1 biochemical activity in the HCT-116 cell line.\n4. The on-target activity of MPI-0479605 has been confirmed through a mechanism-based G2/M escape assay.\n5. The physico-chemical and ADME properties of MPI-0479605 have been optimized for oral bioavailability in mice.",
    "vicuna-13b_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor.",
      "MPI-0479605 is a purine-based lead compound optimized for biological activity.",
      "MPI-0479605 has demonstrated improved Mps1 biochemical activity in the HCT-116 cell line.",
      "The on-target activity of MPI-0479605 has been confirmed through a mechanism-based G2/M escape assay.",
      "The physico-chemical and ADME properties of MPI-0479605 have been optimized for oral bioavailability in mice."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the specific technical language used in these statements, they seem consistent with typical descriptions of pharmaceutical compounds and their properties. All statements describe MPI-0479605 in a manner that suggests they are informing about its characteristics and testing results. However, without access to the original scientific literature or data on MPI-0479605, it's challenging to verify the exact accuracy of statements 3, 4, and 5 with absolute certainty, yet they are presented as if they are based on experimental findings.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "vicuna-13b_response": "Based on the provided document, there is no mention of golimumab being specifically tested for diabetes. The study described in the document is focused on evaluating the efficacy and safety of golimumab in patients with rheumatoid arthritis who have persistent disease despite methotrexate treatment. The study found that golimumab was effective in improving symptoms of rheumatoid arthritis, with 28% of patients achieving a 50% improvement in symptoms after 48 weeks of treatment. Additionally, the study found that golimumab was safe and well-tolerated, with the most commonly reported adverse events being infections. There is no mention of golimumab being tested for diabetes or having any effect on diabetes.",
    "vicuna-13b_fact_raw": "1. There is no mention of golimumab being tested for diabetes in the provided document.\n2. The study focused on the efficacy and safety of golimumab in patients with rheumatoid arthritis.\n3. Patients in the study had persistent rheumatoid arthritis despite methotrexate treatment.\n4. The study reported that 28% of patients achieved a 50% improvement in rheumatoid arthritis symptoms after 48 weeks of golimumab treatment.\n5. The most commonly reported adverse events for golimumab in the study were infections.",
    "vicuna-13b_fact": [
      "There is no mention of golimumab being tested for diabetes in the provided document.",
      "The study focused on the efficacy and safety of golimumab in patients with rheumatoid arthritis.",
      "Patients in the study had persistent rheumatoid arthritis despite methotrexate treatment.",
      "The study reported that 28% of patients achieved a 50% improvement in rheumatoid arthritis symptoms after 48 weeks of golimumab treatment.",
      "The most commonly reported adverse events for golimumab in the study were infections."
    ],
    "vicuna-13b_judge_raw": "1. TRUE (Based on the context, if the statement specifies there is no mention, and no further information is provided to contradict this, it's true.)\n2. UNKNOWN (Without context or the provided document, we cannot determine the focus of the study.)\n3. UNKNOWN (Similarly, without the document, we cannot ascertain the condition of the patients in the study.)\n4. UNKNOWN (Without the document or additional data, we can't verify the reported improvement percentage.)\n5. UNKNOWN (Again, without access to the results of the study, we cannot confirm the most commonly reported adverse events.)",
    "vicuna-13b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "vicuna-13b_response": "Yes, Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by mutations in the LMNA gene, which encodes the nuclear scaffold proteins lamin A and C. These mutations lead to the accumulation of a abnormal form of lamin A, called progerin, which disrupts the normal structure of the nucleus and causes the premature aging symptoms associated with HGPS. The LMNA gene is located on a non-sex chromosome (chromosome 1), and the disorder is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the disorder.",
    "vicuna-13b_fact_raw": "1. Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by mutations in the LMNA gene.\n2. The LMNA gene encodes the nuclear scaffold proteins lamin A and C.\n3. Mutations in the LMNA gene result in the production of an abnormal form of lamin A known as progerin.\n4. The accumulation of progerin disrupts the normal structure of the nucleus.\n5. HGPS is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene to develop the disorder.",
    "vicuna-13b_fact": [
      "Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by mutations in the LMNA gene.",
      "The LMNA gene encodes the nuclear scaffold proteins lamin A and C.",
      "Mutations in the LMNA gene result in the production of an abnormal form of lamin A known as progerin.",
      "The accumulation of progerin disrupts the normal structure of the nucleus.",
      "HGPS is inherited in an autosomal recessive pattern, requiring two copies of the mutated gene to develop the disorder."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hutchinson-Gilford Progeria Syndrome (HGPS) is inherited in an autosomal dominant pattern, meaning only one copy of the mutated gene is required to develop the disorder.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "vicuna-13b_response": "The common variants at 12q14 and 12q24 are associated with an increased risk of developing lung cancer. Specifically, a common variant on chromosomal region 15q24-25.1, marked by rs1051730, has been found to be associated with lung cancer risk. This variant has been shown to have three major haplotypes, with the most common haplotype (G\\_T) being neutral, the haplotype A\\_C being associated with increased risk for lung cancer, and the haplotype G\\_C being associated with reduced risk for lung cancer. Additionally, another variant on 15q24-25.1, marked by rs481134, has been found to independently influence lung cancer risk. The second variant on 15q24-25.1, marked by rs481134, explains an additional 13.2% of population attributable risk for lung cancer.",
    "vicuna-13b_fact_raw": "1. Common variants at 12q14 and 12q24 are associated with an increased risk of developing lung cancer.\n2. A common variant on chromosomal region 15q24-25.1, marked by rs1051730, is associated with lung cancer risk.\n3. The rs1051730 variant has three major haplotypes which influence lung cancer risk differently: G_T being neutral, A_C increasing the risk, and G_C reducing the risk.\n4. Another variant on 15q24-25.1, marked by rs481134, independently influences lung cancer risk.\n5. The variant marked by rs481134 explains an additional 13.2% of population attributable risk for lung cancer.",
    "vicuna-13b_fact": [
      "Common variants at 12q14 and 12q24 are associated with an increased risk of developing lung cancer.",
      "A common variant on chromosomal region 15q24-25.1, marked by rs1051730, is associated with lung cancer risk.",
      "The rs1051730 variant has three major haplotypes which influence lung cancer risk differently: G_T being neutral, A_C increasing the risk, and G_C reducing the risk.",
      "Another variant on 15q24-25.1, marked by rs481134, independently influences lung cancer risk.",
      "The variant marked by rs481134 explains an additional 13.2% of population attributable risk for lung cancer."
    ],
    "vicuna-13b_judge_raw": "1. UNKNOWN: Without specific scientific references, the association of common variants at 12q14 and 12q24 with an increased risk of developing lung cancer cannot be verified as correct or incorrect. These claims would require validation through peer-reviewed research.\n\n2. TRUE: It is well-established in scientific literature that a common variant on chromosomal region 15q24-25.1, marked by rs1051730, is associated with lung cancer risk. This has been noted in studies examining genetic contributions to lung cancer susceptibility.\n\n3. FALSE [correction]: The rs1051730 variant is indeed associated with lung cancer risk, but the major haplotypes typically discussed are usually described as 'risk' and 'non-risk' alleles, with A and G alleles associated with increased and decreased nicotine receptor activity, respectively, rather than carrying neutral risk or exerting different effects as presented in the statement. The specific haplotypes and their effects would need a reference to a scientific study to confirm their exact impact on lung cancer risk.\n\n4. UNKNOWN: Without specific scientific references, the association of another variant on 15q24-25.1 marked by rs481134 with lung cancer risk cannot be verified as correct or incorrect. One would need to consult genetic research data to determine the validity of this statement.\n\n5. UNKNOWN: Determining if the variant marked by rs481134 explains an additional 13.2% of population attributable risk for lung cancer requires access to specific epidemiological studies or genetic research that makes this claim. Without a reference, the accuracy of this statement cannot be evaluated.",
    "vicuna-13b_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "vicuna-13b_response": "The ligands of the Roundabout (Robo) receptors are not specified in the given information. However, the study suggests that Robo4 activates Cdc42 and Rac1 Rho GTPases in endothelial cells and mediates attraction-signaling mechanisms through Rho GTPases in vertebrate vascular guidance.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "vicuna-13b_response": "Based on the provided information, it appears that TFIIIC, a transcription factor in yeast, plays a role in assembling the transcription initiation factor TFIIIB on class III genes after TFIIIC-DNA binding. The second largest subunit of TFIIIC, tau131, is thought to initiate TFIIIB assembly by interacting with Brf1/TFIIIB70. The document also states that a TFIIIC mutant (tau131-DeltaTPR2) harboring a deletion in tau131, removing the second of its 11 tetratricopeptide repeats, was selectively suppressed in vivo by overexpression of B\"/TFIIIB90, but not Brf1 or TATA-binding protein. In vitro, the mutant factor preincubated at restrictive temperature bound DNA efficiently but lost transcription factor activity. The in vitro transcription defect was abolished at high concentrations of B\" but not Brf1. Copurification experiments of baculovirus-expressed proteins confirmed a direct physical interaction between tau131 and B\".\nBased on this information, it appears that tau131, a subunit of TFIIIC, plays a role in the recruitment of both Brf1 and B\" and is involved in the assembly of TFIIIB. It is possible that TFIIIC and its subunits, including tau131, play a role in megakaryopoiesis, a process of blood cell development that produces megakaryocytes, which are the precursor cells for platelets. However, without further information on the specific function of TFIIIC and its subunits in megakaryopoiesis, it is difficult to determine the exact role they play in this process.",
    "vicuna-13b_fact_raw": "1. TFIIIC is a transcription factor in yeast that plays a role in assembling the transcription initiation factor TFIIIB on class III genes.\n2. The second largest subunit of TFIIIC, tau131, is involved in initiating TFIIIB assembly by interacting with Brf1/TFIIIB70.\n3. A TFIIIC mutant with a deletion in tau131 selectively loses transcription factor activity, which can be suppressed by overexpression of B\"/TFIIIB90.\n4. In vitro experiments showed that a mutant form of TFIIIC bound to DNA efficiently but lost transcription factor activity at a restrictive temperature.\n5. The tau131 subunit of TFIIIC has a direct physical interaction with the B\" protein, as confirmed by copurification experiments.\n\nNote: The role of TFIIIC and its subunits, including tau131, in megakaryopoiesis is a hypothesis and not a proven factual statement. Thus, it was not included.",
    "vicuna-13b_fact": [
      "TFIIIC is a transcription factor in yeast that plays a role in assembling the transcription initiation factor TFIIIB on class III genes.",
      "The second largest subunit of TFIIIC, tau131, is involved in initiating TFIIIB assembly by interacting with Brf1/TFIIIB70.",
      "A TFIIIC mutant with a deletion in tau131 selectively loses transcription factor activity, which can be suppressed by overexpression of B\"/TFIIIB90.",
      "In vitro experiments showed that a mutant form of TFIIIC bound to DNA efficiently but lost transcription factor activity at a restrictive temperature.",
      "The tau131 subunit of TFIIIC has a direct physical interaction with the B\" protein, as confirmed by copurification experiments.",
      "te: The role of TFIIIC and its subunits, including tau131, in megakaryopoiesis is a hypothesis and not a proven factual statement. Thus, it was not included."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: A TFIIIC mutant with a deletion in tau131 selectively loses transcription on class III genes, which can be suppressed by overexpression of B\"/TFIIIB90. It is not accurate to say it \"loses transcription factor activity\" without specifying the class of genes affected, as TFIIIC is involved in the transcription of class III genes specifically.\n4. UNKNOWN: Without specific details on the nature of the \"mutant form of TFIIIC,\" the temperature at which the experiments were done, or additional context about the experiments, it cannot be determined whether this statement is true or false.\n5. TRUE\n6. UNKNOWN: This statement appears to be an editor's note rather than a factual claim, so it does not have a truth value. However, it's important to note that the statement indicates caution about the role of TFIIIC in a specific biological process (megakaryopoiesis) which has not been proven.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "vicuna-13b_response": "Based on the information provided in Document-0, it can be inferred that atenolol is metabolized by CYP2D6. The study found that during pregnancy, the dextromethorphan/dextrorphan metabolic ratio was significantly reduced among homozygous and heterozygous extensive metabolizers of CYP2D6, indicating increased CYP2D6 activity. This suggests that CYP2D6 is involved in the metabolism of atenolol, which is a substrate of CYP2D6. Additionally, the study found that poor metabolizers showed an increased metabolic ratio during pregnancy, which is consistent with previous findings of a marked increase in metabolism of the CYP2D6 substrate metoprolol during pregnancy. These findings suggest that CYP2D6 activity is increased during pregnancy, which may be caused by an induction of the CYP2D6 enzyme.",
    "vicuna-13b_fact_raw": "1. Atenolol is metabolized by CYP2D6.\n2. The study referenced reports that the dextromethorphan/dextrorphan metabolic ratio was significantly reduced among homozygous and heterozygous extensive metabolizers of CYP2D6.\n3. Increased CYP2D6 activity during pregnancy is suggested by the study.\n4. The study implies that there is a marked increase in the metabolism of CYP2D6 substrates like metoprolol during pregnancy.\n5. There may be an induction of the CYP2D6 enzyme during pregnancy, according to the study.",
    "vicuna-13b_fact": [
      "Atenolol is metabolized by CYP2D6.",
      "The study referenced reports that the dextromethorphan/dextrorphan metabolic ratio was significantly reduced among homozygous and heterozygous extensive metabolizers of CYP2D6.",
      "Increased CYP2D6 activity during pregnancy is suggested by the study.",
      "The study implies that there is a marked increase in the metabolism of CYP2D6 substrates like metoprolol during pregnancy.",
      "There may be an induction of the CYP2D6 enzyme during pregnancy, according to the study."
    ],
    "vicuna-13b_judge_raw": "1. FALSE [correction]: Atenolol is not primarily metabolized by CYP2D6; it is primarily eliminated by renal excretion.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "vicuna-13b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "vicuna-13b_response": "Based on the information provided in Document-0, the versions of ExpansionHunter that include the PROLANG software are:\n* PROSOFT: This is the original program that was improved to create PROLANG.\n* PROLANG: This is the improved version of PROSOFT that includes new commands and improvements to the old commands. It is an open-source software that is designed to be easily expanded by users with BASIC programming experience.",
    "vicuna-13b_fact_raw": "NO FACTS",
    "vicuna-13b_fact": [],
    "vicuna-13b_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "vicuna-13b_response": "ADAMTS18 is a tumor suppressor gene that plays an important role in regulating hormone receptor signaling in breast cancer. The dysregulation of ADAMTS18 has been found to be associated with many disease processes, including cancer. In this particular study, it was found that ADAMTS18 was silenced or downregulated in breast cancer cell lines and primary breast tumor tissues. The promoter methylation of ADAMTS18 was detected in 70.8% of tumor tissues, but none of the normal tissues. The study also found that the restoration of ADAMTS18 expression in silenced breast cell lines resulted in the inhibition of cell migration and invasion. Additionally, ectopic expression of ADAMTS18 in breast tumor cells resulted in the suppression of breast cancer metastasis in vivo.\nFurther mechanistic studies showed that ADAMTS18 suppressed epithelial-mesenchymal transition (EMT) and inhibited the migration and invasion of breast cancer cells by deregulating AKT and NF-B signaling, by inhibiting the phosphorylation levels of AKT and p65. Therefore, ADAMTS18 can be considered as an antimetastatic tumor suppressor in breast cancer. Its methylation could be a potential tumor biomarker for breast cancer.",
    "vicuna-13b_fact_raw": "1. ADAMTS18 is a tumor suppressor gene that plays a role in regulating hormone receptor signaling in breast cancer.\n2. Dysregulation of ADAMTS18 has been associated with cancer.\n3. The promoter methylation of ADAMTS18 was detected in 70.8% of breast tumor tissues, but not in normal tissues.\n4. Restoring ADAMTS18 expression in silenced breast cell lines inhibited cell migration and invasion.\n5. Ectopic expression of ADAMTS18 in breast tumor cells suppressed breast cancer metastasis in vivo.",
    "vicuna-13b_fact": [
      "ADAMTS18 is a tumor suppressor gene that plays a role in regulating hormone receptor signaling in breast cancer.",
      "Dysregulation of ADAMTS18 has been associated with cancer.",
      "The promoter methylation of ADAMTS18 was detected in 70.8% of breast tumor tissues, but not in normal tissues.",
      "Restoring ADAMTS18 expression in silenced breast cell lines inhibited cell migration and invasion.",
      "Ectopic expression of ADAMTS18 in breast tumor cells suppressed breast cancer metastasis in vivo."
    ],
    "vicuna-13b_judge_raw": "1. TRUE: ADAMTS18 has been indicated in scientific literature to be a tumor suppressor gene and has been implicated in the regulation of hormone receptor signaling pathways in various cancers, including breast cancer.\n2. TRUE: Dysregulation of ADAMTS18 has indeed been associated with the development of different types of cancers.\n3. UNKNOWN: Without specific scientific evidence or data provided, the statement on the exact percentage of breast tumor tissues with ADAMTS18 promoter methylation cannot be verified.\n4. TRUE: Restoration of tumor suppressor genes like ADAMTS18 in silenced cell lines is generally known to inhibit cancer cell migration and invasion, although specific experimental results would be needed to confirm this as a fact.\n5. TRUE: Ectopic expression means introducing a gene from outside the cell, and doing this with tumor suppressor genes like ADAMTS18 in tumor cells could plausibly suppress metastasis, according to cancer biology principles. However, without specific data, this cannot be confirmed as a fact but is consistent with the roles of tumor suppressor genes.",
    "vicuna-13b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "vicuna-13b_response": "The mode of action of Thiazovivin is not specified in the given information. However, based on the provided information, it can be inferred that Thiazovivin and its related compounds are 2-arylimino-3-(3-N-morpholinopropyl) thiazolid-4-ones that selectively inhibit NAD-dependent oxidations of various substrates and possess anticonvulsant activity. These compounds also exhibit depression of CNS activity and potentiate pentobarbital-induced sleeping time in mice. It is important to note that the relationship between these pharmacological effects and the compound's mode of action is not explicitly stated in the given information.",
    "vicuna-13b_fact_raw": "1. Thiazovivin is related to compounds that are 2-arylimino-3-(3-N-morpholinopropyl) thiazolid-4-ones.\n2. Thiazovivin and its related compounds selectively inhibit NAD-dependent oxidations of various substrates.\n3. Thiazovivin and its related compounds have anticonvulsant activity.\n4. These compounds depress CNS activity.\n5. Thiazovivin and related compounds potentiate pentobarbital-induced sleeping time in mice.",
    "vicuna-13b_fact": [
      "Thiazovivin is related to compounds that are 2-arylimino-3-(3-N-morpholinopropyl) thiazolid-4-ones.",
      "Thiazovivin and its related compounds selectively inhibit NAD-dependent oxidations of various substrates.",
      "Thiazovivin and its related compounds have anticonvulsant activity.",
      "These compounds depress CNS activity.",
      "Thiazovivin and related compounds potentiate pentobarbital-induced sleeping time in mice."
    ],
    "vicuna-13b_judge_raw": "1. TRUE\n2. FALSE [correction]: Thiazovivin and its related compounds are known to inhibit Rho-associated protein kinase (ROCK), not NAD-dependent oxidations of various substrates.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "vicuna-13b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  }
]